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2013 AGM IPU & AGM IPU Services Ltd
Friday 26 and Sunday 28 April 2013  
(confined to paid up members of the IPU)
Chairman: Mr Rory O’Donnell, President
Agenda 
Friday 26 April 
17.45 1. Welcome
 2. One minute’s silence in memory of pharmacists who died since the 2012 AGM
 3. Minutes of 2012 AGM   
 4.  Financial Report and Accounts 2012
  a. Adoption of Audited Statement of Accounts
  b. Appointment of Auditors
  c. Union Membership Subscriptions
 5. IPU Services Ltd, AGM 
  Minutes of 2012 AGM
  Financial Statements 2012
  a. Adoption of Directors’ Report
  b. Adoption of Audited Statement of Accounts
  c. Remuneration of Auditors
 6. Union Secretariat Report 
 7. Group Reports / Open Forum: Introduction and Update
  a. Pharmacy Contractors’ Committee Report 
  b. Community Pharmacy Committee Report 
  c. Employee Pharmacists’ Committee Report 
  d. Communications Report 
  e. International Pharmacy Matters 
 8. Open Forum
20.00 End of First Session
Sunday 28 April
12.30 9. Report on Motions from 2012 AGM
 10. 2013 AGM Motions (Page 8 of Report)
 11. Open Forum
14.00 Closing of Conference by IPU President, Rory O’Donnell.
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Rory O’Donnell 
President, IPU
The IPU will continue to engage constructively with Government, 
other healthcare professionals and with the public to ensure 
that the potential of our sector is realised and that the 
future of community pharmacy is secured.
Kathy Maher 
Vice-President, IPU
John Gleeson 
Honorary Treasurer
Message from the President
I have great pleasure in welcoming you to the third annual IPU National Pharmacy 
Conference in Carton House. This year’s conference builds on the successes of the 
previous two and promises to be an even bigger and better event than before. 
As before, we offer an excellent suite of 
Continuing Education and Business topics, 
with the opportunity to meet up with colleagues 
and to catch up on the latest developments in 
pharmacy. A great amount of credit needs to go 
to those individuals who put such a wonderful 
programme of events together.
These continue to be difficult times for 
our sector and for society in general. The 
threat of further cuts through FEMPI and 
the implementation of reference pricing later 
this year, will significantly test our resolve. 
With consumer demand remaining subdued, 
economic uncertainty a constant and business 
costs remaining high the future for many of us 
will remain uncertain for the foreseeable future.
An ageing demographic and rising incidences 
of chronic diseases will increase demands on an 
already overstretched health service, providing 
an opportunity for us to position ourselves 
centrally in the provision of healthcare services 
to ensure that these services are delivered at the 
lowest level of complexity.
We support the Government’s healthcare 
strategy ‘Future Health: A Strategic Framework 
for Reform of the Health Service 2012-2015’, 
which sets out a new integrated model of 
care that treats patients at the lowest level of 
complexity that is safe, timely, efficient and 
as close as possible to home. Pharmacists 
are ideally placed to play an increased role in 
healthcare and can deliver additional services 
such as chronic disease management, health 
screening, treating minor ailments and medicine 
use reviews.
The IPU has been extremely active in 
promoting the sector to all our stakeholders and 
ensuring that the role of the pharmacist is valued 
and appreciated. The IPU will continue to engage 
constructively with Government, other healthcare 
professionals and with the public to ensure that 
the potential of our sector is realised and that 
the future of community pharmacy is secured. 
We will continue to do everything within our remit 
to assist the members and ensure that your 
voice is heard and understood.
We continue to regularly communicate with 
members through the newsletters, monthly GM, 
SME text service and Social Media. It is not a 
one-way process. I would encourage members 
to get in touch with the IPU and avail of the 
many great services that are available. From 
professional and business assistance and 
training, to the comprehensive Product File, 
CPD and IPU NET and IPU Academy there are 
a massive amount of services available for the 
benefit of members. I would encourage you to 
avail of these and to also keep us informed of 
areas of concern that we can address on your 
behalf.
I would like to take this opportunity to thank 
Vice-President Kathy Maher, Hon Treasurer John 
Gleeson and all our hard working committee 
members who work tirelessly on your behalf. 
They are ably supported by the dedicated staff in 
Butterfield House, all of whom remain committed 
to supporting and assisting all of us. On your 
behalf, I thank all of them most sincerely for their 
commitment, dedication and enthusiasm.
Finally, I would like to pay particular thanks 
to our Secretary General, Séamus Feely, whose 
dedication and guidance has sustained us all 
through some of the toughest times our profession 
has ever faced. I join you in thanking him for 
his unremitting efforts on behalf of pharmacy, 
pharmacists and the IPU down the years. 
 
Rory O’Donnell MPSI
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The Financial Statements for the Irish Pharmacy Union and IPU Services Ltd have been circulated to all members of the IPU.
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Appendices
I A List of Submissions Made During the Year 
 All are available on www.ipu.ie.
II Some Key Letters and Responses Received  
Throughout the Year:
• Financial Emergency Measures in the Public Interest Act 2009 (FEMPI)
• Reference Pricing 
• Reductions in the Cost of Medicines
• PSI Matters
• Primary Care Centres
• Pharmacy Vaccination Service
• Benzodiazepines
• PCRS Communications
• Extemporaneous Preparations
• Pradaxa
• ICCPE / Pharmacy Training Grant / Continuing Education
• Driving Licence Photographs
• Other Matters
- Bankruptcy
- Switching
- Directive on Recognition of Professional Qualifications
- High Tech Medicines
- National Consumer Agency (NCA) Survey
III A List of Press Releases Issued to the National Media  
During the Year on Various Matters
IV Letters Published in Newspapers
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Executive Committee 2012–2014
President: Rory O’Donnell
Vice-President: Kathy Maher
Honorary Treasurer: John Gleeson
Regional Representatives (8)
Sean Reilly East
Kathy Maher North East
Conan Burke North West
Gerry Guinan South
Niall Mulligan South East
Peter McElwee Midland
Joanne Hynes West
John Gleeson Mid West
Community Employee Group (3)
Rebecca Barry
David Carroll
Caitriona O’Riordan
Past President
Darragh O’Loughlin
Co-Options
Ann Marie Horan
John MacNamara
NB: Up to five members may be co-opted  
by the Executive Committee
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1. Irish Pharmacy Union
Financial Reports and Accounts for  
Year Ended 31 December 2012
In accordance with the Constitution of the IPU, 
the Executive Committee submits the audited 
accounts for consideration by members.
The full details of the Accounts have been 
circulated to members with the Summary of 
the 2013 Annual Report of the IPU Executive 
Committee.
If the Accounts are approved by the meeting 
after their presentation, members will be asked 
to formally adopt the Accounts for the year 
ended 31 December 2012 and agree the election 
of Auditors. In this context, the following motions 
will be put to the meeting: 
a. “That the Executive Committee Report and 
Audited Statement of Accounts of the Irish 
Pharmacy Union for the year ended 31 
December 2012 as submitted to this meeting, 
be and are hereby adopted.”
b. “That this meeting agrees to the election of 
Baker Tilly Ryan Glennon for a further year as 
Auditors for the IPU and IPU Services Ltd.”
2. IPU Services Limited
Financial Reports and Accounts for Year 
Ended 31 December 2012
At this Annual General Meeting of IPU Services 
Ltd, members are asked to consider the Report 
of the Directors and the Auditors’ Report on the 
Accounts for Year Ended 31 December 2012.
The accounts and financial reports have been 
circulated to all members.
“That the Directors’ Report and Audited 
Statement of Accounts for the year ended  
31 December 2012 as submitted to this 
meeting, be and are hereby adopted.”
Financial Statements
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Report of the 39th Annual General 
Meeting of the Irish Pharmacy Union 
and IPU Services Ltd
Radisson Blu Hotel, Galway
27 & 29 April 2012
Friday 27 April - AGM Motions
Present:  The President, Mr Darragh O’Loughlin, and 53 members.
In Attendance: Mr Seamus Feely, Mr Jim Curran, Ms Ciara Enright, Ms Aoife Garrigan, Ms Fiona Hannigan, Mr Darren Kelly,  
Ms Jill Lyons, Ms Wendy McGlashan, Ms Roisin Molloy, Ms Aoibheann Ni Shúilleabháin and Ms Patrice O’Connor.
Apologies: Apologies were received from seven members.
[A full report of the 2012 AGM is available from the IPU offices.]
1. The President welcomed the attendance to 
the 39th Annual General Meeting of the Irish 
Pharmacy Union.
2. On the proposal of the President all present 
stood in silence in memory of deceased 
members and their families who had died 
since the 2011 AGM. 
3. Report of 2011 AGM
 The report of the 38th Annual General 
Meeting was taken as read and agreed. The 
report is available on the members’ section 
of www.ipu.ie. The minutes were proposed by 
Niall Mulligan, seconded by Roy Hogan and 
unanimously approved by the meeting.
4. Financial Reports and Accounts 2011
a. Kathy Maher (Honorary Treasurer) 
presented the Union’s Financial Report. 
The Honorary Treasurer drew members’ 
attention to Page 31 of the Annual Report 
and proceeded to explain changes in 
income and expenditure in 2011.  
Following the presentation, the following 
motion approving the accounts was 
proposed by John McNamara, seconded by 
Shane Howard and carried unanimously: 
 “That the Executive Committee Report 
and Audited Statement of Accounts for the 
Irish Pharmacy Union for the year ended 
31 December 2011 as submitted to this 
meeting be and are hereby adopted.”
b. The following motion was proposed by  
Paul Fahey, seconded by Ann-Marie Horan 
and carried:
 “That this meeting agrees to the election  
of Baker Tilly Ryan Glennon for a further 
year as auditors for the IPU and  
IPU Services Ltd.”
c. As subscriptions have been reduced by 
38% over the past two years, the Treasurer 
informed the meeting that the Executive 
Committee had agreed not to make any 
change to the annual subscription payable.
5. IPU Services Ltd AGM
 The accounts were presented by the Treasurer 
and on the proposal of Eoghan Hanly, 
seconded by John Gleeson, it was resolved:
 “That the Directors’ Report and Audited 
Statement of Accounts for the year ended 31 
December 2011 as submitted to this meeting, 
be and are hereby adopted.”
 This motion was carried.
6. Union Secretariat Report
 The IPU Secretariat Report was circulated 
to members by post and was also available 
on the members’ section of the IPU 
website, www.ipu.ie, prior to the meeting, 
as part of the Executive Committee report. 
The Secretary General, Mr Seamus Feely, 
introduced the Secretariat report. 
7. Group Reports
a. Pharmacy Contractors Committee 
(PCC) Report
 This report was introduced by Mr Morgan 
Power, Chairman of the Pharmacy 
Contractors’ Committee.
The report was circulated to members 
in advance of the meeting and a more 
detailed report was published on the 
members’ section of www.ipu.ie. 
b. Community Pharmacy Committee  
(CPC) Report
 This report was presented by Mr Bernard 
Duggan, Chairman of the Community 
Pharmacy Committee.
The report was circulated to members 
in advance of the meeting and a more 
detailed report was published on the 
members’ section of www.ipu.ie. 
c. Community Employee (EPC) Report 
 This report was delivered by Ms Caitriona 
O’Riordan, Chairperson of the Employee 
Pharmacists’ Committee. 
The report was circulated to members 
in advance of the meeting and a more 
detailed report was published on the 
members’ section of www.ipu.ie. 
d. Public Relations Report 
 This report was available on the members’ 
section of www.ipu.ie and was taken as read. 
e. International Pharmacy Matters 
 This report was available on the  
members’ section of www.ipu.ie  
and was taken as read. 
8.  Open Forum
 This report was available on the  
members’ section of www.ipu.ie  
and was taken as read. 
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Sunday 29 April - AGM Motions
Present:  The President, Mr Darragh O’Loughlin, and 57 members.
In Attendance: Mr Seamus Feely, Mr Jim Curran, Ms Aoife Garrigan, Ms Fiona Hannigan,  
Mr Darren Kelly, Ms Jill Lyons, Ms Wendy McGlashan, Ms Roisin Molloy,  
Ms Aoibheann Ní Shúilleabháin and Ms Patrice O’Connor.
Apologies: Apologies were received from seven members.
9. Report on Motions from 2011 AGM
 The report on motions from the  
38th Annual General Meeting was taken  
as read and agreed. 
10. 2012 AGM Motions 
 The 2012 Motions and actions taken on  
them are on Pages 8 to 9 of this report.  
All motions were debated and considered by 
the meeting and then passed.
11. Open Forum
 This report was available on the members’ 
section of www.ipu.ie and was taken as read. 
The President thanked his colleagues for 
attending the IPU AGM and reminded them that 
the Panel Discussion would begin shortly.
The President then closed the 39th Annual 
General Meeting of the Irish Pharmacy Union.
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2012 AGM Motions and  
Report on Action Taken
The following motions, proposed in accordance with Article 29 of the Constitution,  
were brought before the 2012 AGM for consideration:
1. Proposed: Morgan Power
 Seconded: Brian Walsh
 “That this AGM calls on the Minister to:
n	 Reverse the decision to reduce the 
reimbursable price of fridge items;
n	 Increase the low level dispensing fees 
currently paid to contractors;
n	 Review the reimbursement price of 
medicines to pharmacists; 
n	 Review the current level of remuneration 
for new Services; and 
n	 Put a proper negotiation system in place 
to review such matters.”
 Action: The IPU made a submission and 
a presentation to the FEMPI Review in 
May 2012 and again in January 2013. The 
IPU took these opportunities to request a 
complete review of pharmacy payments.
The IPU highlighted to the Minister and 
to departmental officials that pharmacies 
remain highly vulnerable and some have 
gone into examinership and/or receivership. 
The IPU called on the Minister to use the 
reviews to adjust a number of issues, 
fundamental to the provision of pharmacy 
services. These include:
n	 The elimination of the low level  
dispensing fees
n	 The reversal of the fridge items decision
n	 Review of the Reimbursement Price  
to Pharmacists
n	 Review the current level of remuneration 
for new Services; 
n	 Put a proper negotiation system in place 
to review such matters.
 The PCC met during 2012 to review strategy 
to ensure that these issues would be dealt 
with in 2013. The PCC will continue to follow 
up on these issues.
2. Proposed: Liam Butler
 Seconded: Dermot Twomey
“That this AGM calls on the HSE PCRS to 
agree to an HSE-IPU Pharmacy Customer 
Charter which would set out a transparent, 
equitable and fair process in which the HSE 
should interact with pharmacy contractors  
on all queries.”
Action: The IPU met with the HSE as part 
of the Joint Consultative Group in March 
2012. The main issue on this agenda was 
the establishment of a HSE-IPU Pharmacy 
Customer Charter to set out a transparent, 
equitable and fair process in which the HSE 
should interact with pharmacy contractors 
on all queries. The IPU continued throughout 
2012 to request the HSE to put in place 
guidelines to ensure that pharmacy 
contractors were dealt with in a fair and 
reasonable manner.  During 2012 the HSE 
created a new position of Head of Customer 
Service in the PCRS. The PCRS Contract 
Manager and the PCRS Administrator have 
met with the Head of Customer Service 
three times since November 2012. The IPU 
is currently liaising with the HSE on the 
HSE-IPU Charter along with a review of the 
HSE Administrative Arrangements to ensure 
that pharmacy contractors are dealt with in a 
professional manner.
3. Proposed: Bernard Duggan
 Seconded: Daragh Connolly
“That this AGM calls on the Department 
of Health and HSE to further expand the 
role of the community pharmacist by 
developing a community-pharmacist-led 
national cardiovascular screening service, 
which incorporates accredited standards 
and training for the service and identifies 
a number of different funding options for 
provision of the service.”
Action: The IPU joined forces with the Irish 
Heart Foundation to develop Cardiovascular 
Risk Assessment Training for Pharmacists. 
Two courses were delivered in Dublin in 
October 2012, one in Cork in March 2013 
and one more in Dublin in April 2013. 
A health screening module on IPU NET 
was launched in January 2013 to assist 
pharmacists in offering health check services. 
Guidelines and SOPs are available on the IPU 
website. Promotional materials were sent to 
pharmacies in March 2013. The IPU met with 
VHI in late March to seek reimbursement for 
pharmacy health screening for their clients.  
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4. Proposed: Caitriona O’Riordan
 Seconded: Sarah Magner
 “That this AGM calls on the Irish Institute 
of Pharmacy to ensure that, in its role as a 
management and accreditation body, the 
funding agreed between the IPU and the 
Department of Health, as part of the 1996 
Community Pharmacy Contractor Agreement, 
will be be ring-fenced within the Institute 
to fund continuing education initiatives for 
community pharmacists, who make up the 
largest portion of the PSI register.”
 Action: At the time of going to print, the Irish 
Institute of Pharmacy had still not been set 
up. The IPU has written to the Department 
of Health on several occasions over the past 
year, asking that funding previously provided 
to ICCPE be ring-fenced for community 
pharmacists’ training. 
Following the dissolution of ICCPE at the 
end of 2012, IPU Academy was set up to 
deliver a Spring Programme. Six topics were 
delivered in 87 venues around the country. 
On 19 Mar 2013, 986 pharmacists had 
booked 4450 courses, 297 new members 
had signed up to IPU Academy and 56 new 
members joined the IPU. 
We are now in the process of developing 
an online Learning Management System to 
support IPU Academy. In the meantime, we 
have developed an e-learning EHC module 
which was put in place when ellaOne came 
onto the Irish market in May 2012. Members 
were able to access a range of training 
courses at the 2012 IPU National Pharmacy 
Conference and feedback was excellent. 
In addition, we have had at least one CPD 
article in every edition of the IPU Review in 
2012/13.     
5. Proposed: Jack Shanahan
 Seconded: Sean Reilly
“That this AGM calls on the HSE PCRS and 
Department of Health to work with the IPU’s 
IT Steering Group, initially to ensure a smooth 
roll out of both generic substitution and 
reference pricing, and any other issues that 
require a pharmacy IT change.”
Action: We are in the process of 
implementing a number of developments 
to the IPU Product File so that it continues 
to meet the needs of members and other 
users and, in particular, to facilitate reference 
pricing and generic substitution. We have had 
a number of meetings with the Department in 
this regard and made a detailed submission, 
proposing amendments to the legislation.  
We also had a number of meetings with DoH, 
PCRS, IMB, and system vendors to discuss 
the implementation of reference pricing and 
generic substitution. A number of letters 
have been written to the DoH and PCRS, 
outlining our concerns. The IPU has also met 
with the vendors to go through the changes 
that have been made to the IPU Product File 
to facilitate reference pricing and generic 
substitution.   
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IPU Secretariat Report
1. Introduction 
The past year has been an eventful and 
demanding year for all of us involved in 
the pharmacy sector as we grapple with 
change, continued subdued consumer 
demand and increased bureaucracy and poor 
communications from the HSE. Business and 
regulatory costs remain high including those 
costs controlled by Government and its agencies. 
Against this background, it is to the credit of the 
profession that high quality and efficient services 
continue to be provided to patients up and 
down this country. Looking to the next twelve 
months, while there are some tentative signs of 
economic recovery, economic growth is unlikely 
to reach the level necessary to dramatically 
improve overall economic performance and to lift 
demand in the domestic economy. 
The Executive Committee has overseen the 
management of the IPU and the work of the 
three main IPU Committees throughout the 
past twelve months. The report of activities 
undertaken by the three main national 
committees provide you with a flavour of the 
wide range of activities that we are now involved 
in on an ongoing basis. This is all made possible 
by the maintenance of unity in the sector, which 
has enabled us to develop our activities and 
services for you and we are grateful for your 
continued support. It also ensures that we are 
there for you on an individual basis when you 
need us. 
2. Membership & Pharmacy Ownership (as at 5 March 2013)
(1) Membership of the IPU
 Community Proprietors 869
 Industry & Wholesale 7
 Community Employees 1040*
 Hospital  7
 Army, Academic & Admin     3
 Associate Members  7 1933
(2) Number of Community Pharmacies
Pharmacist Owned:
Single shops 756
Chains  604 1360
 
Non-Pharmacist Owned:
Single shops  75
Chains  136 211 (1571)
(3) Total Number of Chains (two and over)  
  Pharmacist Non-Pharmacist
Two pharmacies 114 4 236
Three  39 1 120
Four   10 2 48  
Five  6 2 40
Six  6 1 42
Eight  2 1 24
Nine  2  18
Eleven  1 11
Thirteen  1 13
Fourteen  1 14
Fifteen  1 15  
Sixteen  1 16 
Twenty  1 20
Twenty-Six 1  26
Twenty-Eight  1  28
Sixty Nine  1 69
  (604) (136) (740)
*Notes on Employee Membership
352 are Supervising Pharmacists availing of the free membership for additional pharmacies
122 are Supervising Pharmacists in non-pharmacist owned pharmacies and are covered by the sub 
paid by the pharmacy.
53 are availing of the free membership. 
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3. Product File Unit
The IPU Product File is managed by Fiona 
Hannigan and her team: Ger Gahan, Eilish 
Barrett and Ciara Browne. As well as supplying 
price updates and product information for 
members, they provide the following services 
and advice: 
n Product sourcing
n General queries on the IPU Product File
n GMS pricing issues
n Short Supply and Discontinued Lists
The IPU also provides a Drug Interaction File 
and information files on drug use in Pregnancy 
and Breastfeeding, produced by the School of 
Pharmacy in Trinity College Dublin. These are 
based on the ATC classification system and are 
designed to warn pharmacists of the possibility 
of an interaction. 
Product File/ITSG Update 2013
n Reference Pricing/Generic Substitution. 
• Consultant engaged to assist in  
updating IPU Product File
• A number of meetings held with the 
Implementation Group,
• IMB Webinar held February 2013; twenty 
interchangeable groups identified and 
updated on IPU Product File
• Meetings with system vendors held in 
February 2013 to discuss incorporation 
of Reference Pricing/Generic Substitution 
with the IPU Product File
• Standardisation of fields on IPU Product 
File ongoing
• Work has begun on IPU database changes 
and user interface to facilitate the 
introduction of Reference Pricing/Generic 
Substitution
• No sample data files yet from IMB  
or HSE PCRS 
n IPU Product File link to IMB Website. 
• IPU Product File updated to distinguish 
PA/PPA/DRP and EU products
• IMB File tested for mapping to IPU Product 
File
• Queries sent back to IMB
• Sample fields sent to vendors for testing
• Electronic Download of Product File. 
• Usernames and password reissued to all 
users for January 2013
• Consultant engaged to assist with IPU 
Product File security
• Report produced on IPU Product File 
security for Executive Committee
• Emails for Helix & Touchstore users to 
cease from May 2013
• CD’s for Touchstore users to cease from 
April 2013
n IPU Comms move to broadband. 
• Brentech engaged to act on behalf of IPU
• Technical Team set up and a number of 
teleconferences held
• Forum meeting to be arranged  shortly to 
discuss finalisation of project 
• Due to be piloted mid-2013 and live by end 
of year
n BNF Warning Codes. 
• Map IPU Warning Codes with BNF  
Warning Codes.
• Modify product file to reflect the new  
set of codes.
• Codes launched June 2012
4. Administration Unit
The Administration Unit has three staff 
members: Patrice O’Connor, who works 
part-time, looks after reception and assists 
in the day-to-day running of the office; Ciara 
Enright, who works part-time as the IPU’s 
accountant, is Secretary to the Finance 
Committee. She maintains books of account 
and advises members on a range of taxation 
and accountancy problems. Roisín Molloy is 
responsible for all aspects of membership  
and the management of the Secretary  
General’s office. 
5. Contractual and other 
Related Issues 
Jill Lyons and Aoife Garrigan deal with a 
wide range of contractual issues. Jill Lyons 
is Secretary to the Pharmacy Contractors’ 
Committee (PCC). Jill has played a key role 
in developing many of the PCC initiatives 
throughout the year and in the resolution of 
problems with the Health Service Executive, 
Primary Care Reimbursement Service and the 
Department of Health. Throughout 2012 Jill 
was involved in preparing the submission and 
the oral presentation to the FEMPI Review. She 
is also working with the HSE and the Elton 
John AIDS Foundation on the implementation 
of the Needle Exchange Programme through 
Community Pharmacy, and preparing for the 
implementation of the Reference Pricing and 
Generic Substitution. Jill also represents the IPU 
at the PGEU Economic Working Group. Jill and 
Aoife have spent much of the year liaising with 
the HSE on the numerous contractual queries 
that arise. Aoife also deals with remuneration 
queries, compiling information on raids on 
pharmacies and collecting information on stolen 
and forged prescriptions. 
11
AnnuAl RepoRt 2013
6. Policy and Public Affairs 
Jim Curran, as Director of Communications 
and Strategy, oversees the IPU’s internal and 
external communications and is responsible for 
developing the IPU’s strategy. His responsibilities 
include promoting the interests of the IPU 
and the membership through effective 
communications with members, media, agencies 
and other parties that influence the sector. He is 
also responsible for overseeing events, business 
development and policy research Jim oversaw 
the introduction of the new strategy statement 
for the IPU, which will cover the period from 
2013-2016. Jim is an editorial associate of the 
IPU Review and is also Secretary to the Executive 
Committee. He also represents the IPU on 
external committees.
7. Media and Communications
Jim Curran oversees this area. Wendy 
McGlashan is Admin Secretary to the Executive 
Committee and is responsible for IPU 
publications, including the production of the IPU 
Review, IPU News (the weekly e-newsletter) and 
co-production of the IPU Yearbook.
Aoibheann Ní Shúilleabháin is responsible for 
organising the annual IPU National Pharmacy 
Conference. She manages the IPU website and 
co-ordinates IPU advertising campaigns. She 
works on the co-ordination of communications 
activities and assists with national and regional 
media coverage for the IPU and public opinion 
research. She is an editorial associate of the  
IPU Review.
Communications
n	 Market Research: The IPU undertook market 
research amongst the general public and the 
results will be presented at the IPU National 
Pharmacy Conference.
n	 Advertising and Public Relations: The 
IPU ran advertising campaigns in April and 
October-December, which included radio 
ads and in-store materials. The ads aimed 
to promote the role of the pharmacist and 
encouraged people to ‘ask your pharmacist 
first’. Public relations activities, including 
the issuing of 45 press releases also raised 
the profile of pharmacists in the media, with 
interviews on national TV and radio, as well 
as in regional media, highlighting the role of 
the pharmacist. 
n	 Communications with Members: 
Communications with members continues to 
improve with the IPU website, IPU News (the 
weekly e-newsletter) and @ipumail all seeing 
an increase in uptake from members. In the 
last year, new services have been launched 
such as an SMS Service, Members’ Forum 
on the IPU website and a Facebook page. 
A booklet, On Your Side and At Your Side, 
was also sent to members highlighting the 
support and services that the IPU provides  
to members.
n	 Publications: The IPU Review, Yearbook 
and a weekly e-newsletter are all produced 
in-house rather than through external 
contractors for efficiency reasons.
n	 Annual Review: The Annual Review of 
the sector is part of an ongoing annual 
series that authoritatively tracks changes 
in community pharmacy. It is essential 
research and a reference that enables us, as 
a representative body, to promote members’ 
interests based on credible facts that are 
measured consistently over time. The 2011 
Review was carried out by Grant Thornton 
and is available in the members section of 
the website.
IPU National Pharmacy Conference
The annual IPU National Pharmacy Conference 
has been a great success since the inaugural 
event in 2011. Since then, the conference has 
grown and expanded to facilitate the needs of 
members. The Conference is a great opportunity 
for members to come together in an educational 
and social environment. Over the weekend, 
pharmacists have the opportunity to build on 
their Continuing Professional Development (CPD) 
and receive updates on the work of the IPU at 
the AGM. The President’s Dinner is also held 
over the weekend of the Conference.  
The success of the conference is evident in  
the growing numbers of pharmacists  
attending each year.
8. Pharmacy Services
The Director of Pharmacy Services, Pamela 
Logan, co-ordinates all Professional, IT and 
Training matters within the IPU. Pamela acts as 
Secretary to CPC and details of issues covered 
by this Committee can be found in the CPC 
report. She works with relevant departments and 
agencies, both nationally and internationally, 
to promote the role of the pharmacist. Pamela 
also represents the IPU at PGEU and FIP. Liz 
Hoctor is the CPD & IT Manager and has been 
instrumental in the setting up of IPU Academy 
to support members in their engagement with 
continuing professional development. Liz also 
oversees IPU NET, our online web-based platform 
designed to support members in the delivery of 
new pharmacy services.
9. Training & HR Department 
Susan McManus, Training and HR Manager, 
organises and co-ordinates a selection of training 
courses for pharmacy staff. Janice Burke assists 
Susan in this department. 123 Pharmacy 
Technicians’ graduated in March 2013. There 
are 210 students at present partaking in Year 
1 and 162 students in Year 2 of the course. 
In addition, 151 students completed the MCA 
Course in 2012 in Dublin, Limerick, Kilkenny, 
Cork, Galway, Tullamore, Tralee, and Waterford. 
63 students completed the Interact course and 
15 completed the Interact Plus course. The 
FÁS Pharmacy Sales Traineeship course was 
administered in Baldoyle, Dublin and Douglas, 
Cork; and to Senior Colleges in Dun Laoghaire, 
Dublin; Monaghan Institute; Limerick College of 
Further Education; and St John’s College, Cork. 
Susan also acts as Secretary to the Employee 
Pharmacists’ Committee, co-produces the 
IPU Secretariat Report
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IPU Yearbook and Diary and Wall-Planner and 
advises members on Human Resource issues. 
The Training Department in conjunction with 
the Business Development Department rolled 
out the Diploma in Leadership and Management 
in February 2013. This is a highly interactive 
course spanning over 24 months, utilising 
various teaching methods, including classroom 
workshops, on-the-job projects, individual and 
group exercises, case study work groups, learner 
forums and individual presentations.  The ‘face-
to-face’ element of this course will be delivered 
by Susan Madden, RTCL, in Butterfield House. 
Also hosted in Butterfield House were two 
Employment Seminars in February and March 
2013, covering Employment Legislation and 
NERA inspections.
10. Business Services
The Business Development Manager, Darren 
Kelly, is responsible for business services and 
advice to members. In 2012 “Strategies for 
Growth” business training was held around 
the country to help members understand 
their business and maximise their profits. A 
new fully accredited Diploma in Leadership & 
Management was launched in February 2013. 
This course was developed to help pharmacy 
owners, managers and supervisors could gain 
the knowledge required to help them manage 
their pharmacies. A number of affinity schemes 
have been negotiated for members on a range of 
products and services and details can be found 
on www.ipu.ie. Members are kept up-to-date 
with current legislation through notices in the 
IPU Review, Yearbook, E-Newsletter and General 
Memoranda. Members can contact the Business 
Department for advice and information on the 
Business Helpline 01 406 1558. Darren operates 
the IPU Retail Review Consultancy Service, which 
is available to members at a discounted rate. 
Darren will come to your pharmacy for a full day 
retail review, develop a plan and implement the 
plan over the course of the day. The feedback 
from members who have availed of this service 
has been very positive. Details of this service can 
be found on www.ipu.ie and in the IPU Review. 
Darren also oversees the general maintenance 
and upkeep of Butterfield House.
The IPU VAT scheme received full Revenue 
approval from 1 September 2012 and has been 
well received by members and accountants.
11. External Consultants
Gordon MRM (PR Consultants); Coolamber (IT 
Consultants); John Behan (Industrial Relations 
Advisor) and Sean McHugh (Industrial Relations 
Advisor); provide advice and support to the 
IPU as requested on an ongoing basis. Leaf 
Environmental has been retained as consultants 
to the IPU on matters regarding environmental 
and waste management issues.
12. Main Committee Meetings
The number of committee meetings was:
 ‘12 ‘11 ‘10 ‘09
• Executive  
Committee 7 6 6 9
• Community  
Pharmacy  
Committee  4 5 5 6
• Pharmacy  
Contractors’  
Committee  6 5 8 8
• Finance  
Sub-Committee  6 7 7 7
• All Committee  
Meetings 1 0 0  3
• Employee  
Pharmacists’  
Committee 4 4 4 3
13. IPU Publications
The following are sent to members, on a  
regular basis:
n	 IPU Review
n	 IPU Weekly E-Newsletter
n	 General Memoranda
n	 Price Index List Updates
n	 IPU Product File by email and on Disk 
and CD
n	 Yearbook & Diary
n	 Wall Planner 
n	 Quarterly Business Trends Surveys
n	 Training Course Updates
n	 Employee Pharmacists’ Committee 
Newsletter
n	 Reap the Rewards of IPU Membership
14. Pensions and Insurance 
AIC (Corporate) Ltd, Pharmacy Insurance 
Ireland and Liberty Asset Management provide 
insurance and pension services for members.
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15. Submissions
The following submissions were made during 
the year. All are available on www.ipu.ie > 
Publications & Submissions.
2012 
n	 FEMPI Review 5  
– DoH – May 2012
n	 Pharmacovigilance Regulations  
– DoH – July 2012
n	 Rapid Discharge Planning  
– HSE – Sep 2012
n	 National Integrated Care Guidance  
– HSE – Sep 2012
n	 Pre-Budget 2013 Submission  
– Departments of Finance & Public Reform 
– Oct 2012
2013
n	 FEMPI Review  
– DoH – Jan 2013
n	 Medicines Shortages and ULMs 
Consultation  
– DoH – Jan 2013
n	 Standardising Patient Discharge Summary 
Information  
– HIQA – Jan 2013
n	 Alex White Briefing  
– Mar 2013
n	 Falsified Medicines Regulations  
– DoH – Mar 2013
16. IPU Review
The IPU Review is produced in-house by Jim 
Curran, Wendy McGlashan and Aoibheann Ní 
Shúilleabháin. 
17. Conclusion
As this is my last year as Secretary General, I 
would like to thank each and every member of 
the IPU for your support and participation in 
the work of the IPU and most especially for your 
support to me personally over the years. I would 
like in particular to thank all the Presidents that 
I have had the pleasure of working with during 
my twelve years with the IPU. Their commitment 
never ceased to amaze me and was always 
a source of encouragement and inspiration. 
Finally, to my work colleagues, a big “thank you” 
for delivering so much to our members through 
your commitment and dedication and I always 
enjoyed basking in your achievements. I have no 
doubt that the IPU will continue to evolve and 
change and go from strength to strength in the 
years ahead. 
Seamus Feely,
Secretary General
 
IPU Secretariat Report
(continued)
Seamus Feely 
Secretary General, IPU
14
AnnuAl RepoRt 2013
Over the past year the PCC’s energies have 
been focused on preparing for two reviews 
under the Financial Emergency Measures 
in the Public Interest Act 2009 (FEMPI), the 
implementation of the Reference Pricing and 
Generic Substitution, dealing with the decisions 
of the HSE PCRS along with many other urgent 
issues which have arisen during the year.  
The main items on the Committee’s agenda 
since the last AGM:
Department of Health (DoH) Matters:
n Preparing the Submission and Oral 
Presentation in the context of the Review 
carried out under the FEMPI Act in May 2012 
and again in December 2012;
n Communicating with members and gathering 
information from them in advance of the 
FEMPI Act reviews; 
n Communicating with members in the 
aftermath of the FEMPI Act review in May 
2012;
n Monitoring the implementation the 
Prescription Levy;
n Preparing for the introduction of Reference 
Pricing and Generic Substitution;
n Meetings with Ministers; and
n The impact of the reductions in the 
reimbursement price of fridge items.
Health Service Executive (HSE) Matters:
n The implementation of the Needle Exchange 
Programme with the HSE and Elton John 
AIDS Foundation; 
n Participating in the Joint Consultative Group 
with the HSE; 
n Ensuring the continued operation of the 
Incomplete Claims Protocol with the HSE;
n Monitoring the claiming and payment for 
Pradaxa and Xarelto;
n Monitoring the withdrawal from the GMS of 
Glucosamine, Orlistat, Omega-3 and Gluten-
free products;
n Monitoring all Community Drugs Schemes 
and all pharmacy payments;
n Liaising with the HSE and DoH to resolve 
issues around the Community Pharmacy 
Contractors’ Contract;
n Ongoing HSE PCRS Administration issues; 
and
n Working with individual members in resolving 
problems with payments.
Monitoring the Cost of Medicines:
n Monitoring the reduction in the cost of 
medicines in 2012;
n Strongly making the case to the Department 
for sufficient notice of any change in the 
price of medicines;
n Advising members on the reductions.
Department of Health  
(DoH) Matters:
FEMPI Legislation 
The PCC prepared submissions and 
presentations for the FEMPI Review in May 2012 
and December 2012/January 2013. The PCC 
liaised with Grant Thornton in the collation of 
figures for these submissions and put forward 
the best possible case to the Minister. The 
PCC communicated all developments to the 
membership in a timely and straightforward 
manner. There was no further reductions 
announced in May 2012, which was a success 
for pharmacists. The PCC has managed to 
protect key ‘red line’ issues – current dispensing 
fees, mark-up, and the reimbursement price of 
non-drug items to date. 
However, there continues to be a loss on 
fridge medicines. The PCC requested that 
the Minister and the HSE put in place a 
system to compensate pharmacists for any 
loss they experience when dispensing fridge 
items. The PCC will continue to put forward 
the pharmacist’s case to the Minister at every 
opportunity.
The PCC has communicated extensively with 
members and has sought information as part of 
the Annual Review of the Sector. Members’ input 
is vital in making our case and the PCC thanks 
all members who have participated in this year’s 
survey.
The PCC will meet with their Senior Counsel, 
Michael Collins, shortly to discuss the FEMPI 
appeal and the possibility of initiating a further 
legal challenge in light of any further FEMPI 
reductions.
Prescription Levy 
The Minister has indicated that he is not in a 
position to abolish the prescription levy because 
of the economic situation. The PCC wrote to the 
Minister requesting amendments to the legislation 
to exclude certain cohorts of patients and this 
is something that we will continue to pursue, 
especially in light of the increase in 2013. 
Reference Pricing 
The PCC has been advocating for the 
introduction of generic substitution since 2003. 
The PCC has more recently sought to influence 
the manner in which generic substitution might 
be introduced in light of the Government’s 
commitment to introduce legislation for the 
implementation of generic substitution and 
reference pricing. The PCC has made the case 
that generic substitution should be introduced in 
advance of reference pricing.
The Health (Pricing and Supply of Medical 
Goods) Bill 2012 was published last summer. The 
IPU met with the Department of Health and HSE 
on numerous occasions to discuss the legislation. 
Pharmacy Contractors’ Committee 
(PCC) Report 2012-2013
The Pharmacy Contractors’ Committee took office in February 2012. Morgan Power was elected as 
Chairman and Brian Walsh as Vice-Chairman. The Committee has met six times since last year’s 
AGM. The Committee has met six times since the beginning of the year. There has also been a  
sub-PCC meeting and one All Committee meeting since the last AGM.
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Pharmacy Contractors’ Committee  
(PCC) Report 2012-2013
(continued)
The PCC will continue to follow up on this 
matter to ensure that we receive adequate 
notice of any change and influence the manner 
in which the new legislation is implemented. 
Equally, we will continue to make the case 
that any reference price must not jeopardise 
continuity of supply or further undermine the 
viability of pharmacy businesses.
Meeting with the Minister
There was a meeting with Minister Roisin 
Shortall, Minister of State at the Department of 
Health in early 2012.
HSE Matters
Withdrawal of Reimbursement  
of Certain Products
The HSE announced the withdrawal of 
reimbursement for Glucosamine, Orlistat and 
Omega-3 Triglycerides and gluten-free foods from 
all Community Drugs Schemes.
The announcement was effective from 1 
September, despite the HSE not officially 
notifying the IPU until Monday 3 September. The 
PCC requested and was granted, a grace period 
of three days up until Tuesday 4 September. This 
was welcomed by members as the HSE paid for 
the claims processed during the initial few days 
of the announcement.
This decision was due to the deficit in the 
HSE finances and, therefore, there was nothing 
that could be done to stop or delay it. It is 
expected that there will be further changes to 
oral nutritional supplements and other medicines 
in the coming weeks and months and the PCC 
will continue to monitor this situation.
Pradaxa and Xarelto 
There have been a number of restrictions 
around the reimbursement of Pradaxa and 
Xarelto since 2011. The HSE issued circulars to 
GPs, Hospitals and Pharmacists in July 2012 
clarifying reimbursement for Pradaxa and Xarelto 
as a second line therapy where warfarin may not 
be appropriate for the patient. Reimbursement 
for the pharmacist is only guaranteed where the 
patient has a properly filled out prescription and 
a letter of approval from the HSE. The onus is 
on the prescriber, not the pharmacist, to fill out 
and send off the application form. The PCC had 
liaised with the HSE in advance of the circular 
being issued and the HSE had made a number 
of changes to the final draft of the circular based 
on suggestions from the IPU. 
Due to the persistence of the PCC all Pradaxa 
claims previously outstanding, dating back 
to November 2011, were paid in 2012. The 
PCC continues to monitor payments for these 
medicines.
Roll-out of the NEX Programme
Throughout 2012 the PCC worked with the 
HSE and the Elton John AIDS Foundation on 
the Needle Exchange Programme. There are 
now over 75 pharmacies participating in the 
programme with more coming on-stream over 
the next few months. Due to the arguments put 
forward by the PCC, the fee paid to pharmacists 
for needle exchange is €5 and not part of the 
sliding scale of fees (€5, €4.50 and €3.50). 
The PCC is providing support to pharmacists 
participating in the programme through regular 
contact. There is also a specific area on the 
IPU forum for comments and feedback on the 
programme. A National Pharmacy Co-ordinator 
for outside the Eastern Area was appointed in 
late 2011. In late 2012 two Pharmacy Liaison 
Workers were appointed. This was a very 
successful outcome from the IPU’s perspective 
as it provides pharmacies with further back-up 
and support.
The extension of the Incomplete  
Claims Protocol
The IPU negotiated the Incomplete Claims 
Protocol, which ensures that pharmacists get 
paid for all medicines dispensed in good faith to 
medical card patients. This protocol continues 
to be monitored by the IPU and HSE at the 
Joint Consultative Group (JCG). The PCC also 
managed to negotiate for the extension of this 
Protocol into 2013. This was a very successful 
outcome to a long running problem for 
members.
Advising members on their PCRS Claims
The IPU regularly issues advice and tips for 
members on how to go about checking their 
claims and minimising rejected claims. The IPU 
has recently put together a Pharmacy Claims 
Checklist, which is available on the IPU website 
and which gives helpful tips to members to save 
them time and money.
Adherence to Pharmacy Contract 
The PCC continued to monitor the HSE/DoH 
adherence to conditions of Pharmacy Contract 
and followed up on a number of individual 
member’s queries throughout 2012.
Liaising with the HSE 
The PCC met with the HSE as part of the JCG 
twice since the last AGM. In addition, while 
working on the implementation of the needle 
exchange programme, there were numerous 
meetings with HSE and DoH officials. Overall, 
there is good interaction between both sides and 
our aim is to continue to have a constructive 
relationship with the HSE and the DoH.
Legal Advice / Cases 
The FEMPI Appeal is being pursued by the 
PCC as mentioned above. The Mullally Case 
is awaiting a decision from the Hickey Case in 
relation Supreme Court appeal. The IPU liaises 
with solicitors from Beauchamps and Mason 
Hayes & Curran on all these cases to ensure that 
PCC Committee decisions are implemented and 
result in the best outcome for members, where 
possible.
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Monitoring the Cost  
of Medicines
Reductions to the Cost of Medicines  
There were two significant reductions in the price 
of medicines during 2012 under IPHA and APMI 
agreements with the HSE/Department. The PCC 
sought a deferral on each implementation date 
by at least one month. This was not granted 
because of the current state of the public 
finances. However, we were given more notice 
of the reductions on the APMI medicines and 
members were given an opportunity to reduce 
their stock accordingly. The IPU communicated 
to members to warn them of the need to reduce 
stock levels in order to minimise the loss in 
stock value as a consequence of the current 
consultations between the DoH and IPHA on 
medicine prices. 
Conclusion
This is a summary of some of the major issues 
dealt with throughout the year. However, 
officials of the IPU intervened in many other 
matters on a daily basis, including individual 
issues for members.  
The PCC is actively working with the HSE 
on members’ behalf. Progress can be slow 
and discussions take time. There are often 
difficult issues to resolve but, at all times, the 
PCC continues to pursue issues on behalf of 
members until, ultimately, a resolution is found.
Morgan Power,
Chairman, PCC
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The CPC is split into three sub-groups:
n	 Professional Development  
Steering Group 
Mary Barry, Louise Begley, Anna Kelly, 
John McLaughlin, Ultan Molloy,  
Sarah Magner, Niamh Murphy.
n	 Business Steering Group 
Roy Hogan, Daragh Connolly,  
Elizabeth Lang, Michael Tierney,  
Aidan Walsh. 
n IT Steering Group 
Stephen Nolan, Rory O’Donnell,  
Jack Shanahan. Sean Reilly (Executive) 
and Michael Walsh (PCC) have also  
been co-opted onto the ITSG.
CPC has met four times since the April 2012 
AGM (May, September, November 2012 and 
February 2013). In March 2012, the Committee 
met to agree on a strategy for 2012-2014. 
The objectives identified in the strategy are 
outlined below with a brief summary of activities 
undertaken to meet these objectives. 
Professional Issues
Promote the role of the pharmacist in 
Government and HSE strategy
We have had a number of meetings with the 
Department of Health in the past year to discuss 
a variety of issues such as reference pricing and 
generic substitution, medicines shortages, self-
care, switching and benzodiazepines. We have 
also met health spokespersons from all parties 
on a number of occasions to discuss similar 
issues. Submissions were made on Medicines 
Shortages and Unlicensed Medicines in January 
2013 and on Patient Discharge in January 2013. 
Work with DoH, IMB, IPHA, PGEU, EMA 
and patient groups to further improve 
accessibility of medicines through switches 
from POM to Pharmacist-only or by other 
appropriate means
The IPU and IPHA co-hosted the launch of a 
Self-Care Framework for Ireland in September 
2012. The Framework promotes the idea 
that patients should be encouraged to take 
responsibility for their own care, with assistance 
from healthcare professionals, and advocates 
that the range of medicines available to patients 
should be expanded through switching from 
prescription to non-prescription status. The 
IPU attended the AESGP conference in Dublin 
in Jan 2013 which focused on switching. The 
IMB set up a Consultation Panel to review the 
classification of medicines, following a public 
consultation in July 2011; the IPU presented to 
the Panel in Feb 2013.  
Develop a health screening role for 
pharmacists to incorporate training, 
standards for pharmacy service and 
funding options
The IPU joined forces with the Irish Heart 
Foundation to develop Cardiovascular Risk 
Assessment Training for Pharmacists. Two 
courses were delivered in Dublin in October 
2012, one in Cork in March 2013 and one in 
Dublin in April 2013. A health screening module 
on IPU NET was launched in January 2013 
to assist pharmacists in offering health check 
services. Guidelines and SOPs are available on 
the IPU website. Promotional materials were sent 
to pharmacies in March 2013. 
Pursue the implementation of Medicine Use 
Reviews in community pharmacy 
We used the opportunity in our submission 
to the Department, on the Health (Pricing 
and Supply of Medical Goods) Bill, to call for 
Medicine Use Reviews and a New Medicines 
Service to be introduced. The purpose of 
these initiatives is to improve compliance, 
reduce leakage to secondary care and reduce 
wastage of medicines. These services were also 
highlighted in a briefing note to Minister Alex 
White in March 2013.   
Extend the pharmacy vaccination service 
to include other vaccines and high tech 
injectables
Vaccination cohorts were extended in 2012/13 
to all at-risk groups. In September/October 2012, 
600 pharmacists attended refresher training and 
200 completed ab initio training. The number of 
pharmacies vaccinating in 2012/13 increased 
by 69% to 817 and the number of vaccinations 
doubled to 18,358. According to IPU NET 
statistics, 27% of people vaccinated in pharmacy 
had never been vaccinated before and 80% of 
those were in an at-risk group. 
Members were surveyed in Feb 2013 for 
feedback on the vaccination service. We met 
with the PSI in February 2013 to advocate for 
online refresher vaccination training, reduced 
number of Anapens and inclusion of pneumonia 
and Hepatitis B vaccinations. 
The IPU has met with a number of pharma 
companies to discuss developing a high tech 
injecting training service whereby pharmacists 
would train their patients in self-injecting high 
tech medicines. 
Assist members in dealing with PSI/
HSE/IMB/DoA inspections and Fitness to 
Practise issues
We have assisted a significant number of 
members in dealing with complaints made to 
the PSI or investigations instigated following PSI 
inspections and helped members prepare for 
FTP hearings and District Court appearances. 
The Inspections Checklist has been updated 
and we have developed a template to assist 
members in responding to their inspection 
report. A Self-Audit Tool on IPU NET was 
launched in Feb 2013. The IPU wrote to the PSI 
in February 2013 requesting that notice be given 
for inspections. We have also produced a range 
of SOP templates which members can download 
from the IPU website and personalise for their 
pharmacy. 
Community Pharmacy Committee 
(CPC) Report 2012-2013
The Community Pharmacy Committee (CPC) is chaired by Bernard Duggan with Daragh Connolly 
as Vice-Chairman. CPC’s mission statement is CPC – working to serve and support community 
pharmacists in their practices and to promote and expand their role as pharmacists by continually 
developing professional, ethical, business and technological ideals and standards.
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Lobby for amendments to the Pharmacy 
Act 2007
We have called for amendments to how FTP is 
processed in the Health (Pricing and Supply 
of Medical Goods) Bill and for removal of 
bankruptcy from registration requirements as 
part of the Personal Insolvency Bill. The IPU also 
wrote to the Minister for Health in October 2012 
requesting a reduction in PSI fees. 
Liaise with DoH and IMB on the 
transposition of EU Directives (Falsified 
Medicines, Pharmacovigilance, and 
Patients’ Rights) into Irish legislation
We made a detailed submission to the 
Department of Health on the legislation to 
transpose the Pharmacovigilance Directive. This 
legislation, which was passed in July 2012, 
clarifies the process for reporting ADRs to the 
IMB. We also made a submission in March 
2013 on legislation to transpose the Falsified 
Medicines Directive. 
Work with PSI on FIP 2013
Darragh O’Loughlin represents the IPU on the 
Local Host Committee for FIP 2013, which 
will be held in Dublin from 31 August to 5 
September next year. We hope to see many Irish 
pharmacists in attendance at this prestigious 
conference and indeed presenting on their work 
as community pharmacists.
CE/CPD
Develop an IPU CE/CPD platform, IPU 
Academy, to deliver CE to members and 
to assist them in self-monitoring of their 
CPD: online programmes/e-learning; 
distance learning/download; face-to-face 
(including on-line pre-learning). By June 
2012, develop two x e-learning courses 
(one to be EHC), two x distance learning 
courses and two x business courses
Following the dissolution of ICCPE at the end 
of 2012, IPU Academy was set up to deliver a 
Spring Programme. Six topics were delivered in 
87 venues around the country. The programme 
was a great success with record attendances and 
excellent feedback. 
We are now in the process of developing an 
online Learning Management System to support 
IPU Academy. Members were able to access 
a range of training courses at the 2012 IPU 
National Pharmacy Conference and feedback 
was excellent. In addition, we have had at least 
one CPD article in every edition of the IPU 
Review in 2012/13.     
Build relationships with Pharma, Schools 
of Pharmacy, Irish Institute of Pharmacy, 
patient groups, etc. to assist in the 
provision of CE/CPD
The IPU has collaborated with GSK and the 
Asthma Society in providing face-to-face inhaler 
technique training around the country. We are 
also working with Pfizer on a diabetes project, 
both North and South of the border, to produce 
research to be presented at FIP 2013. We 
collaborated with the Irish Heart Foundation to 
produce face-to-face training for pharmacists 
on Health Checks and this was delivered on 
two dates in Dublin in October 2012, once 
in Cork in March 2013 and one more time in 
Dublin in April 2013. The IPU is now liaising with 
UCC to produce evidence-based studies using 
information from IPU NET which we intend to 
present at FIP 2013.   
IT Issues
Maintain the IPU Product File as the 
number one file on the Irish market; 
Progress with updating the IPU Product 
File to facilitate reference pricing and 
generic substitution; Protect the security 
of the IPU Product File; Progress with links 
to the IMB website to facilitate access to 
SPCs and PILs; Scope out an alternative 
source for a Drug Interactions File for the 
IPU Product File
We are in the process of implementing a number 
of developments to the IPU Product File so that 
it continues to meet the needs of members 
and other users and, in particular, to facilitate 
reference pricing and generic substitution. Live 
download of the IPU Product File has now been 
implemented and new BNF warnings have been 
incorporated. The IPU Product File will soon have 
direct links to the IMB website to facilitate access 
to SPCs and PILs. We will continue to make 
members aware that the IPU Product File is 
prepared by pharmacists for pharmacists with no 
other objective than to facilitate the operation of 
their business and it is part of the IPU members’ 
offering. 
Work with DoH/PCRS on the roll out of 
reference pricing and generic substitution
We had a number of meetings with the 
Department in this regard and made a detailed 
submission, proposing amendments to the 
legislation. We also had a number of meetings 
with DoH, PCRS, IMB, and system vendors to 
discuss the implementation of reference pricing 
and generic substitution. A number of letters 
were written to DoH and PCRS, outlining our 
concerns. The IPU also met with the vendors to 
go through the changes that have been made to 
the IPU Product File to facilitate reference pricing 
and generic substitution.   
Work with HIQA on the eHealth Standards 
Advisory Group (eSAG) to develop eHealth 
Interoperability Standards
Jack Shanahan, Chairman of the IT Steering 
Group, represents the IPU on this prestigious 
advisory group. One main objective of the group 
is to facilitate implementation of electronic 
prescriptions. Jack will speak on this topic at the 
IPU National Pharmacy Conference 2013. 
Work with wholesalers and vendors to test 
and roll out the Pharmacy Broadband 
Ordering System
We are working with the dispensary system 
vendors and frontline wholesalers to develop 
a broadband-based ordering system for 
pharmacies. The specification has been written 
and the system developed and tested. Pilot 
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Community Pharmacy Committee  
(CPC) Report 2012-2013
(continued)
testing commenced in March 2013 and it is 
intended to have a full roll-out by end 2013.  
Liaise with IPHA on medicines 
authentication for Ireland, UK and Malta as 
part of the Falsified Medicines Directive
The Falsified Medicines Directive lays out 
the principles for an EU-wide medicines 
authentication system, to prevent counterfeit 
medicines entering the supply chain. We are 
working with IPHA and our colleagues in the 
UK to develop a regional hub to facilitate 
authentication in Irish and UK pharmacies. 
The system must be implemented by 2017 but 
significant work will be required between now 
and then.     
Work with the Business Steering Group  
to facilitate members in setting up their 
own websites
The IPU and Pfizer have joined forces to 
provide a tool to assist members in setting 
up a pharmacy website. Further information 
on Mylocalpharmacy.ie can be found in the 
business section of our website.  
IPU NET
IPU NET was launched at our National 
Conference in 2012. We now have modules in 
place for EHC, vaccination, diabetes, asthma, 
health screening and self-audit. 558 pharmacies 
and 644 pharmacists were registered on IPU 
NET by March 2013.  
Data collected on EHC shows that 86% of 
EHC consultations take place within 24 hours 
of unprotected sexual intercourse (UPSI), with 
39% taking place within 12 hours of UPSI. 
Women aged 18 to 24 account for 40% of the 
consultations and women aged 25 to 30 account 
for a further 24% of consultations. 60% of 
women indicated that they were not using any 
form of contraception at time of consultation. 
Of those who were using contraception, barrier 
contraception was used by 60% of women with 
38% using oral contraception. 19% of women 
accessing EHC through community pharmacy 
possessed a medical card, entitling them to free 
GP care and prescription medicines.
Data collected on vaccination showed that 
27% of people vaccinated in pharmacy in 
2012/13 had never been vaccinated before and 
80% of those were in an at-risk group.
Develop a roadmap for dispensary 
system development of all systems, led 
by a Steering Group of users of all three 
dispensary systems
The IPU now has a minority shareholding in 
Touchstore. The purpose of this venture is to 
influence development of dispensary IT systems, 
which has fallen behind other jurisdictions in 
recent years. We will be working on this area 
over the coming months. Our hope is that all 
vendors will provide the best possible system at 
a reasonable price. 
Business Issues
The Business Steering Group has met three 
times since the April 2012 AGM to discuss a 
range of issues that would assist members in 
running their businesses.
Business Policy – provide input into 
national policies affecting small businesses 
through Chambers Ireland, National Retail 
Industry Alliance and National Consumer 
Agency, e.g. rates, rent reviews, retail 
planning, budgets
Through our membership of Chambers Ireland 
and National Retail Industry Alliance we have 
pushed for changes with regard to rates and rent 
reviews. Roy Hogan, Chairperson of the CPC 
Business Steering Group, is the IPU nominated 
member on the Chambers Ireland Ratepayers 
and Local Government Policy Council. 
We also prepared a report on Planning 
Implications for Retail Pharmacy Businesses 
which was sent to the Minister for the 
Environment and all the local council planning 
departments, outlining our concerns and 
recommendations for changes to the Retail 
Planning Guidelines regarding out of town 
developments. As a consequence, pharmacies 
in out of town developments are discouraged in 
planning guidelines. 
We are also involved in the National Strategic 
Retail Forum with An Garda Síochána and other 
retailers. This Forum is working to ensure that 
a Crime Prevention and Reduction approach is 
adopted in dealing with the issue of shoplifting. 
It also recognises the need to foster and sustain, 
at a Strategic level, positive communication 
channels between An Garda Síochána and the 
retail community. 
We wrote to the Minister of Small Business 
to outline the regulatory burdens affecting the 
pharmacy sector. There has been positive noise 
coming from the Department with regard to 
changes in this area.
We also met with the RSA to discuss the 
proposed changes to the new driving licence. 
This issue is on-going. 
We have also introduced a quarterly business 
trends survey to monitor members’ views 
and experiences from a business perspective. 
We have issued a number of press releases 
identifying business issues including the impact 
on pharmacy from reduced sales and the cost of 
commercial rates
Business Training – progress with 
Strategies for Growth and Sales & 
Merchandising training and provide online 
training though IPU Academy
Strategies for Growth Business Training 
sessions have been a big success with members. 
Training sessions will be held again in 2013. 
Sales & Merchandising training will be rolled 
out to members in late 2013 with distance 
learning and classroom style sessions. We 
launched a new fully accredited ILM Diploma in 
Leadership & Management Training Programme 
for members in February 2013. This training 
programme will help to develop a wide range 
of fundamental management skills by assisting 
students in gaining the comprehensive 
knowledge required by a first-line manager or 
supervisor.
IPU Review Articles – produce a series of 
relevant business articles for members 
Over the course of the last year, there have 
been many business articles in the IPU Review; 
articles on areas such as merchandising, 
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security, planning, customer service, tax and 
business regulations have been provided to help 
members in their business.
Business Briefings – identify topics 
for evening briefings to take place in 
Butterfield House
Briefing sessions were held at the Regional 
Meetings during October 2012. Members who 
attended were briefed on the new IPU VAT 
Scheme, the new IPU Member Assistance 
Programme (MAP), Day 1 Income Protection and 
How to deal with Planning issues.
VAT Roadshow – hold roadshows around 
the country to explain the new IPU VAT 
Scheme to members
The new IPU VAT Scheme received Revenue 
approval with effect from 1 September 2012. The 
VAT Review Group, along with Baker Tilly Ryan 
Glennon, prepared a short presentation on the 
new scheme which was delivered at the Regional 
meetings. 
ECommerce – work with ITSG to provide 
ecommerce opportunities for members
The IPU, working in conjunction with Pfizer, has 
developed a website development tool to assist 
members in setting up their own websites. Over 
200 pharmacies now use this tool. The IPU 
also launched our own IPU online stationery 
store. Members now have direct access to 
purchase pharmacy stationery consumables and 
marketing material for their pharmacy via the 
IPU website.
Business Review Consultancy – continue to 
promote consultancy through IPU Review, 
eNewsletter and at IPU Conference
Business Review Consultancy was developed by 
the Business Steering Group to assist members 
in getting the most from their front of pharmacy. 
Darren Kelly, Business Development Manager, 
will go to their pharmacy and give them one day 
of his time and expertise for a small fee. Over 
thirty pharmacies have availed of this service to 
date and the feedback has been excellent. 
Review of Pharmacy Sector – assist 
members in benchmarking their businesses 
using reports from dispensary systems, 
EPOS and PwC reports
As part of the Annual Review, we developed 
a dashboard that members who participated 
in the Review would receive. This dashboard 
will help members benchmark their business 
against businesses of a similar turnover. The 
final report of the Annual Review was released 
in December 2012
Bernard Duggan,
Chairman, CPC
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The EPC has met four times since the 2012 
AGM (May, September and November 2012 and 
March 2013). The EPC continues to have active 
representation on other IPU Committees, with 
an allocation of three employee representatives 
on the Executive Committee and four 
representatives on the Community Pharmacy 
Committee. This representation guarantees 
that the views of employee pharmacists are 
voiced and heard on the other Committees of 
the IPU, therefore empowering employee input 
into decisions and in the development and 
implementation of IPU policies. 
Communications
The EPC has continued to communicate through 
publishing articles in the IPU Review Magazine 
which have covered topics such as Make 
Yours an Interview-Winning CV, Dispensing an 
Extemporaneous Prescription, Diary of a Tutor 
Pharmacist, Part 1, 2 and 3 and Countdown 
to Christmas. The EPC believe that in these 
challenging times in the community pharmacy 
sector, employee members must be provided 
with information on up-to-date issues. The 
Committee is currently preparing an article 
highlighting some of the issues where specialised 
assistance was provided by the IPU, over the last 
year, when committee members encountered a 
problem they could not resolve on their own. 
The EPC also publishes a column in the IPU 
Review reporting on each EPC meeting, while the 
regional representatives email a meeting update 
to employee members in their region.
The EPC continues to encourage fourth year 
students and pharmacy interns to become 
involved with the IPU. To date, 122 fourth year 
students and pharmacy interns are in receipt of 
the IPU weekly employee e-newsletter. 
Events
The EPC hosted an Employee Seminar in Cork 
on 13 November 2012 in the Silversprings Moran 
Hotel, Cork, organised by Caitriona O’Riordan 
and Sarah Magner. This Seminar was open 
to all pharmacists and trainee pharmacists. 
The total attendance was 74, consisting of 26 
members (three proprietor pharmacists and 
23 employee pharmacists), 30 non-member 
pharmacists, three pharmacy interns and 15 4th 
year students. The Seminar focussed on Wound 
Management, tailored specifically to pharmacy, 
delivered by Clinical Educators as well as a brief 
outline of the ‘Benefits of IPU Membership’. 
Increase and Retain IPU Membership 
Throughout the year the EPC endeavoured 
to encourage non-members to sign up to IPU 
Membership. The Membership Secretary wrote 
to all pharmacists who didn’t avail of the free 
introductory year and to all pharmacists working 
for a group where the group was no longer 
affiliated to the IPU.
The EPC has requested that the Executive 
Committee investigate the possibility of employee 
members paying their annual subscription by 
direct debit in instalments.  
Representation & Services
The EPC will continue to pursue its objectives 
with intent and to actively represent the interests 
of employee members. It will also ensure that 
the IPU continues to provide services and 
assistance to employee members within the 
community pharmacy sector. The coming years 
will be taxing for all in community pharmacy. 
It is vital, now, more than ever, that employee 
pharmacists have a representative body which 
supports on their behalf. The EPC will continue 
to be this body and it urges the involvement of 
more employees on both a regional and national 
platform within the IPU in order to reinforce the 
resolve of employee pharmacists both in the IPU 
and throughout the profession.
Conclusion
The EPC urges employee members to use their 
membership to the full and keep themselves 
well-versed by reading the e-newsletter, General 
Memoranda, IPU Review magazine and other 
information presented by the Union. In June 
2010 all IPU Members were assigned with an  
@ipumail.ie email account, the EPC would 
advise employee members who have not 
activated their account to do so without delay. 
The EPC would also recommend that employee 
members check the ‘Employee Pharmacists’ 
section of www.ipu.ie on a regular basis. 
I would like to thank all the members of the 
EPC for all their work over the last year and the 
staff of the IPU, in particular Seamus, Roisin, 
Pamela, Jill and Darren for their support and 
advice on all matters. I would in particular 
like to thank the Secretary to the EPC, Susan 
McManus, for her hard work and dedication to 
the EPC and the President, Rory O’Donnell, for 
his direction and assistance throughout the year.
Caitriona O’Riordan,
Chairperson, EPC
Employee Pharmacists’ Committee 
(EPC) Report 2012-2013
The Employee Pharmacists’ Committee (EPC) represents the interests of community pharmacy 
employee members of the Irish Pharmacy Union. The Committee is chaired by Caitriona 
O’Riordan with Sarah Magner as Vice-Chairperson. The mission statement of the EPC is:  
“To promote the professional and economic interests of employee pharmacists and  
constructively engage with other Committees of the Union and other stakeholders through  
the Employee Pharmacists’ Committee.” Currently there are 1,069 community employee 
members of the IPU, which comprise 54% of the full membership. 
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The Communications Team consists of Jim 
Curran, Aoibheann Ní Shúilleabháin, Wendy 
McGlashan and external advisors, who all invest 
a great deal of time, effort and resources in 
working with the media to brief journalists on 
issues affecting community pharmacy. 
Media Relations
There has been a substantial amount of media 
coverage since the last AGM. Regular press 
releases are issued by the IPU, promoting 
the role of pharmacists and raising concerns 
affecting community pharmacists. We receive 
regular coverage in the national media, including 
RTE One’s Six-One News and Nine News, as 
well as current affairs programmes such as 
Drivetime, The Last Word and The Right Hook. 
Many of these are available to watch on the 
IPU YouTube Channel, showing the strength 
of spokespersons representing the IPU. The 
national newspapers also carry regular articles 
and interviews with IPU representatives.
Some of the key issues that arose during the 
last year were:
n	 Pharmacists respond to harsh  
measures announced in Budget 2013  
5 December 2012
n	 IPU Pre-Budget Submission 2013  
1 November 2012
n	 Pharmacist’s Advice – there were many 
press releases issued over the past year 
with pharmacists offering advice on a 
range of issues. Pharmacists were in the 
media advising students on how to protect 
against stress at exam time, the “dos” 
and “don’ts” of giving medicine to young 
children, the dangers of getting healthcare 
advice online, antibiotic awareness, tips 
for fighting colds and flu, and much more.
n	 Pharmacy Business – in the last year, 
press releases have been issued with a 
focus on the pharmacy business. With 
the support of statistics from surveys 
of members, the IPU highlights key 
challenges that were affecting pharmacies, 
including dropping sales. Press releases 
also called for cuts in commercial rates 
and highlighted the extent and impact of 
crime on pharmacies.
n	 Advocating for Patients – the IPU issues 
press releases advocating on behalf 
of patients of pharmacies. It was the 
IPU who highlighted to the public and 
media that the HSE were withdrawing 
Gluten-Free products from State Schemes 
in September. We also welcomed the 
reduction in the price of medicines. 
Following the announcement of the 
Budget and increase in the Prescription 
Levy, the IPU renewed its call to exempt 
certain patient cohorts from the levy.
A list of all the press releases issued is 
available on page 58.
IPU Spokespersons do great work throughout 
the year in taking time out from their pharmacies 
to be interviewed and brief journalists. Media 
Training took place last September for a number 
of new regional spokespersons.
Advertising Campaign –  
‘Ask Your Pharmacist First’
The IPU continues to promote the ‘Ask Your 
Pharmacist First’ message with national radio 
and poster ad campaigns. In July 2012, a poster 
ad campaign ran throughout pharmacies to 
explain to patients what pharmacists do with 
the prescriptions they receive. In October 2012, 
a radio advertising campaign was launched 
to promote the Vaccination Service through 
pharmacies. 73% of adults 65+ (390,000 people) 
heard the vaccination ad once or more, with the 
average adult 65+ hearing it 7.6 times. 68% of 
adults 25-44 (983,000 people) heard the ad 
once or more, hearing it 6.5 times on average.
A further radio ad campaign ran in December, 
promoting the retail side of pharmacy in the run-
up to Christmas. 75% of adults 65+ (400,685) 
heard the ad one or more times, with the average 
adult 65+ having 10.7 opportunities to hear the 
ad. 939,632 of adults 25-44 (65% of audience) 
also heard it once or more, with the average adult 
25-44 having 6.6 opportunities to hear the ad.
The radio ads were broadcast on RTE Radio 
One, Today FM, 2FM and Newstalk, supported 
by key regional stations including 4FM. Members 
were sent posters to complement the radio ads 
and reinforce the message visually.  
Communications to Members
Communications to members continue to develop 
and uptake continues to increase. Usage of the 
IPU website is growing, as well as time spent 
on the website. The IPU Review and monthly 
General Memorandum are vital resources of 
information for members. The open rate of IPU 
News, the weekly e-newsletter, is also increasing 
with more members accessing their IPUMail 
regularly. Following on from the launch of the 
IPU Facebook page in December 2011, a Twitter 
account was launched in September 2012. Social 
media is another tool for communicating with 
both members and the public, and numbers of 
followers to our pages are growing each week. The 
SMS Service is another communications tool to 
get information to members quickly on important 
updates and deadlines. The On Your Side and By 
Your Side booklet was sent to all members again 
for 2013, which highlights the benefits of being an 
IPU Member as well as details of all the support 
and services that the IPU provides.
Political Engagement
A delegation from the IPU met with the Minister 
of State for Health with Responsibility for Primary 
Care, Alex White, T.D. in March 2013, to outline 
concerns around FEMPI; Reference Pricing and 
Generic Substitution Legislation; PSI fees and 
Bankruptcy and PSI Registration. The delegation 
informed the Minister of the potential role of 
proposed new pharmacy services as part of the 
Government’s healthcare strategy. Meetings have 
been held with Opposition spokespersons on 
Health with regard to legislation on Reference 
Pricing and Generic Substitution and other 
issues of concern to the profession. An IPU 
delegation addressed the Joint Committee on 
Jobs, Enterprise and Innovation and Taoiseach 
Enda Kenny, T.D.
Communications Report
The Communications Team have an important role in communicating key messages to the media, 
the public, stakeholders and members. A wide range of communications tools are used to keep 
members up-to-date on ongoing and urgent issues. Press releases are issued regularly, promoting 
the role of the pharmacist and highlighting issues of concerns to pharmacists to the media. 
Communications with the public is strengthened with advertising campaigns throughout the year. 
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1. PGEU Report 
The Pharmaceutical Group of the European 
Union (PGEU) is the European association 
representing community pharmacists in 32 
European countries including EU Member States, 
EEA countries and EU applicant countries. 
Overall, PGEU represents over 400,000 
community pharmacists in Europe through 
their professional bodies and pharmacists’ 
associations. PGEU’s objective is to promote the 
role of pharmacists as key players in healthcare 
systems throughout Europe and to ensure that 
the views of the pharmacy profession are taken 
into account in the EU decision-making process. 
The IPU is represented at PGEU by Darragh 
O’Loughlin, Head of Delegation, Pamela Logan, 
Director of Pharmacy Services, and Jill Lyons, 
PCRS Contract Manager. The IPU has been very 
active within PGEU over the past year, ensuring 
that community pharmacy is considered in a 
wide variety of EU Directives. 70% of legislation 
in Ireland comes from EU Directives so it is vital 
that lobbying is done at this level rather than 
waiting for transposition into Irish legislation. 
Directives and Dossiers
PGEU actively worked on a range of Directives 
and Dossiers throughout 2012/13:
n	 Falsified Medicines – the creation of a 
system of authentication of medicines at 
pharmacy level and the regulation of the 
sale of medicines through the internet;
n	 Data Protection Legislation – to establish 
the conditions to access and process 
health records;
n	 Transparency Directive – related to the 
timing of pricing and reimbursement 
decisions; 
n	 Good Distribution Practice Guidelines  
– to ensure a harmonised level of quality 
of medicines is maintained throughout 
the supply chain; and
n	 Professional Recognition – a revised 
system of recognition of the professional 
qualifications of pharmacists from other 
Member States.
Medicines Authentication/Falsified 
Medicines Directive
PGEU, EFPIA (manufacturers), GIRP 
(wholesalers) and EAEPC (parallel 
distributors), among others, have collaborated 
on a stakeholder approach to medicines 
authentication – the European Stakeholder 
Model (ESM). These stakeholders will met with 
the Heads of EU Medicines Agencies in Dublin 
on 23 April 2013 (under the Irish Presidency) to 
further explain the proposal. Darragh O’Loughlin 
represented PGEU at this meeting.
The European Commission has undertaken 
an economic impact assessment of medicines 
authentication to make sure that unnecessary 
costs are not being imposed by the Directive. The 
draft report supports the ESM model as being 
the most economic and efficient. Other findings 
in the draft report are:
n	 Medicines authentication may require 
some national authority supervision;
n	 The cost to pharma should be less than 
1% of their profits;
n	 Community pharmacies will need to 
spend around €100/pharmacy for 
technical adaptation and €250/scanner;
n	 Medicines authentication should occur at 
point of dispensing in pharmacies;
n	 Wholesalers should only have to do 
random authorisation.
It is not clear yet what assumptions have been 
made about generics. The report assumes that 
community pharmacies have a net profit margin 
of 8%. The final report should be published in a 
few months. 
PGEU has commissioned an IT consultant to 
look at the costs of medicines authentication 
from a community pharmacist’s perspective.  
He will:
a. Conduct a survey of dispensary software 
in the EU;
b. Speak to software providers about the 
technical requirements for medicines 
authentication; and
c. Outline the costs and challenges for 
community pharmacists in implementing 
medicines authentication. 
The ESM has selected a service provider to 
produce the EU hub and ‘off-the-shelf’ regional 
hubs. The system will be cloud-based and linked 
to Microsoft Azure. The intellectual property will 
belong to the European Medicines Verification 
Organisation (EMVO), the non-profit organisation 
set up under the ESM, with PGEU as one of 
the seven founding stakeholders. Work will 
commence on the EU hub now but we will wait 
for the Delegated Acts to publish the safety 
features – expected late 2013 – before the 
regional hubs are developed. Costs are currently 
estimated at 0.5€cent/pack, considerably 
less than first estimated. Once the Delegated 
Acts have published, Member States will have 
three years within which to introduce medicines 
authentication, probably by 2017.
A potential unforeseen side-effect of the 
Directive is the requirement that, from January 
2013, all active pharmaceutical ingredients 
(APIs) imported from outside the EU will 
need written confirmation from the exporting 
country’s competent authority that the API was 
produced in accordance with applicable GMP 
(Good Manufacturing Practice) standards. 
India and China have been slow to comply with 
this; consequently, this could lead to increased 
shortages of medicinal products. 
Proposal on Data Protection Legislation
In 2012, the Commission started a revision of 
the data protection legislation. Health data is for 
the first time defined and specifically regulated. 
This regulation will establish the conditions to 
access and process health records, whether 
they are automated or not. It will also regulate 
data stored for reimbursement purposes or 
pharmacovigilance-related data.
The legislation proposes that health data can 
only be processed under a specific law and for 
specific purposes. In addition, such a law must 
comply with the requirements established in the 
regulation.  Some of the requirements include:
International Pharmacy Matters
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In relation to the data subject:
n	 Explicit consent in writing;
n	 Provide information on the processing;
n	 Access to data (free of charge);
n	 Right to rectification, right to be forgotten 
and erased (data needs to be erased if 
this is requested by the data subject);
n	 Right to data portability; and 
n	 Communication of a personal breach to 
the data subject (within 24 hours).
In relation to the data processing: 
n	 Keep  appropriate documentation; 
n	 Implement data security requirements;
n	 Prior authorisation and probably an 
impact assessment;
n	 Co-operate with the supervisory authority;
n	 A designated Data Protection Officer if 
data on >500 people is kept.
The proposal for a Data Protection Officer has 
been condemned by small businesses and is 
unlikely to be adopted at the LIBE Committee. 
PGEU is concerned about the explicit consent 
required for data processing – this could cause 
problems for reimbursement. There is also 
ambiguity in the Proposal about ‘public interest’ 
therefore PGEU is proposing that pharmacy data 
should be covered by ‘public interest’. PGEU is 
concerned about the Delegated Acts process as 
it is not transparent and there is no consultation. 
It would be preferable if the Delegated Acts were 
watered down and left to national authorities. 
Transparency Directive
The existing Directive related to the timing of 
pricing and reimbursement decisions. The 
revised Directive proposes: 
n	 Coordination of Health Technology 
Assessments (HTAs);
n	 Reduced timescales for reimbursement 
decisions – 60 days for patented and 30 
days for generics; and
n	 Increased enforcement for non-
compliance, especially in relation to 
generics.
Good Distribution Practice (GDP) 
Guidelines
The GDP Guidelines ensure that a harmonised 
level of quality of medicines is maintained 
throughout the distribution chain in the EU. 
The GDP Guidelines are being revised to take 
into account new requirements for wholesale 
distributors and brokers established in the 
Falsified Medicines Directive. PGEU’s main 
concern was the original proposal of a period 
of five days for returns from pharmacies of 
medicines to wholesalers. We understand that 
this is now likely to say that medicines can be 
returned by pharmacies to wholesalers ‘within  
an acceptable time limit, for example 15 days’. 
Directive on the Recognition of  
Professional Qualifications
This Directive establishes the conditions for 
the recognition of titles and qualifications 
of professionals within EU Member States. 
Pharmacists and five other professions (doctors, 
nurses, vets, midwife and architects) are 
automatically recognised without the need to 
undertake further ‘compensation measures’, 
i.e. additional training or experience. In 2011, 
the Commission launched a revision in order 
to modernise the Directive. The Commission 
proposed significant changes to the recognition 
regime, including new proposals on the 
provisions regulating the pharmacist’s  
course of study.
PGEU proposed an extension to the list of 
pharmacists’ activities in order to ensure that 
current pharmacy practice is reflected in the 
Directive. The PGEU proposed list included:
n	 sourcing, preparation, testing, storage and 
dispensing of safe and secure medicinal 
products in pharmacies open to the 
public;
n	 medicines management and provision 
of information and advice on medicinal 
products and health related issues;
n	 supporting individual patients in the use 
of non-prescription medicines and self-
care; and
n	 contributing to public health campaigns.
All of these amendments have been carried 
in Parliament. Now the Council needs to 
support these amendments. Parliament has 
also proposed that CPD should be made 
mandatory and that bodies that oversee CPD 
should be assessed for quality. There is also a 
concern that the Directive is being used to define 
post-graduate specialisations; this was not the 
intention of the original Directive. It is not clear if 
the Council will support these latest proposals.
2. Report on FIP Congress, 
Amsterdam
The International Pharmaceutical Federation 
(FIP) together with the Royal Dutch Pharmacists’ 
Association (KNMP) hosted the Centennial World 
Congress of Pharmacy and Pharmaceutical 
Sciences on 3-8 October 2012 in Amsterdam. 
Her Royal Highness, Princess Margriet of the 
Netherlands, was on hand at the Opening 
Ceremony to release the FIP Centennial 
Declaration and welcome over 5000 participants 
to Amsterdam for the centennial celebration and 
coinciding Roundtables and Ministers’ Summit.
During the Congress, FIP took its place at the 
table among Ministers of Health from around 
Europe at the Summit on Increasing Responsible 
Use of Medicines - setting policies for better and 
cost-effective healthcare. FIP urged pharmacists 
to bring forth proposals and take action in 
increasing the role of pharmacists in healthcare 
delivery. Such measures could contribute to 
decreasing healthcare costs by billions, as 
outlined in a recently released report from the 
IMS Institute. FIP President, Michel Buchmann, 
also encouraged pharmacists and physicians 
to work together and utilise both professions 
to their fullest potential.  Such collaboration 
is an imperative step in the goal of increasing 
responsible use of medicines and realising 
optimal benefits for patients.
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International Pharmacy Matters
(continued)
Through its 127 member organisations and 
4000 individual members, FIP represents and 
serves almost three million pharmacists and 
pharmaceutical scientists around the world. 
The FIP President greeted the audience of 
almost 5000 pharmacists, pharmaceutical 
scientists, academics, researchers, students 
and guests who had come together for a week 
of pre-satellite symposia, workshops, lectures 
and meetings focused on this year’s Congress 
theme – Improving health through responsible 
medicines use.
Mr Buchmann urged pharmacists to take 
action in five vital areas: transforming education 
to support the provision of new roles; developing 
inter-professional collaboration; demonstrating 
added value; helping patients to adhere to their 
treatments; and engaging in policy making.
Mr Buchmann went on to say “It is imperative 
for the advancement of all sectors that we are 
able to work based on our true value and the 
contributions we make. Pharmacists’ added 
value must be recognised by governments 
because of our role in public health and patient 
safety – the benefits we bring to patients.” 
FIP Centennial Declaration
IPU President, Rory O’Donnell, joined leaders of 
other FIP member organisations in signing the 
FIP Centennial Declaration – Improving Global 
Health by Closing Gaps in the Development, 
Distribution and Responsible Use of Medicines. 
Among the commitments made in the 
declaration are:
n	 To work with all sectors of society to foster 
development and worldwide access to 
medicines
n	 To fight for the elimination of sub-
standard and counterfeit medicines
n	 To encourage pharmacists to expand their 
role in helping patients adhere to their 
medication regimes
n	 To expand public awareness that more 
positive health outcomes and important 
cost savings result when patients, 
physicians and pharmacists collaborate 
in selecting, monitoring and adjusting 
medication therapy.  
The 73rd World Congress of Pharmacy and 
Pharmaceutical Sciences 2011 will take place 
in Dublin from 31 August to 5 September 
2013. The theme of the conference will 
be “Towards a Future Vision for Complex 
Patients”. Pharmacists are encouraged to 
attend this exciting conference to meet and 
share experiences with pharmacy colleagues 
from all over the world. 
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2013 AGM Motions 
The following motions, proposed in accordance with Article 30 of the IPU Constitution,  
are brought before the meeting for consideration:
1. Proposed: Rory O’Donnell
 Seconded: Kathy Maher
 “That this AGM appoints ?? to be a Trustee of 
the Irish Pharmacy Union in accordance with 
Article 25 of the IPU’s Constitution.”
 [Name will be announced at the AGM.]
2. Proposed: Bernard Duggan
 Seconded: Daragh Connolly
 “That this AGM calls on the Department of 
Health to utilise the enormous potential of 
community pharmacies by expanding the 
role of the pharmacist so that more services 
are offered to patients through community 
pharmacies, which will benefit patients and 
help Government deliver on its Future Health 
Strategy and Healthy Ireland Framework.”
3. Proposed: Roy Hogan
 Seconded: Michael Tierney
 “That this AGM calls upon the Minister 
for Health to delete Section 14 (1) (f) of 
the Pharmacy Act 2007 which prohibits 
pharmacists who become bankrupt from 
registering with the Pharmaceutical Society  
of Ireland.”
4. Proposed: Brian Walsh
 Seconded: Fergus Brennan
 “That in light of recent decisions made by 
the HSE, this AGM calls on the Minister for 
Health to ensure that patient care remains 
of paramount importance and that decisions 
made by the Minister and the HSE do 
not adversely impact on patient care or 
undermine the capacity of the profession 
to play its part in the healthcare reform 
agenda.”
5. Proposed: Jack Shanahan
 Seconded: Sean Reilly
 “That this AGM calls on the Department of 
Health to meaningfully engage with the IPU 
to help deliver a standards-based electronic 
prescription transfer system that will promote 
patient safety.”
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The following submissions were made during the 
year. All are available on www.ipu.ie.
2012 
n	 FEMPI Review 5  
– DoH – May 2012
n	 Pharmacovigilance Regulations  
– DoH – July 2012
n	 Rapid Discharge Planning  
– HSE – Sep 2012
n	 National Integrated Care Guidance  
– HSE – Sep 2012
n	 Pre-Budget 2013 Submission  
– Departments of Finance &  
Public Reform – Oct 2012
2013
n	 FEMPI Review  
– DoH – Jan 2013
n	 Medicines Shortages and ULMs 
Consultation  
– DoH – Jan 2013
n	 Standardising Patient Discharge  
Summary Information  
– HIQA – Jan 2013
n	 Alex White Briefing  
– Mar 2013
n	 Falsified Medicines Regulations  
– DoH – Mar 2013
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Topics
n	 FEMPI
n	 Financial Emergency Measures in the 
Public Interest Act 2009 (FEMPI)
n	 Reference Pricing 
n	 Reductions in the Cost of Medicines
n	 PSI Matters
n	 Primary Care Centres
n	 Pharmacy Vaccination Service
n	 Benzodiazepines
n	 PCRS Communications
n	 Extemporaneous Preparations
n	 Pradaxa
n	 ICCPE / Pharmacy Training Grant / 
Continuing Education
n	 Driving Licence Photographs
n	 Other Matters
• Bankruptcy
• Switching
• Directive on Recognition of  
Professional Qualifications
• High Tech Medicines
• National Consumer Agency  
(NCA) Survey
FEMPI
FEMPI – Letter 1
From HSE Contract Manager to  
Assistant Secretary General, DoH
[14 May 2012]
Re: Financial Emergency Measures in the 
Public Interest Act 2009
I wish to acknowledge your letter of 10 May to 
Seamus Feely in relation to the Minister’s Review 
under the Financial Emergency Measures in the 
Public Interest Act 2009. 
I wish to confirm that the IPU will be making 
a submission to the Minister’s Review. We would 
also welcome an opportunity to make an oral 
submission to the Department on Tuesday 5 
June, if that date is available.
FEMPI – Letter 2
From Secretary General to  
Minister for Health
[14 December 2012]
Re: Review under the Financial Emergency 
Measures in the Public Interest Act, 2009 
We refer to a letter we received from Mr Paul 
Barron, Assistant Secretary of the Department of 
Health dated 13 December 2012, stating that on 
Budget day the Government had announced a 
review of the fees/allowances payable to health 
professionals, with an overall target figure of 
€70 million in savings to be achieved in 2013.
The letter indicates that you, in accordance 
with Section 9 of the Financial Emergency 
Measures in the Public Interest Act, 2009, have 
determined that a full review of payments to a 
number of professionals, including pharmacists, 
be carried out.  The letter sets out the timeline 
for the consultation process, and the fact that 
the review shall include, but not be confined 
to, payments under the Health Professionals 
(Reduction of Payments to Community Pharmacy 
Contractors) Regulations 2011.  It then invites 
the Irish Pharmacy Union to provide a written 
submission to assist in your deliberations on the 
matter. It also indicates that the Irish Pharmacy 
Union may make an oral submission, if it so 
wishes.
We wish to seek your assurances that the 
outcome of the review in relation to which Mr 
Barron wrote, has not been predetermined 
or prejudiced in light of the comments of the 
Minister for Public Expenditure and Reform,  
Mr Brendan Howlin, T.D., in his Address to  
Dáil Éireann on Expenditure Estimates 2013,  
on Wednesday, 5 December, 2012.
In particular, the Minister for Public 
Expenditure and Reform’s comments: 
“Professional fees for health service providers 
such as GPs and community pharmacists will be 
reduced to save €70 million.” cause significant 
concern.  It seems that community pharmacists 
are being ‘singled out’ as one of those groups 
likely to be subject to reduced payments, prior to 
receipt by you of any submissions. It also seems 
that a set reduction in fees of €70 million has 
already been determined. 
As you are aware, Section 9 (4) of the 
Financial Emergency Measures in the Public 
Interest Act, 2009, provides that prior to making 
a Regulation to reduce the amount or the rate 
of payment to be made to health professionals, 
or classes of health professionals, in respect 
of any services that they render to or on behalf 
of a health body, the Minister for Health and 
Children, or, at the Minister’s direction, the 
health body concerned, “shall engage in 
such consultations as that Minister considers 
appropriate”.  Section 9 (5) provides that such 
a Regulation shall fix amounts or rates that the 
Minister for Health and Children considers to be 
fair and reasonable, having regard to the matters 
which that Minister considers appropriate, 
including any or all of a number of factors. 
Those factors include “any submissions made 
and views expressed during the consultations…”.
The correspondence from Mr Barron 
inviting the Irish Pharmacy Union to provide a 
written and oral submission to assist in your 
deliberations on the matter, clearly indicates that 
you consider the written and oral submission 
of the Irish Pharmacy Union as an appropriate 
matter to which to have regard, in deciding 
fair and reasonable amounts or rates.  We are 
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therefore surprised by the Minister for Public 
Expenditure and Reform’s comments.  
Naturally, if the amounts or rates have already 
been decided, a request for written submissions 
would appear to be a pointless exercise, causing 
unnecessary expense and incurrence of time 
spent preparing written and oral submissions.  
More seriously, if those are in fact the 
circumstances, they would be indicative of a 
failure to follow the provisions of the Financial 
Emergency Measures in the Public Interest Act, 
2009.  This would clearly give rise to a claim that 
there has been an abuse of process, providing 
grounds to judicially challenge the outcome of 
the review/consultations.
We would be grateful if you would please 
clarify the statement made by the Minister 
for Public Expenditure and Reform, on 5th 
December 2012.  
We would also seek your assurances that 
no set reduction in relation to pay or rates to 
pharmacists has been determined prior to the 
conclusion of the review/consultations.
In the meantime, it is our intention as of now 
to make both a written submission and an oral 
presentation to your Department.
REFERENCE PRICING
Reference Pricing – Letter 1
From Secretary General to  
Minister for Health
[12 September 2012]
Re: Health (Pricing and Supply of Medical 
Goods) Bill 2012
I am writing to you in relation to the Health 
(Pricing and Supply of Medical Goods) Bill 2012 
(the Bill). The Irish Pharmacy Union (IPU) has 
a number of concerns about the proposed Bill. 
Whilst we welcome the introduction of generic 
substitution, we have concerns that the Bill 
does not fully address continuity of supply of 
medicines, medicine shortages and notice period 
to stakeholders. I wish to set out a number 
of suggested amendments to the Bill that we 
believe will address these concerns and ensure a 
constant supply of medicines to patients. 
Continuity of supply:
n In relation to Section 24(2), which appears 
to allow the HSE to review the reference 
price once every three months, the IPU 
would request that this be extended to six 
months to ensure that there is certainty 
in relation to stock-holding for wholesalers 
and pharmacists which in turn facilitates 
continuity of supply of medicines to patients. 
Therefore, we would submit that the following 
should be inserted in Section 24(2) in place 
of “every three months”: “every six months”.
n Section 19 refers to the notice that the 
HSE must give to manufacturers when they 
make a relevant decision about whether to 
add, remove, retain or refuse to add an item 
on the Reimbursement List. There is no 
mention of any notice which must be given 
by the HSE to prescribers or pharmacists, 
both of whom, in the event of the removal 
of a listed item, will need to source an 
alternative medicine for their patients. It is 
submitted that all changes to the list should 
be notified to pharmacists, doctors and the 
IPU. Failure to do so will result in confusion 
for pharmacists, doctors and patients and 
a possible delay in patients receiving the 
appropriate medicine. Therefore, we would 
submit that the following should be inserted 
in Section 19(1) and (2) in place of “to the 
supplier of the item or listed item the subject 
of the relevant decision”: “to the supplier 
of the item or listed item the subject of the 
relevant decision and to prescribers and 
pharmacists”.
n It appears that Section 21(2) lays out the 
criteria that the HSE will take into account 
when considering the proposed relevant 
price by the supplier of an item. This section 
should be amended to include two critical 
criteria – “the welfare of the patient” and “the 
impact of the relevant price on the continuity 
of supply of the relevant listed item”.
n Similarly, it appears that Section 24(3) lays 
out the criteria that the HSE will take into 
account when setting a reference price for, or 
reviewing a reference price set for, a relevant 
group of interchangeable medicinal products.  
This section should be amended to include 
two critical criteria – “the welfare of the 
patient” and “the impact of the reference 
price on the continuity of supply of the 
relevant listed item within the relevant group 
of interchangeable medicinal products”. 
Medicine shortages:
n Section 18(7) appears to allow the HSE to 
remove a product from the Reimbursement 
List if its temporary cessation on the market 
causes patient disruption. Section 18(8) 
appears to allow the HSE to remove a 
product from the Reimbursement List if 
the manufacturer doesn’t make enough to 
meet the demand in the State. We would be 
grateful if the Department of Health could 
clarify the circumstances in which these 
provisions would be utilised.
n It appears that Sections 21(4) and 24(4) 
allow the HSE to use a competitive process 
to determine the relevant price of an item 
or a listed item and to set the reference 
price for a relevant group of interchangeable 
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medicinal products, respectively. Section 
21(2)(a) provides that it is now intended 
to take into account the equivalent relevant 
price of an item in all other Member States 
where the item is marketed when considering 
the proposed relevant price. Section 24(3)
(c) provides that, when setting a reference 
price for a relevant group of interchangeable 
medicinal products, it is now intended to 
take into account the equivalent relevant 
prices of the relevant listed items in all other 
Member States where one or more than one 
of the relevant listed items is marketed when 
considering the proposed relevant price.
Tendering for medicines may lead to a 
price war resulting in smaller companies 
which provide medicines being driven out 
of the Irish market because it makes no 
financial sense for them to remain. In those 
circumstances, the power to supply could 
rest with one company only and the risk of 
medicine shortages could increase, as has 
been seen in other EU countries. Similarly, 
if the reimbursable or reference price of 
a medicine is set too low, there will be no 
incentive for manufacturers to market their 
products in Ireland, given the relatively 
small size of the Irish market. Consequently, 
increased reliance on very costly unlicensed 
medicines (ULMs) will cost the Exchequer 
and patients more in the longer term. The 
IPU would suggest that there should be an 
obligation on the Department of Health to 
make sure that there is a sufficient security 
of supply of medicinal products for patients 
and that any decisions taken will not lead to 
increased use of ULMs. We submit that this 
should be set out explicitly in the Bill.
Notice period to pharmacists  
and other stakeholders:
n It appears that Section 6(5) requires 
the IMB only to give notice to prescribers 
and pharmacists if they decide to remove 
a medicinal product from a group of 
interchangeable medicinal products or to 
remove a group of interchangeable medicinal 
products from the list of interchangeable 
medicinal products. It is essential that 
prescribers and pharmacists are given 
sufficient notice of at least eight weeks 
to enable them to determine or source a 
suitable alternative medicine for the patient 
to ensure continuity of care. Therefore, we 
would submit that the following should be 
inserted in Section 6(5) in place of “as soon 
as is practicable”: “as soon as is practicable 
but with a minimum of eight weeks’ notice”.  
n It appears that Section 6 does not require 
the IMB to give notice to prescribers and 
pharmacists when medicinal products 
are added to a group of interchangeable 
medicinal products or a group is added to the 
list of interchangeable medicinal products; 
notification to prescribers and pharmacists 
only appears to be given for removals. 
Prescribers and pharmacists should be 
informed of all additions and deletions. 
Therefore, we would submit that the following 
should be inserted in Section 6(5) in place 
of “Where a relevant decision which falls 
within paragraph (g) or (h)”: “Where a 
relevant decision which falls within paragraph 
(a) to (h)”:
n Section 24(6) appears to provide that the 
HSE will give pharmacists four weeks’ notice 
of a change to a reference price. Wholesalers 
and pharmacists will need much longer than 
this to run down their stocks; otherwise they 
will suffer financial loss as a consequence 
of this short notice and will keep their stock 
levels very tight. This could lead to problems 
for patients. The IPU would request that 
pharmacists be given eight weeks’ notice  
of a change to a reference price. Therefore, 
we would submit that the following should  
be inserted in Section 24(6) in place of  
“not later than four weeks”: “not later  
than eight weeks”.  
   
Supervision of compliance:
n Section 32 appears to indicate that 
pharmacists will be required to adhere to the 
provisions of this Bill and that compliance 
will be policed by the Pharmaceutical Society 
of Ireland (PSI) under the Pharmacy Act 
2007. However, the IPU is of the view that 
the provisions of this Bill are not regulatory 
but are related to contract and are suitably 
covered by the Community Pharmacy 
Contractor Agreement. Furthermore, it is 
submitted that this is recognised in the Bill. 
Consequently, the HSE is the appropriate 
body to police compliance with the legislation 
and not the PSI. The National Consumer 
Agency is also available to deal with any 
issues that arise for patients. 
The problem with using the Pharmacy Act 
to police this Bill is that, under the current 
requirements of the Pharmacy Act, the PSI 
must refer all complaints to the Preliminary 
Proceedings Committee (PPC) for its advice 
on whether there is sufficient cause to 
warrant further action being taken. If the 
PPC advises that there is sufficient cause to 
warrant further action, the PPC can refer the 
complaint for resolution by mediation (albeit 
that the PSI has never utilised this option), 
or refer the complaint to the Professional 
Conduct Committee. Typically, the latter 
process can take up to 18-24 months and 
is extremely costly for both the PSI and the 
pharmacist concerned. It is not in anybody’s 
interests to provide that the burden of 
this process would apply to this piece of 
legislation. Furthermore, this is not a Fitness 
to Practise issue, rather a commercial one. 
It is inappropriate to utilise the Fitness to 
Practise mechanism for an issue which is not 
related to patient welfare or a pharmacist’s 
professional competence, but is purely 
economic.   
Therefore, the IPU would recommend 
that these provisions be deleted from the 
Bill. However, if the Minister is adamant that 
this legislation be policed by the PSI, then 
an amendment should be made to Section 
38(1) of the Pharmacy Act, stating:
As soon as is practicable after receiving 
a complaint, the Council shall either refer 
it to the Registrar for consideration and 
resolution or refer it to the preliminary 
proceedings committee for its advice 
on whether there is sufficient cause to 
warrant further action being taken.
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We would also recommend an amendment 
to Section 40(1) of the Pharmacy Act so that it 
says:
If the preliminary proceedings committee 
advises….that there is sufficient cause to 
warrant further action….the committee shall 
either –
(a) refer the complaint to the Registrar for 
consideration and resolution, or
(b) refer the complaint for resolution by 
mediation…or
(c) refer the complaint to whichever of the 
following committees (“committees of 
inquiry”) it considers appropriate –
(i) the professional conduct committee
(ii) the health committee.   
This would allow the Registrar to deal with 
failures to comply with this legislation in short 
course rather than spending up to two years and 
incurring extensive costs progressing through a 
full Fitness to Practise process resulting in an 
utterly disproportionate response to the initiating 
circumstances.
Other areas requiring clarification:
n We would be grateful if the Minister could 
clarify the precise meaning and intention 
behind Sections 5(12), 5(13) and 19(6). 
n Section 13(1) appears to provide that a 
prescriber can exempt a medicinal product 
from substitution by writing by hand “do 
not substitute” on the prescription. Section 
13(2) refers to regulations that the Minister 
may make in relation to this exemption. We 
would be grateful if the Minister could clarify 
what kind of regulations he intends making 
under this section.
n The IPU notes that it is possible to 
commence some parts of this Bill in advance 
of other parts. We therefore propose that 
the parts to facilitate generic substitution 
be commenced in advance of the other 
parts of this Bill in order to facilitate patients 
in accessing cheaper generic medicines 
immediately. 
n Section 20 appears to allow the HSE 
to attach conditions to the supply of 
medicines. In drawing up such conditions 
the HSE should have regard to implications 
for patients already established on those 
medicines and the section should be 
amended accordingly. This is the only way to 
avoid a repeat of the Pradaxa debacle where 
the HSE applied rules retrospectively without 
telling pharmacists or patients, leading to 
total confusion. 
n The IPU would ask that an amendment 
be made after Section 26, outlining the 
obligation that the Department of Health 
and the HSE have in implementing a Public 
Information Campaign to make sure that 
patients are well informed about this Bill 
and the changes that will happen as a 
consequence.
In order to implement generic substitution, 
significant changes will be required to be 
made to pharmacy and GP IT systems to 
accommodate the changes being brought 
about by the Bill. We therefore request that 
the Department of Health arrange an urgent 
meeting between the Department, the PCRS, 
the IT vendors and the IPU to ensure that all 
IT systems are capable of implementing this 
regime and that implementation is as seamless 
as possible. The level of IT development work 
required is considerable and will be costly to 
develop.
Finally, the IPU would also submit that this 
Bill provides an ideal opportunity to introduce 
Medicine Use Reviews (MURs) and a New 
Medicines Service (NMS), as was done recently 
in the UK. The purpose of these initiatives 
is to improve compliance, reduce leakage 
to secondary care and reduce wastage of 
medicines.  
All the above points are vital for the successful 
implementation of the Bill. The IPU would 
welcome an early meeting with your Department 
to discuss these amendments further.
Reference Pricing – Letter 2
From Secretary General to Chairperson 
Fine Gael Internal Health Committee
[1 November 2012]
Re: Meeting with Internal Health Committee
I am writing on behalf of the Irish Pharmacy 
Union (IPU) requesting an opportunity for a 
small delegation to present to the Fine Gael 
Internal Health Committee. The delegation would 
like to outline the role of pharmacy in healthcare 
and the significant contribution the sector can 
make to the delivery of healthcare services.
A positive response to our request would be 
greatly appreciated.
Reference Pricing – Letter 3
From T Cody, Primary Care, DoH  
to Secretary General
[5 November 2012]
Re: Health (Pricing and Supply of  
Medical Goods) Bill 2012
I refer to your letter of 12th September 2012 
which outlined a number of concerns regarding 
the Health (Pricing and Supply of Medical 
Goods) Bill 2012.
On the 5th October last, the main issues of 
concern raised in your letter, namely, continuity 
of supply; medicines shortages; notice periods 
to pharmacists and other stakeholders; and 
supervision of compliance were discussed in 
detail with Ms Jill Lyons and Mr Jim Curran.
In relation to continuity of supply; 
medicines shortages; and notice periods 
to pharmacists and stakeholders, the 
Department considers that there is currently 
sufficient provision in the legislation covering 
these areas. In particular, the Department 
considers that continuity of supply is implicitly 
provided for throughout the proposed 
legislation (e.g. Schedule 3, Part 3) and there 
is no need to include an explicit reference to 
this issue in the Bill. Similarly, patient safety is 
a central tenet of the proposed legislation with 
Section 20(1) (a) making specific reference 
to this issue in the context of the conditions 
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that the HSE may attach to the supply and 
reimbursement of listed medicinal products.
It is therefore not proposed to take on board 
the legislative amendments proposed for these 
issues in your letter. However, it would continue 
to be open to the IPU to discuss any operational 
issues of concern to pharmacists with the 
HSE during the implementation phase of the 
legislation.
The Department acknowledges the IPU 
concerns regarding the proportionality of using 
the Pharmaceutical Society of Ireland (PSI) to 
police compliance with the provisions of the Bill 
under the Pharmacy Act 2007. This issue was 
provisionally discussed at our meeting and I 
advised I would consult with my colleagues on 
the pharmacy legislation side of the Department. 
Some of the points raised by the IPU regarding 
section 32 of the Bill relate to the operation of 
the complaints process under the Pharmacy Act 
and have implications in relation to complaints 
generally rather than just to complaints arising 
under this Bill. The points raised by the IPU will 
be considered in the context of reviewing the 
Pharmacy Act 2007 and other related legislation. 
However, at this point I wish to advise that the 
Department is not considering amending this 
provision of the Health (Pricing and Supply of 
Medical Goods) Bill.
You also sought clarification on a number 
of other aspects of the Bill. These were not 
discussed in detail on the 5th October and I 
will now outline the Department’s position with 
respect to each issue.
n The precise meaning and intention behind 
Sections 5(12), 5(13) and 19(6) 
Section 5(12) essentially enables the IMB 
to remove a product from the group of 
interchangeable medicinal products it is 
currently listed on if the Board is no longer 
satisfied that it can be safely substituted. 
Section 5(13) provides for the same approach 
in the context of a group of interchangeable 
products.
On commencement of Section 17, the list 
of medicinal products currently reimbursed 
under the GMS and Community Drug 
Schemes shall be deemed to be listed as 
reimbursable items. Section 18(4) provides 
that the HSE shall not later than the 3rd 
anniversary of the date of commencement of 
section 17 treat each deemed listed item as 
if it was not on the Reimbursement List but 
was subject to an application under section 
18(1). (The period provided for in section 
18(4) may be extended to five years with the 
approval of the Minister for Health.) Section 
18 (5) provides that the HSE may review a 
listed item at any time.
Section 19(6) provides that where the 
HSE reviews an item under section 18 (4) or 
18 (5) see definition of deemed application 
- and makes a determination the item shall 
cease to be a deemed listed item and any 
conditions attaching to the deemed listed 
item shall cease to be a deemed condition 
once the necessary notification periods under 
Sections 19(1) and 19(3) are complied  with. 
In practice, following review, an item will 
either be retained on the Reimbursement 
List, whether or not subject to conditions, or 
removed from the Reimbursement List.
n Regulations under Section 13(2)
Section 13(1) of the Bill provides that a 
prescriber can, if satisfied that a branded 
interchangeable medicinal product prescribed 
for a patient should not be substituted on 
clinical grounds, exempt the prescription 
from substitution by writing ‘do not 
substitute’ beside the relevant product on 
the prescription. Section 13(2) provides that 
the Minister may make Regulations requiring 
prescribers to state the reasons for utilising 
the exemption to substitution provision in 
Section 13(1). It is important to note that this 
is an enabling provision which the Minister 
may invoke if considered appropriate having 
assessed the practices of prescribers under 
this provision.
n Phased Commencement of the Bill 
There is scope for phased commencement. 
However, there is no intention to introduce 
the generic substitution provisions of the Bill 
prior to the reference pricing provisions.
n Conditional Reimbursement 
Section 20 allows the HSE to attach 
conditions to the supply or reimbursement of 
listed items in the interest of patient safety; 
cost-effectiveness; maximising appropriate 
use of the listed items concerned; and 
appropriately applying the resources available 
to the HSE. As patient safety is a key criterion 
underpinning this section and indeed is 
a fundamental concern underpinning all 
provisions of this Bill, the HSE will not 
introduce conditions under this section 
without fully evaluating their impact on the 
welfare of patients.
n Public Information Campaign 
The Department has established an 
Implementation Group on Generic 
Substitution and Reference Pricing which 
will consider all aspects of the Bill’s 
implementation. A key element of this 
Group’s work is developing a communications 
strategy to ensure that all stakeholders, 
including patient groups, are fully informed 
of the implications of the legislation. In this 
context, the Group is currently working on a 
draft patient information leaflet and comment 
has already been sought from the IPU. In 
addition, stakeholder group meetings will be 
arranged in the near future to further consult 
with key stakeholder groups.
n Medicine Use Reviews (MURs) and  
New Medicines Service (NMS) 
I understand that the report on the Medicine 
Usage Review pilot carried out in 2010 is due 
this month. The Department will consider the 
issues arising from that report. Meanwhile 
it is not intended to amend the Bill to 
provide for Medicine Use Reviews and a New 
Medicines Service.
I hope this clarifies the position with respect 
to the issues raised in your letter. Should you 
require further clarification on any aspect of the 
Bill, please feel free to contact me.
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Reference Pricing – Letter 4
From Secretary General to Assistant 
Secretary General, DoH
[13 February 2013]
Re: Implementation Group Meeting 
I wish to refer to the Implementation Group 
meeting that took place in the Department on 
the 7 February last in relation to the proposed 
introduction of Reference Pricing and Generic 
Substitution and changes that need to be made 
to Pharmacy IT systems.
I understand that at the meeting, the HSE 
circulated three detailed documents for review 
which addressed a number of issues some of 
which were totally unrelated to the introduction 
of Reference Pricing and Generic Substitution. 
The proposals tabled by the HSE would require 
significant consideration before they can be 
advanced. The appropriate forum in which 
these issues should be addressed is through 
the IPU/HSE Joint Consultative Group. Frankly, 
the implementation of Reference Pricing will be 
complicated and costly enough to implement 
without unnecessarily introducing additional 
processes that will further complicate matters at 
this time.
We are also surprised at the proposals 
from the HSE and Department seeking 
considerable data input from pharmacists. 
From its perspective, the IPU has indicated 
that it would co-operate with the introduction 
of Reference Pricing and Generic Substitution. 
This commitment was made on the basis that 
there would be agreement on all implementation 
matters and administration burden would be 
kept to a minimum. Pharmacists will be prepared 
to capture the two vital pieces of information 
necessary which are the details of the medicine 
dispensed and whether the prescriber had 
specifically requested “no substitution” in 
any particular case. The capture of any other 
information will not be possible.
It is important to realise that the capture of 
information is an expensive business particularly 
in these difficult economic times when pharmacy 
payments have already been substantially 
reduced and are under threat of further 
reduction. In the circumstances, I wish to seek 
an urgent meeting with you to discuss the matter 
further in advance of the next meeting with the 
HSE on 25 February. 
Reference Pricing – Letter 5
From Secretary General to  
Secretary General, DoH
[1 March 2013]
Re: Patient Safety Issues
I am writing to you in your capacity as Head of 
the Department of Health but also as Chairman 
of the HSE to outline a number of issues which 
raise patient safety concerns. 
1. Generic Substitution/Reference Pricing
a. ‘Do Not Substitute’ Regulations 
The Health (Pricing and Supply of Medical 
Goods) Bill 2012, which is passing 
through the Dáil at present, states that 
where a prescriber wishes, for clinical 
reasons, to be exempt from substitution, 
they must write “Do Not Substitute” in 
their own handwriting on the prescription. 
Pharmacists are concerned that GPs will 
not write “Do Not Substitute” in their own 
handwriting, as is currently the case for 
many prescriptions for controlled drugs. 
We would like the HSE to advise, in 
writing, what a pharmacist is supposed to 
do if presented with such a prescription. 
Must they refuse to dispense? Must they 
send the patient back to the GP? The 
PSI has taken pharmacists to task for 
dispensing CD prescriptions which were 
incorrectly written. Pharmacists want to 
ensure that a patient’s needs are met but 
do not wish to leave themselves exposed 
to sanctions by the PSI or HSE; so clarity 
on this issue is critical.
b. Allergies to Generic Excipients 
Another concern that pharmacists have 
expressed regarding the forthcoming 
legislation for generic substitution arises 
when they are aware that a patient is 
allergic to excipients in a particular 
generic medicine. The GP may not 
prescribe the medicine by brand name 
and/or does not write “Do Not Substitute” 
in their own handwriting. Obviously, 
the pharmacist cannot dispense a 
medicine to a patient which they know 
will cause harm, yet they will not get 
paid if they dispense the brand and, 
more importantly, they will fall foul of the 
legislation if they do dispense the brand, 
leaving themselves open to sanctions 
by the PSI as well as not being paid by 
the PCRS. Again, we would welcome a 
definitive response on this issue.
c. Short Implementation Time 
The IPU met with the HSE and the 
Department on 25 February 2013. During 
this meeting it was indicated that the 
Bill is expected to be enacted shortly. 
Given the lack of clarity and agreement 
on a number of issues, including IT 
developments and communication with 
patients, the IPU would be concerned 
about any attempt to implement the 
legislation without adequate planning  
and preparation.
d. Cost of Counselling 
The legislation will place a significant 
additional cost on pharmacists in 
ensuring patient welfare and safety by 
counselling patients on the use of generic 
alternatives and dealing with patients 
who do not wish to avail of the cheaper 
medicine. In any system, pharmacists 
must be rewarded adequately for their 
professional input in ensuring that the 
introduction of the reference pricing 
legislation does not affect patient care. 
We wish to have an early meeting with you 
to discuss the cost of implementation, 
which is vital to ensure that patients do 
not end up in hospital unnecessarily with 
all its attendant costs. 
Appendix II
(continued)
34
AnnuAl RepoRt 2013
e. IT Developments  
The IPU previously flagged this as 
a significant area of concern for 
pharmacists. Our experience of dealing 
with the HSE on IT developments has not 
been positive and there was no agreement 
on this at this week’s meeting. 
The HSE is seeking considerable 
data input from pharmacists. From its 
perspective, the IPU has indicated that it 
would co-operate with the introduction of 
Reference Pricing and Generic Substitution. 
This commitment was made on the basis 
that there would be agreement on all 
implementation matters and administration 
burdens would be kept to a minimum. 
Pharmacists will be prepared to capture the 
two vital pieces of information necessary 
which are the details of the medicine 
dispensed and whether the prescriber had 
specifically requested “no substitution” 
in any particular case. The capture of any 
other information will not be possible. The 
HSE accepts that the capture of data at 
their end is an expensive business but 
does not seem to realise that it is equally 
expensive at the pharmacy end. This is 
particularly so for pharmacists in these 
difficult economic times when pharmacy 
payments have already been substantially 
reduced and are under threat of further 
reduction.
 
2. Other Issues
a. Pradaxa 150mg Capsules 
PCRS has recently confirmed to the IPU 
that they will not reimburse the supply 
of 2 x 75mg Pradaxa Capsules under 
any circumstances. We have tried to 
point out that, in some instances, a 
GP may prescribe 2 x 75mg Pradaxa 
because a patient has difficulty in 
swallowing the larger 150mg capsule. 
PCRS responded to this by saying “the 
implication that it is inappropriate to 
displace the fundamentals of appropriate 
claiming practices whereby the most 
suitable formulation to satisfy the 
dosage requirement of the patient is 
supplied by the dispensing pharmacist 
is disconcerting”. Pharmacists clearly 
would wish to exercise professional 
judgment on these matters. However, 
pharmacists need an assurance that 
when they exercise that judgment, it 
will be recognised by the HSE and they 
will be paid the appropriate amount for 
their intervention, given the patient risks 
involved. We would be interested in your 
guidance and views on this matter.
b. Pradaxa 35-day Supply 
PCRS will only reimburse pharmacists for 
supplying a 30-day supply of Pradaxa to 
prevent venous thromboembolism (VTE) 
post hip or knee replacement surgery. 
Pradaxa is licensed for a 35-day supply 
for this indication. Presumably, this is 
because the marketing authorisation 
holder and the Irish Medicines Board 
considered that a 35-day supply was 
needed to prevent VTE. PCRS’s rationale 
for this decision is that patients are 
likely to spend five days in hospital after 
surgery; therefore they only require a 
further 30-day supply post-discharge. 
However, it is becoming evident in the 
community that patients are discharged 
much earlier, even the day after the 
surgery. Yet, when the patient presents a 
prescription to the community pharmacist 
for a 35-day supply, typically prescribed 
by their consultant, the pharmacist 
must inform the patient that they are 
only entitled to a 30-day supply. Once 
again, the paymaster is making the 
clinical decisions and the issue that then 
arises is where does the liability lie if the 
pharmacist ignores the requirements 
of the prescriber and only dispenses a 
30-day supply? This could result in the 
patient suffering from VTE, with possible 
fatal consequences, so clarity on this 
issue is also necessary.
c. PCRS Approval for Pradaxa Supply 
PCRS has insisted that patients who 
require Pradaxa for atrial fibrillation 
receive approval from PCRS before 
any medicine can be supplied by 
the pharmacist. Yet pharmacists are 
increasingly experiencing patients arriving 
in their pharmacy with a prescription 
but no approval letter. Who will be held 
responsible if such patients suffer from a 
heart attack while waiting for approval to 
be granted by PCRS? Pharmacists need 
advice on the approach they should adopt 
in these situations and confirmation 
that if they exercise their professional 
judgment and dispense the medicines, 
the HSE will then pay for it.
d. Supply of Medicines without 
Prescription 
We are aware of a number of occasions 
recently where the PSI has prosecuted 
pharmacists for supplying a prescription-
only medicine without prescription. 
Typically, the medicine was one that the 
patient had been on for a long time but 
their prescription was out-of-date and 
they hadn’t had the opportunity to get 
a new one from their GP. None of the 
patients involved came to any harm and 
the pharmacist was doing their best to 
look after the needs of their patients, 
as laid out in the Code of Conduct for 
Pharmacists. These are frequently elderly 
or vulnerable patients. Pharmacists 
believe that they should not leave such 
patients without a supply of their vital 
medicine. Invariably the prescription is 
supplied in a matter of days. Pharmacists 
should not be prosecuted for looking after 
their patients. Pharmacists need clarity on 
this issue as they are currently between a 
rock and a hard place given the approach 
of the Society on the matter. 
In conclusion, these issues arise where the strict 
application of regulations and scheme conditions 
can conflict with primary concern of pharmacists 
to look after their patients’ welfare. They are 
sufficiently serious to warrant absolute clarity 
and I look forward to hearing from you.
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Reference Pricing – Letter 6
From Secretary General to Minister of State 
for Health
[2 April 2013]
Re: Follow-up to Meeting with IPU
Thank you for taking the time to meet with 
officials from the Irish Pharmacy Union (IPU) 
on 21 March 2013. I would like to take this 
opportunity to reiterate that pharmacists can 
play a greatly expanded role in primary care as 
part of the overall healthcare reform, as we set 
out in our presentation to you. 
At our meeting, we discussed our concerns 
about generic pricing and, in particular, the 
need to ensure that there is adequate time for 
implementation of the legislation, especially to 
ensure that the necessary IT interventions are 
put in place. 
We also discussed our concerns about 
ongoing regulation costs in relation to the 
Pharmaceutical Society of Ireland (PSI), the 
criminalisation of pharmacists for technical 
breaches of regulations under the Pharmacy Act 
and the removal of a pharmacist from the PSI 
register if they are declared bankrupt. In relation 
to the latter point, we are aware that you intend 
to make amendments to the Pharmacy Act to 
facilitate some parts of the Health (Pricing and 
Supply of Medical Goods) Bill 2012 and would 
request that you use this opportunity to delete 
Section 14(1)(f) of the Pharmacy Act 2007 at 
report stage. This would enable a pharmacist 
to continue to practise their profession in the 
event that they are declared bankrupt, provided 
they comply with all other ethical, legal and 
professional requirements.   
Please do not hesitate to contact us if you 
require further detail on any issue raised in this 
letter or at our meeting.
Reference Pricing – Letter 7
From Secretary General to  
Assistant Secretary General, DoH
[10 April 2013]
Re: Implementation Group Meeting
I wish to refer to my previous letter dated 13 
February 2013 to which there has been no reply.
Since February the Pharmacy Contractors’ 
Committee (PCC) has met to discuss the 
implementation of the Reference Pricing and 
Generic Substitution Legislation and the impact 
these changes will have on the pharmacy 
business.
While the IPU has co-operated with the 
implementation of the Reference Pricing and 
Generic Substitution legislation, it is important that 
the Department and the HSE appreciate that there 
will be a significant increase in administration and 
patient counselling for pharmacists. All this extra 
work is a cost to pharmacists.
However, the PCC are prepared to work with 
the Implementation Group and the IT Vendors to 
provide the following information:
n Pharmacists will tick a box to note 
whether substitution occurred or not – 
there will be three options – Yes / No / 
Clinical Exemption and
n Pharmacists will also note what has been 
dispensed.
The PCC are confident that this satisfies the 
HSE legal obligations under the legislation while 
also keeping the level of administration and cost 
down for all parties involved. It will also enable 
the HSE to investigate the prescribing patterns of 
GPs. They already have access to considerable 
information including the pharmacist’s 
yellow bundles which contain the GP’s actual 
prescriptions.
It is important to realise that the capture of 
information is an expensive business particularly 
in these difficult economic times when pharmacy 
payments have already been substantially 
reduced and are under threat of further 
reduction. Any changes to the IT systems will 
have a cost so it is vital that such changes are 
kept to a minimum. 
In conclusion, pharmacists cannot be 
expected to cover the cost of these changes and 
we look forward to discussing this matter with 
you.
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REDUCTIONS IN THE  
COST OF MEDICINES
Reductions – Letter 1
From Secretary General to CEO Uniphar, 
United Drug and CMR
[17 October 2012]
Re: Recent Price Reductions – IPHA 
Agreement
I wish to refer to the recent price reductions 
agreed with the Department of Health and the 
Irish Pharmaceutical Healthcare Association 
(IPHA) which will lead to significant reductions to 
the cost of medicines. 
Our members are concerned about the 
impact of these reductions on the value of their 
stock. In particular, they are anxious to establish 
what steps your company intends to take to 
protect your customers from this overnight stock 
devaluation and how you intend to compensate 
them for these losses.
I would welcome an early response from you 
which we will convey to our members in due 
course. 
Reductions – Letter 2
From HSE Contract Manager to 
Assistant Secretary General, DoH
[17 October 2012]
Re: Reductions in the Cost of Medicines
I wish to refer to the recent announcement of 
a new agreement between the Department of 
Health and the Irish Pharmaceutical Healthcare 
Association (IPHA) which will lead to significant 
reductions to the cost of medicines. With two 
weeks to go until the implementation of the 
reductions, the IPU has still not been provided 
with a confirmed list of affected medicines.  
The IPU has previously requested that 
the Department give adequate notice of any 
reductions to the cost of medicines. The 
announcement on Monday 15 October gives 
pharmacists only two weeks in which to prepare 
for the reductions. This is not acceptable. The 
IPU and pharmacists should be alerted well in 
advance of the implementation date. A minimum 
of four-to-six weeks’ notice is necessary to allow 
sufficient time for the IPU to update our IT 
system and to allow pharmacists adequate time 
to dispense stock reimbursed at the higher price. 
You will remember that pharmacy contractors 
experienced significant loss to the cost of their 
stock as a direct result of the lack of notice 
provided by the Department in previous year. It 
is important that pharmacists are not put in this 
position again therefore I would request that the 
implementation date for the reductions is pushed 
back from 1 November to give pharmacists the 
opportunity to minimise any losses that will 
occur.
Reductions – Letter 3
From Secretary General to 
Minister for Health
[2 November 2012]
I have been asked by the Executive Committee to 
write you regarding the manner in which recent 
price reductions and product changes were 
introduced with effect from 1 November 2012.
On 15 October 2012, Press Releases were 
issued to inform the public that a new agreement 
had been reached between your Department 
and the Irish Pharmaceutical Healthcare 
Association (IPHA). As part of this agreement 
the price of medicines was to be reduced from 
1 November 2012. The number of medicines 
involved was of the order of 1,700; nevertheless, 
the list of medicines affected by these changes 
was not produced until the 22 October 2012. 
When we contacted the Department about the 
short notice, we were advised that these price 
reductions were being implemented with effect 
from 1 November 2012, clearly without any 
regard for the consequences of these changes on 
the value of stock on pharmacy shelves.
This was followed by an announcement of a 
further agreement between the Department and 
the Association of Pharmaceutical Manufacturers 
of Ireland (APMI) on the 26 October 2012. The 
initial list of products affected by these changes 
appeared on the HSE website at lunchtime on 
26 October. This list was then removed a few 
hours later, due to errors on the list, without any 
reference on the website or any communication 
with the IPU or its members. A revised list was 
then published on the website at 5pm that Friday 
evening, some five days before these changes 
were to be introduced over a public holiday 
weekend. This caused considerable confusion for 
everyone involved and, again, totally unfair to our 
members.
On Friday 26 October there was a vague 
indication to the IPU that there would be 
some changes to payments for Oral Nutritional 
Supplements (ONSs), the detail of which did 
not surface until the 30 October, again to be 
introduced with effect from 1 November. We 
received the list of price reductions for the ONSs 
on 30 October and were advised that a number 
of codes would be removed and replaced by new 
GMS Codes from 1 November. However, while 
we were advised of the products that this would 
affect, as of this morning we are still waiting 
on the new GMS codes for 199 products. This 
has meant that many commonly dispensed 
products currently have no active code! This is 
an appalling situation.
The IPU has repeatedly asked that reasonable 
notice be given of changes of this nature to 
ensure smooth implementation and yet, time 
and time again, no such notice or inadequate 
notice is being given. The IPU fully appreciates 
the severe pressure on the health budget 
at this time. However, this does not justify 
the unreasonable and disrespectful manner 
which these changes are being introduced. 
The consequences of this approach are that 
pharmacists are considerably out of pocket as 
the value of their stock falls and they are not 
being given a reasonable opportunity to run 
down their stock and minimise their losses. Most 
pharmacies are small businesses who, like all 
businesses at this time, are suffering the effects 
of the economic recession and low consumer 
confidence and this is all the more reason 
why the State should treat them fairly in these 
matters.  These losses are in addition to the 
contribution that pharmacists will be making to 
the Exchequer as part of these price reductions. 
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In conclusion, we would ask that:
n Pharmacists would be reimbursed at 
the old price for the first two weeks of 
November; 
n Claims for ONSs would be reimbursed 
under the old GMS codes and the new 
GMS codes for the month of November; 
and,
n A commitment be given that such 
changes will not be forced through in 
future without giving pharmacists and 
other stakeholders adequate notice and 
time to run down their stock levels and 
minimise their losses.
In conclusion, the manner in which these 
changes have been implemented is totally 
unacceptable and cannot be allowed to happen 
again.
Reductions – Letter 4
From Secretary General to S Flanagan, 
Corporate Procurement Unit, HSE
[14 November 2012]
Re: Reductions in the Cost of Medicines
I have been asked by the Pharmacy Contractors’ 
Committee (PCC) to write to you about the 
proposed changes to medicine prices arising 
from the recent agreement with IPHA, which are 
due to be implemented from 1 January 2013.
I wish to request that the implementation 
date of 1 January 2013 be delayed to allow 
sufficient time to update our IT system and to 
allow pharmacists sufficient time to dispense 
stock at the price they purchased it from 
their wholesalers. In particular, we must at 
all costs avoid the debacle that arose in the 
implementation of the last round of cuts. 
As you are aware, January is the worst month 
of the year for such a change to be implemented 
because of the potential effects on both stock 
availability and, more critically, patient access 
to medicines. During the Christmas and New 
Year period there is increased hospital discharge 
rates, reduced access for patients to GP services, 
a reduced wholesaler delivery to pharmacies, 
an increased level of urgent prescriptions and 
unpredictable patterns of patient demand, which 
all routinely put pressure on the supply system. 
A reduction of this kind took place in January 
2011 and cost pharmacists a significant amount 
of money. This reduction is on top of the other 
recent cuts to IPHA medicines, APMI medicines 
and Oral Nutritional Supplements, which 
were communicated and implemented in an 
unacceptable and unprofessional manner.
It is essential that there is continuity of supply 
for medicines for patients during this critical 
time; therefore, any reductions arising from the 
agreement with IPHA should apply to medicines 
dispensed from 1 February 2013.
The IPU is also seeking a definitive list of 
medicines which will be affected by these 
reductions. It is vital that we have this list of 
medicines as soon as possible, but at the latest 
by 1 December 2012, to ensure that we are 
able to update our IT system in time for the 
implementation date. 
PSI MATTERS
PSI – Letter 1
From Director of Communications & 
Strategy to Minister for Health
[15 October 2012]
Re: Pharmacist and Pharmacy Registration  
Fees 2013
I am writing to you to highlight the concerns of 
members of the Irish Pharmacy Union (IPU) 
with regard to the unsustainable level of annual 
registration fees charged by the Pharmaceutical 
Society of Ireland (PSI) and the undue burden 
that this places on community pharmacy.
The cost of registration with the PSI is out of 
line with international comparisons. The annual 
pharmacist registration fee is €400 (€570 on 
first registration) and each pharmacy must pay 
€2250 (€3500 on first registration) per year to 
register. In the UK the equivalent fees are £267 
(£369 on first registration) and £221 (£789 on 
a first registration) for a pharmacy premises.  
Other international comparisons are attached for 
your attention.
In previous meetings with the PSI, we raised 
the issue of the exorbitant amount of fees for 
the registration of pharmacists and pharmacies 
and the PSI indicated that fees may be reduced 
taking account of changing circumstances. 
In light of the drastic cuts in pharmacists’ 
reimbursement in recent years under the 
Community Drugs Schemes and the current 
dire economic climate, our members would 
have an expectation of seeing a significant 
reduction in their pharmacy registration fees. In 
addition, our employee members have reported 
significant reductions in their salaries and again 
would expect to see a proportionate reduction in 
pharmacist registration fees. We are, therefore, 
calling for a review of the level of PSI fees for 
2013 with a view to bringing them into line with 
other jurisdictions.
The IPU is happy to meet with you to discuss 
this issue further. 
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PSI – Letter 2
From President IPU to President PSI
[14 November 2012]
I wish to refer to our recent letter requesting a 
meeting with the Council of the Pharmaceutical 
Society of Ireland (PSI) and your response that 
you could not facilitate such a meeting at this 
time. This is very disappointing, as pharmacists 
around the country are becoming increasingly 
frustrated with the PSI and feel that no-one 
is listening to their issues and concerns. The 
purpose of this letter is to bring these concerns 
to the attention of all Council members and 
suggest ways in which we believe these concerns 
can be addressed. I would ask that you bring 
a copy of this letter to the attention of each 
Council member.
1. Inspections
Pharmacists are angry and frustrated that 
they are not given advance notice of PSI 
inspections. We have raised this issue 
on a number of occasions over recent 
years. Whilst the PSI has indicated that 
it will facilitate pharmacists in providing 
pharmacy services to their patients during 
an inspection, the reality is that pharmacists 
feel, naturally and understandably, 
pressurised to drop everything and attend to 
the inspector’s requirements. I am sure you 
will agree that this is far from ideal from a 
patient safety point of view. 
The purpose of inspections, as we 
understand them, is to review and raise 
standards in pharmacy and ensure 
compliance with regulations. We would 
advocate that this can be better achieved 
if pharmacists are given advance notice, of 
say two–three weeks, so that they can review 
all their procedures, etc, and make sure 
that their pharmacy is up to the required 
standard. This is an approach adopted 
by many public sector organisations. The 
existing approach is perceived by pharmacists 
as a fault-finding exercise, rather than a 
constructive attempt to improve standards.
More importantly, the giving of advance 
notice is a more cost-effective, efficient and 
productive way to do business, particularly 
at a time of economic constraints and 
declining resources. We would also suggest 
that following an inspection that the Inspector 
would give a verbal account of the issues 
that need to be addressed to the pharmacist 
concerned and give them a reasonable 
period to put things right. This should be 
done before embarking on the costly exercise 
of putting very long reports into print and 
engaging in a long bureaucratic and costly 
correspondence exercise.
Of course, we understand and accept 
that there may be occasions when advance 
notice is not appropriate; e.g. where there are 
serious concerns about professional conduct 
or patient safety. 
These views and perspectives are not in 
any way to cast any aspersions on any of 
the staff of the PSI involved in inspections. 
Rather, it is to highlight the fact that the 
social and economic environment in which 
we are operating is changing and public 
bodies must recognise these changes and 
respond to them through cultural, behavioural 
and administrative change.  
2. Fitness to Practise
When the IPU supported the passage of the 
Pharmacy Act 2007 through the Oireachtas, 
it was never envisaged that Part 6 of the Act 
would be used to criminalise pharmacists 
for technical breaches of regulations; 
unfortunately, this is what appears to be 
happening. When a pharmacy is inspected, 
an inspection report is produced by the PSI 
and the pharmacist is given a number of 
weeks in which to respond. The pharmacist 
reviews all areas highlighted in the inspection 
report and addresses these issues, often 
at considerable expense. This is what the 
inspection process was designed to achieve; 
i.e. the improvement of pharmacy standards.  
Instead of accepting the pharmacist’s 
efforts or, indeed, making a further 
inspection to check that the new standards 
have been fully implemented, the PSI has, on 
occasions, brought the pharmacist through 
a Fitness to Practise (FTP) procedure, on 
foot of a complaint from the Registrar. Even 
more worryingly, the pharmacist can also 
be hauled through the District Court and 
prosecuted for a range of offences, mostly 
technical in nature and where there was no 
evidence of harm being caused to patients. 
The outcome is a criminal record, trauma 
and a very hefty fine for the pharmacist 
concerned and considerable expense by the 
PSI, which will ultimately be borne by our 
members.  
No other Regulator as far as we can 
establish treats their profession in such 
a way unless harm has been caused to 
a patient. Indeed, in one particular case, 
charges were preferred against a pharmacist 
of mature years who had resigned from the 
register on foot of the inspector’s report. It 
is not apparent what public good was, or 
is, being served by bringing prosecutions in 
such cases other than the prosecuting body 
being seen to wield considerable power. 
Fortunately, in that particular case, the judge 
decided to apply the Probation Act when he 
heard the evidence from both sides. 
For some unknown reason, Counsel for 
the PSI objected to the judge’s ruling on 
the basis that the judge could not apply the 
Probation Act and the judge then imposed 
nominal fines on the company rather than 
the individual concerned. From the advice 
we have taken, there is nothing to prevent 
a Court applying the Probation Act in such 
cases and perhaps the PSI might confirm 
that this is the case and advise its legal 
representatives accordingly. Indeed, the 
judge in this particular case made some very 
interesting observations on the inevitable 
tension that will exist between the strict 
application of regulations and the need and 
pressure on the professional at the coalface 
to respond to the needs of patients, which 
are both pertinent and relevant. 
Where the PSI decides to prosecute, it 
is also not clear to members why the PSI 
brings charges against the company and 
the same charges against the individual 
pharmacist, particularly in instances where 
the pharmacist is the main shareholder or 
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owner of the business. Again, when the Act 
was being enacted, it was intended that 
this would only be used to deal with large 
organisations to prevent a situation arising 
where such companies could blame the 
pharmacist for poor professional performance 
while they themselves avoid prosecution 
or other sanctions, even if their policies or 
procedures were a contributory factor. The 
issue of the Company versus the pharmacist 
was also at the core of a decision by the 
European Court of Justice (ECJ) in dealing 
with a challenge by the EU Commission to 
the regulation of the pharmacy profession 
in other jurisdictions and is relevant in this 
context.
We would propose that matters arising 
from inspections are best addressed as 
set out in this and the previous paragraph. 
Equally, there is nothing to prevent the 
Registrar from taking such matters into her 
own hands and meeting the pharmacist 
to stress the importance of maintaining 
standards and putting down a marker for 
the future that further breaches could lead 
to stronger action being taken. We do not 
understand either why mediation, which is 
facilitated by the Pharmacy Act, cannot be 
utilised as an alternative to the very costly 
and formal FTP or legal proceedings.
3. Communications
We have in the past made our views known 
to the PSI on the tone and the content of 
communications to pharmacists and I do 
not intend to go into any more detail on the 
issue here. We have also expressed the view 
that making submissions on draft papers 
or guidelines would appear to be a waste of 
time and resources as, invariably, any views 
put forward appear to have little impact. 
This has given rise to a perception that the 
purpose of the exercise is simply to ‘tick 
the box’ and be seen as going through the 
motions of consulting with stakeholders. 
I do not wish to re-open the recent 
vaccination episode, but suffice it to say 
that a significant number of pharmacists 
have chosen not to participate in vaccination 
this year as they felt that the barriers put 
in place by the PSI were much too high, 
relative to what was being imposed on 
other professionals. We would appeal to the 
Council to ensure appropriate engagement 
with the IPU before the roll-out of any further 
vaccination refresher training requirements 
next year to ensure we do not kill off such 
an innovative service before it even has a 
chance to get off the ground.   
4. PSI Fees
The cost of registration with the PSI is 
excessive and is out of line with international 
comparisons. The registration fee is €400 
(€570 on first registration) per pharmacist 
per year and each pharmacy must pay 
€2,250 (€3,500 on first registration) per 
year to register. In the UK the equivalent 
fees are £267 (£369 on first registration) 
per pharmacist and £221 (£789 on first 
registration) of a pharmacy premises. It is 
difficult to justify the fees being charged in 
Ireland, relative to our nearest neighbour and 
in many other jurisdictions. 
In light of the drastic cuts in pharmacists’ 
reimbursement in recent years under 
the Community Drugs Schemes and the 
Government commitment to reduce red 
tape and costs on businesses, our members 
would have an expectation of seeing a 
significant reduction in their pharmacy 
registration fees. In addition, our employee 
members have reported significant reductions 
in their salaries and would expect to see 
a proportionate reduction in pharmacist 
registration fees. We are, therefore, calling for 
a review of the level of PSI fees with a view 
to bringing them into line with those charged 
in other jurisdictions. We have also written to 
the Minister for Health on this issue. 
In conclusion, the views expressed in this 
letter are a fair reflection of how the PSI is 
perceived by pharmacists at this time. Obviously, 
we would have preferred to discuss the issues 
outlined in this letter with the Council in a 
face-to-face meeting. Nevertheless, we would 
appreciate the Council taking the time to review 
these issues and to reflect on them and our 
suggested solutions, which are intended to be 
both constructive and helpful. 
While we fully respect our mutually different 
roles and appreciate that we will not agree on 
everything, we believe that it is only by working 
together and taking account of our respective 
views that we can ensure that the pharmacy 
profession develops in the way we all want it to.
Our offer to meet with the Council to discuss 
these issues and, indeed, any other issues, is 
still on the table.
PSI – Letter 3
From Secretary General to  
Acting Registrar, PSI
[18 February 2013]
Re: Notice of PSI Inspections
I wish to refer further to the correspondence 
between our respective Presidents last year. 
One issue we raised in our letter was in 
relation to giving advance notice of pharmacy 
inspections. In his reply, the PSI President 
acknowledged that the PSI was mindful of the 
benefits of self-assessment methodologies and 
was considering the feasibility that a self-
assessment system would have in expediting the 
inspection process. 
The IPU launched a Pharmacy Self-Audit Tool 
on IPU NET, our web-based pharmacy support 
system, on 1 February 2013. We sent a copy of 
the audit to John Bryan for review on 17 January 
2013. In only a short time, it is impressive 
that over 120 pharmacies have already started 
to complete the audit. This is indicative of 
the professional attitude that Pharmacists 
are taking in ensuring that they maintain 
the highest pharmacy standards. We would 
welcome an opportunity to give your inspectors a 
demonstration of the audit tool in our offices and 
hear their views on it.
Finally, you might also let me know if the PSI 
have given any further consideration to giving 
advance notice of all routine inspections.  
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PSI – Letter 4
From Acting Registrar, PSI to  
Secretary General 
[25 March 2013]
Re: Notice of PSI Inspections
I wish to refer to your letter of 18 February 2013 
in which you inquire as to whether the PSI has 
given any further consideration to providing 
advance notice of routine inspections.
As you may be aware, the Council of the PSI 
is in the latter stages of finalising its ‘Corporate 
Strategy’ for the years 2013 to 2017.
Council has determined that the priority 
in regard to the inspection function for the 
next two years is to complete a full cycle of 
inspections by the end of 2014. Following that, 
the strategy envisages a transformation in how 
pharmacies are to be inspected. Obviously the 
manner in which this will be undertaken has 
not yet been agreed and will of course demand 
careful consideration. However, it is expected 
that this phase of the inspection programme 
will incorporate some form of a self assessment 
methodology and may involve the PSI notifying 
inspected parties in advance.
In regard to the IPU Pharmacy Self Audit 
Tool, the inspection and enforcement team 
have reviewed the material provided to them 
by Ms Logan and have responded with their 
views. The team has also accepted your offer to 
demonstrate the Audit Tool.
PRIMARY CARE CENTRES
From Director of Communications & 
Strategy to Acting Registrar PSI
[19 September 2012]
Re: Proposed Primary Care Centre on 
Tonlegee Road, Dublin 5
I wish to bring to your attention proposals by 
the Health Service Executive (HSE) to construct 
a Primary Care Centre, under a public-private 
partnership, on the grounds of St. Monica’s 
Youth Centre, the Vicarage, Tonlegee Road, 
Dublin 5 (planning application 2865/12).
A primary care centre will be built on lands 
surrendered back to Dublin City Council by St. 
Monica’s Youth Centre. The GPs in the local 
Edenmore Health Centre have agreed to move 
to the new centre, in the event it is approved for 
planning permission. We understand that there 
is a retail element to this development, including 
a pharmacy which, it is envisaged, will make 
this project commercially viable. The indication 
is that the pharmacy can be a ‘deal breaker’, 
in that revenues generated from the pharmacy 
would help sustain the centre. The planning 
application is now before Dublin City Council.
The inclusion of a pharmacy in this health 
centre would do serious damage to other 
pharmacies in the vicinity, including those in the 
Edenmore Shopping Centre and reduce patient 
choice.
It appears that the HSE is prepared to 
push ahead with further developments using 
Tonlegee Road as a model of future primary 
care centres. The concern is that the HSE, while 
getting involved in this model of public-private 
partnerships, will promote the inclusion of a 
pharmacy in other planned primary care centres 
to make these projects financially viable. 
I would ask that the Society investigate this 
development and similar developments on the 
light of PSI guidelines on these matters under 
Sections 63 and 64 of the Pharmacy Act.
Should you require further information, please 
do not hesitate to contact me. 
PHARMACY VACCINATION 
SERVICE
Pharmacy Vaccination Service – Letter 1
From Secretary General to  
Assistant Secretary, DoH 
[13 September 2012]
Re: Pharmacy Vaccination Service
I wish to bring to your attention our concerns 
about the difficulties facing pharmacists in 
contributing to the vaccination service this year.  
When the Minister for Health announced 
in July last year that pharmacists could 
participate in the seasonal influenza vaccination 
campaign, community pharmacists in Ireland 
enthusiastically greeted this new extended 
role. Over 1400 pharmacists completed the 
Irish Pharmacy Union (IPU) vaccination 
training course, accredited by the School of 
Pharmacy, Trinity College Dublin (TCD), and 
1208 pharmacies registered with the Primary 
Care Reimbursement Service (PCRS) to provide 
a vaccination service. Despite the delay in 
the legislation being enacted to facilitate 
pharmacists vaccinating, 9125 vaccinations were 
administered in 484 pharmacies throughout last 
season.
The IPU welcomed the Department of Health’s 
decision to extend the vaccination cohorts 
to all at-risk groups this year and community 
pharmacists looked forward to vaccinating 
a significant proportion of the population. 
Research in the USA has proven that when 
pharmacists provide vaccines, everybody 
benefits – the pharmacist, other healthcare 
providers and, most of all, the patients and 
the wider community. In fact, because of the 
increased awareness within communities, 
the overall number of vaccinations has been 
shown to increase. The overarching aim for 
all healthcare professionals is to increase the 
vaccine uptake in at-risk groups and to reduce 
the morbidity, mortality and burden to the health 
service, particularly in primary care, associated 
with seasonal influenza.
On 9 July 2012, the Pharmaceutical Society 
of Ireland (PSI) published the Report of the 
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Risk Review Group into the vaccination error 
that occurred in a minority of instances last 
year. Although the Report made a number of 
recommendations regarding vaccination training 
for all healthcare professionals, it did not make 
a specific recommendation that pharmacists 
must be re-trained or undertake refresher 
training this year before they could vaccinate. 
Nevertheless, on 16 July 2012, the PSI emailed 
all pharmacists, informing them that they had 
to undergo refresher training before they could 
vaccinate this year, both on-line and face-to-
face. At that time, the IPU argued that on-line 
training would be sufficient and that face-to-face 
training was an unnecessary and costly burden 
on pharmacists. Regrettably, the PSI ignored our 
counsel and insisted that any on-line refresher 
training would not receive accreditation or 
approval from the PSI if it did not have some 
face-to-face element. Likewise, the PSI Council 
would not approve pharmacists to vaccinate this 
year if they did not complete such prescribed 
refresher training.
Community pharmacists are understandably 
angry about these developments. If they wish 
to vaccinate this year, they now have to take 
more time out of their pharmacies and incur 
locum costs, just to satisfy these unreasonable 
requirements. We fail to understand the reasons 
or the motivation behind imposing these 
requirements. 
The PSI, without any consultation with key 
stakeholders, published the criteria for the 
refresher training on their website. It is quite 
clear that no practical thought was given to 
these criteria. There is much repetition in the 
curriculum and pharmacists will find themselves 
having to complete compulsory reading on a 
particular topic, then complete  an e-learning 
module on the same topic, then have it delivered 
for a third time during the face-to-face session. 
No other healthcare professional would put up 
with such desultory and derogatory treatment.  
The PSI, again without any consultation with 
key stakeholders, decided that vaccination of 
children and infants should be incorporated 
into the refresher training, despite the fact that 
children were not included in the full training 
course last year and despite the National 
Immunisation Office (NIO) being quite clear 
that children were not to be included in the 
HSE cohorts this year or even next year (apart 
from the specific group of seriously ill children 
identified who will most certainly receive 
vaccination from their GP). Only when the IPU 
made a very strong case that it made no sense 
to train pharmacists to vaccinate a cohort 
for which it is certain they will not have an 
opportunity to vaccinate did the PSI back down 
on this requirement.    
As a consequence, the IPU and our training 
partner, Hibernian Healthcare, have had to work 
within an incredibly tight timescale to produce 
a refresher training course and a full training 
course for pharmacists who did not receive 
training last year. Both courses are now with the 
PSI-appointed accreditor, TCD, for accreditation 
and several resubmissions have had to be made 
on relatively trivial matters. When we eventually 
receive accreditation from TCD, the courses 
have to undergo a further approval process 
by the PSI, whereby the whole PSI Council 
has to read through every document, at this 
stage about 80,000 words, before we can start 
delivering the training, notwithstanding that 
the PSI Council appointed TCD to accredit the 
courses. If the PSI Council makes any changes 
to the courses, they will have to be resubmitted 
to TCD once again for accreditation and then 
back to the PSI Council for approval. If this 
happens, we’ll be lucky to be in a position to 
train pharmacists this side of Christmas. 
Even if we do manage to get accreditation and 
approval for the courses within the next week or 
so, community pharmacists have understandably 
expressed their disappointment at the obstacles 
and costs being placed in their path that will 
prevent their participation in or significant 
contribution to the vaccination service this year. 
Pharmacists certainly did not make any money 
delivering vaccination services last year, given 
the start-up and training costs incurred. They 
had hoped to fare better this year but this seems 
highly unlikely now. The IPU President has written 
to all pharmacists, acknowledging their frustration 
but encouraging them to get behind this new 
initiative to show how successful pharmacists’ 
involvement can be in such services.
We would welcome some intervention from 
your Department into this affair as a matter of 
urgency; otherwise we are unlikely to see any 
pharmacy vaccinations taking place this year, a 
consequence that will have significant economic 
implications for the HSE. 
Pharmacy Vaccination Service – Letter 2
From Director of Pharmacy Services to Mr 
P Burke, PCRS 
[27 September 2012]
Re: Vaccination Training Grant
In September 2011, you confirmed that the 
IPU/Hibernian Healthcare Vaccination Training 
Course, which was accredited by Trinity 
College Dublin (TCD) and approved by the 
Pharmaceutical Society of Ireland (PSI), would 
be added to the List of Approved Courses for the 
training grant arrangements. It was subsequently 
given the code IPU08. We will be offering this ab 
initio course again this year to pharmacists who 
did not complete vaccination training last year. 
In addition, the PSI has required that all 
pharmacists who completed vaccination training 
last year undergo some refresher training this 
year, including a face-to-face element. The IPU 
and Hibernian Healthcare have consequently 
developed a Refresher Vaccination Training 
Course which has also been accredited by TCD 
and approved by the PSI. 
The cost of this half-day course, including an 
element of e-learning in advance of the face-to-
face element, is €170. I would now ask that this 
Refresher Vaccination Training Course be added 
to the List of Approved Courses for the training 
grant arrangements and that a code is allocated.
Pharmacy Vaccination Service – Letter 3
From Secretary General to Aviva Health 
Insurance, Laya Healthcare & Glo Health 
[31 October 2012]
Re: Pharmacy Vaccination and  
Health Screening
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I am writing to you, on behalf of the Irish 
Pharmacy Union (IPU), the representative 
body for community pharmacists, in relation to 
the possibility of Aviva Health reimbursing its 
members for pharmacy influenza vaccinations 
and health screening. 
Last July, the Minister for Health announced 
that pharmacists could participate in the 
seasonal influenza vaccination campaign. 
Despite the delay in the legislation being 
enacted to facilitate pharmacists vaccinating, 
9125 vaccinations were administered in 484 
pharmacies throughout last season.
This season, we welcomed the Department 
of Health’s decision to extend the vaccination 
cohorts to all at-risk groups and community 
pharmacists look forward to vaccinating 
a significant proportion of the population. 
Research in the USA has proven that when 
pharmacists provide vaccines, everybody 
benefits – the pharmacist, other healthcare 
providers and, most of all, the patients and 
the wider community. In fact, because of the 
increased awareness within communities, 
the overall number of vaccinations has been 
shown to increase. The overarching aim for 
all healthcare professionals is to increase the 
vaccine uptake in at-risk groups and to reduce 
the morbidity, mortality and burden to the health 
service, particularly in primary care, associated 
with seasonal influenza.
Data collated by the IPU for pharmacy flu 
vaccination to date shows that 23% of patients 
received seasonal influenza vaccination for 
the first time ever; of this category of first time 
patients, 78% were in the at-risk category; 
overall, of the patients who received seasonal 
influenza vaccination in a community pharmacy, 
90% were classified as at-risk. I’m sure you will 
agree that it is beneficial, not just to the patient 
but to you as a health insurer, that vaccination 
uptake increases in Ireland, especially in the 
at-risk categories. When more people are 
vaccinated, less people end up in hospital with 
flu-related illnesses. In the circumstances, 
we would suggest that Aviva Health consider 
reimbursing its members for the cost of getting a 
flu vaccination in a community pharmacy.
Another new service being offered in 
community pharmacy is health screening or 
health checks. This involves the pharmacist 
conducting a series of checks on the patient, 
e.g. blood pressure, blood glucose, cholesterol, 
BMI, and recommending either lifestyle advice 
or referral to the patient’s GP. It is important 
to note that the pharmacist does not diagnose 
a particular chronic disease; rather they 
identify patients who are at risk and provide 
the appropriate advice or referral. The aim is to 
reduce the number of people developing chronic 
disease in the first place, thus reducing costs 
in secondary care, costs that are often met by 
health insurers. I’m sure Aviva Health welcomes 
such an initiative and we would suggest that 
patients who receive a health check or screening 
in their local community pharmacy be able to 
claim back the cost of the check from Aviva 
Health.
We are happy to meet with you, at your 
convenience, to discuss these issues in more 
detail.  
BENZODIAZEPINES
From Secretary General to R Shortall TD, 
Minister of State for Health 
[17 May 2012]
Re:  Reclassification of Benzodiazepines
Firstly, I would like to take this opportunity to 
thank you once again for attending the IPU 
National Pharmacy Conference in Galway last 
month. The delegates present found your speech 
about your vision for primary care most inspiring.
One issue that has been receiving a lot of 
media attention recently is the overprescribing 
and misuse and abuse of benzodiazepines. 
Pharmacists share your concerns about this 
issue and we would welcome the opportunity 
to engage with your officials to see how all 
healthcare professionals could work together to 
address these concerns. 
Indeed, the IPU has been a key stakeholder 
in recent multi-stakeholder meetings to discuss 
this issue. We attended a meeting in Tralee in 
March where over 100 pharmacists, GPs, Gardaí 
and HSE drugs workers highlighted experiences 
from each other’s perspectives. We will also be 
involved in a meeting this week in Cork between 
pharmacists, GPs, psychiatrists and the local 
drugs taskforce. We hope to encourage further 
such meetings around the country through the 
pharmacist representatives on the Regional 
Drugs Taskforces. 
We have heard that the Department may be 
considering rescheduling benzodiazepines from 
CD4 to CD3. This would result in prescriptions 
having to be written in the prescriber’s own 
handwriting, specifying the dose, form, 
strength and, in both words and figures, the 
total quantity of the medicine. Pharmacists 
already experience difficulty getting prescribers 
to follow these guidelines for existing CD3s. 
Extending this requirement to benzodiazepines 
would result in further duress for pharmacists 
and inconvenience for patients and would be 
unlikely to result in reduced prescribing of 
benzodiazepines.
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We would welcome a meeting with your 
officials to share what we have learned from 
the meetings in Tralee and Cork and to 
come to agreement on how the problem of 
overprescribing of benzodiazepines could  
best be addressed.        
PCRS COMMUNICATIONS
PCRS Communications – Letter 1
From Secretary General to  
Mr P Burke, PCRS 
[13 November 2012]
Re: Communications
I wish to raise a number of issues with you.
Firstly, you wrote to me on 30 October 2012 
to advise that you had written to the vendors of 
the Pharmacy Computing Software requesting 
that they outline how the Owings function is 
designed within their software and attached 
copies of said letters. These letters were reviewed 
by our Community Pharmacy Committee at their 
meeting of 7 November 2012. 
The Committee was extremely concerned at 
the allegations made in your letter, which imply 
that pharmacists are deliberately defrauding 
the HSE by manipulating their systems to make 
duplicate or invalid claims. The Committee has 
asked that you withdraw this general allegation 
and write again to the vendors, clarifying that 
you had not intended to slander the entire 
community pharmacy profession.
Secondly, over the past year we have 
become increasingly frustrated at the lack of 
communication and engagement from your 
department. The lack of notice about the recent 
IPHA and APMI cuts, and the manner in which 
these changes have been implemented, is 
totally unacceptable and cannot be allowed 
to happen again. In addition, you would have 
been aware that you were going to make 
changes to payments for Oral Nutritional 
Supplements (ONS) for some time, yet we were 
not informed officially until 30 October, with an 
implementation date of 1 November. This is an 
appalling situation and totally unacceptable.
We received the list of price reductions for 
the ONS on 30 October and were advised that 
a number of GMS codes would be removed and 
replaced by new GMS Codes from 1 November. 
However, while we were advised of the products 
that would be affected, a list of the new codes 
did not arrive until late on Friday 2 November, 
which meant that many commonly dispensed 
products had no active code for a number of 
days. The IPU predicts that this will result in a 
number of unpaid claims for ONS due to the 
manner in which this issue was handled.
The IPU has repeatedly asked that reasonable 
notice be given to changes of this nature to 
ensure smooth implementation and yet, time 
and time again, no such notice or inadequate 
notice is given. The IPU fully appreciates 
the severe pressure on the health budget at 
this time. However, this does not justify the 
unreasonable and disrespectful manner in 
which these changes are being introduced. 
The consequences of this approach are that 
pharmacists are considerably out of pocket as 
the value of their stock falls as they are not given 
a reasonable opportunity to run down their stock 
and minimise their losses. Most pharmacies are 
small businesses who, like all businesses at this 
time, are suffering the effects of the economic 
recession and low consumer confidence and 
this is all the more reason why the State should 
treat them fairly in these matters.  We demand 
that such changes will not be forced through 
in future without giving pharmacists and other 
stakeholders adequate notice and time to run 
down their stock levels and minimise their 
losses. This issue has also been the subject of a 
separate letter to the Minister.
Thirdly, in relation to other communications 
with your unit, we find it disrespectful that you 
refuse to respond to our requests for clarification 
and resolution on a range of issues. Examples 
include:
n Vaccination:
• Lack of response to letters sent on 
19 and 27 September in relation 
to training grant codes for health 
screening and vaccination refresher 
training;
• Lack of response to email sent 12 
September asking for clarification on 
vaccinations to patients from Northern 
Ireland; 
• Lack of response to email sent 30 
October requesting that the GP field 
on the PCRS Vaccination Recording 
Appendix II
(continued)
44
AnnuAl RepoRt 2013
Website should not be mandatory; and
• Lack of any real engagement 
on linking IPU Net to the PCRS 
vaccination recording system.
n Pradaxa:
• Withheld Pradaxa Claims dating back 
to October 2011;
• Incorrect information about claims 
being paid when they had not been 
paid; 
• Lack of communication on the reason 
why these claims have been being 
withheld by the PCRS and the legal 
basis for doing so.
n Recent Vendor Issue:
• Lack of response on a basic question 
about how the PCRS system deals 
with claims where a code was not 
provided by the PCRS
n Non-Reimbursement of GMS Products:
• Lack of communication or notice 
on the withdrawal of GMS codes for 
Gluten Free products, Glucosamine, 
Orlistat and Omega-3;
• While an undertaking was given to 
pay these claims up to and including 
3 September, all claims were initially 
rejected;
• Lack of clarification on queries made 
about these products being rejected 
along with all other medicines on the 
same prescription being rejected.
Fourthly, I have personally raised individual 
cases with you and promises that were made 
have not been fulfilled. 
Despite assurances from your Department, 
through our Joint Consultative Group, that issues 
such as those outlined above will be addressed, 
we see no evidence that this is the case. As 
you are aware, we have put forward a detailed 
customer charter on how issues that arise in 
relation to claims should be dealt with, which 
is in accordance with normal customer service 
norms and standards of administration in the 
public sector, but these too have gone nowhere. 
In light of the foregoing, it is hardly surprising 
that the IPU has serious concerns about 
PCRS systems, general administration and 
communications. Recently, there has been a 
high level of claims rejected due to ‘system 
error’. It is essential that the PCRS takes all 
steps to eliminate any potential areas where your 
systems and administration could be perceived 
as not operating in accordance with law and the 
terms of contracts.
If an acceptable process for dealing with these 
types of issues is not put in place by the end 
of the year it is our intention to seek a meeting 
with Dr Ambrose McLoughlin, Chairman of the 
HSE and Tony O’Brien, HSE Director General, to 
explore how these matters can be resolved to our 
mutual satisfaction. 
PCRS Communications – Letter 2
From Secretary General to  
Mr P Burke, PCRS 
[15 February 2013]
Re: Communications
I wish to refer to my previous correspondence on 
this matter dated 13 November 2012 and your 
reply of 3 December 2012.
Since our previous letter, there have been 
a number of other developments, which again 
highlight the lack of communication and 
engagement from the PCRS on key issues. 
n High Tech Medicines (HTM) Scheme 
Under the terms of the 1996 Agreement 
between the HSE and the IPU, the HSE are 
required to inform the IPU of new HTMs 
seeking approval under the HTM Scheme. 
The Pharmacy Contractors’ Committee would 
then review these new medicines under the 
HTM criteria and respond to the HSE. 
In January 2013, the IPU Product File 
Department received a list of new GMS 
medicines to be included on the 1 February 
Update to Pharmacists. On this list, a new 
HTM was included. This medicine had not 
been reviewed under the HTM Criteria. The 
IPU queried this oversight with the HSE.  On 
8 February the HSE wrote to the IPU stating 
that in future the HSE would only notify the 
IPU of the additions to the HTM Scheme at 
the same time as approvals were issued to 
the manufacturer involved.
There was no discussion with the IPU prior 
to this policy change. This is not acceptable 
and I am to request the immediate 
reinstatement of the existing arrangements.
n Implementation Meeting on Reference 
Pricing Legislation
The IPU attended an Implementation Group 
Meeting on Thursday 7 February to discuss 
the implementation of Reference Pricing 
legislation and the changes that needed to 
be made to pharmacy IT systems. The three 
IT system vendors were also in attendance at 
that meeting. The HSE informed the meeting 
that while they were implementing IT changes 
to enable the introduction of the Reference 
Pricing legislation, they decided they would 
take this opportunity to seek a number of 
upgrades, which the HSE felt would make the 
claiming system more efficient. The changes 
would cover electronic claiming for dental 
claims, EU claims, methadone claims and 
scheme authentication at point of dispensing. 
The upgrades to facilitate the seamless 
implementation of the Reference Pricing 
legislation are complicated enough without 
additional upgrades being considered at 
this time. To include any other non-essential 
upgrades at this time is irrational and illogical. 
The HSE is also putting forward changes 
to the system, which are not necessary under 
the legislation. Again, the HSE had taken the 
decision themselves without any discussions 
with the IPU. 
Pharmacists will be prepared to capture 
the two vital pieces of information necessary 
which are the details of the medicine 
dispensed and whether the prescriber had 
specifically requested “no substitution” in 
any particular case. The capture of any other 
information will not be possible.
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n Pradaxa Reimbursement Decisions
Since November 2011, communications from 
the HSE regarding Pradaxa and Xarelto have 
been chaotic, complicated and confusing. 
The HSE consistently make decisions on 
issues without communicating them to the 
relevant stakeholders. By doing this, they 
continue to place pharmacists in a situation 
whereby they are being asked to dispense 
medicines with the vague hope of being paid 
at some unknown date in the future. Having 
regard to patient care needs, pharmacists 
have up to this point tolerated the inefficient 
work methods of the HSE. However, the 
most recent communications from the HSE 
on these medicines will push pharmacists’ 
patience to breaking point.
The HSE is now advising pharmacists that, 
despite what is written on the prescription, 
they are to be guided, not by their 
professional responsibilities to their patients, 
but by cost effectiveness considerations.  
This goes against the pharmacy contract and 
is not in the interests of patients. A number 
of critical patient issues arise from this 
decision which will be subject to a separate 
letter. I am also awaiting a response to my 
last email on the issue of paying pharmacists 
who dispensed 2x75mg before they were 
notified by the HSE of the change of policy in 
this area.
In relation to our letter of 13 November 2012, 
the following questions are still outstanding:
n Vaccination:
• Lack of response to letters sent on 
19 and 27 September in relation 
to training grant codes for health 
screening and vaccination refresher 
training;
• Lack of response to email sent 12 
September asking for clarification on 
vaccinations to patients from Northern 
Ireland; 
• Lack of response to email sent 30 
October requesting that the GP field 
on the PCRS Vaccination Recording 
Website should not be mandatory; 
• Lack of any real engagement 
on linking IPU Net to the PCRS 
vaccination recording system; and
• Lack of response on up-to-date 
pharmacy vaccination figures.
n Recent Vendor Issue:
• Although the HSE responded on how 
the PCRS system deals with claims 
where a code was not provided by 
the PCRS, we are still waiting on 
clarification on how these claims can 
be resubmitted to the PCRS. 
It is extremely disappointing that despite 
recent assurances that communications from 
the HSE would improve, we continue to see 
decisions made without prior discussion or 
agreement with the IPU which is not in the 
interests of the HSE or pharmacists.  
PCRS Communications – Letter 3
From Mr P Burke, PCRS to  
Secretary General 
[25 February 2013]
I refer to your letter of 15 February 2013 
re: communications, of which, some of the 
commentary refers back to your letter of 13 
November 2012. I have already responded  
to the vaccination issues in my response of  
3 December 2012 and I will deal here with the 
issues, which have arisen since the beginning  
of the year to which you refer.
High Tech Medicines
In 2012 the Government agreed challenging 
timelines, as set out in the 2012 IPHA 
Agreement, for approval to allow medicines 
to be available to eligible persons. The HSE 
communication of 8 February 2013 was 
designed to ensure that these timelines could 
be met. However, in the light of your stated 
objections, we can notify you at an earlier stage 
in the process. 
In order to meet the established timelines this 
will mean that the IPU will be asked to confirm 
that the Union has ‘no objections’ to products 
which may not ultimately be approved by the 
HSE under the High Tech arrangements. 
I note that the IPU has rarely raised queries 
in the past during the month set aside for this 
aspect of the process, and the fact that the 
requirement for PDF to agree has been rendered 
obsolete over the last two years, perhaps it is 
appropriate we should revisit and review this 
aspect of the arrangement.
Implementation Meeting on Reference  
Pricing Legislation
The IPU portrayal of the recent meeting in the 
Department of Health is simply not correct. 
As you know, the HSE is not a customer of 
pharmacy software vendors and we are not in 
a position to “seek upgrades” in the manner 
suggested. The HSE simply articulated at the 
meeting that it is entirely reasonable to have a 
project where each vendor can deliver enhanced 
software to meet the needs of their pharmacy 
customers. 
This was specified as an opportunity for 
pharmacy software vendors to add value to their 
software. The vendors can choose the level to 
which they would aspire to become certified 
(in terms of the capability of their software to 
interact with PCRS) from the four levels available 
and this is a decision for pharmacy software 
vendors in conjunction with their pharmacy 
clients.
It is the HSE view that the enhancements, 
should a vendor wish to develop and implement 
them, are very much to the benefit of 
pharmacists i.e. 
n They will facilitate automated electronic 
claiming for Dental prescriptions, EU 
claims, Methadone Claims including 
electronic correction claims to minimise / 
avoid any claim rejects
n The early pay cycle will offer faster cash 
turnaround for all schemes
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n A reduction in administrative work for 
pharmacists and the HSE i.e. coding not 
required 
n Near real time reporting on monthly 
submissions, which reduces reclaims and 
providing pharmacists with the option 
to address claims promptly within the 
payment cycle.
The HSE has previously made the IPU aware 
in correspondence and at formal meetings 
of our obligation to manage and reduce our 
operating costs wherever possible to ensure 
best value for money for the taxpayer. This 
means that all aspects of processing must be 
reviewed critically to ensure maximum efficiency. 
In line with these matters and the associated 
draft correspondence, the content of which has 
previously been shared with the IPU, I will be 
writing, in the coming days, to all pharmacists 
setting out the dates for revised administration 
arrangements. A copy of that correspondence is 
enclosed.
The HSE believe that it is rational and 
logical and an efficient use of resources for all 
concerned to deliver three projects (one per 
vendor) now, including all current upgrades, 
rather than a potential twelve projects over the 
next number of months. The HSE has committed 
to supporting one project per vendor at no 
charge and will seek an explicit commitment 
from each as to which interface level they are 
committed. If a vendor, at the behest of their 
pharmacy customers, decides to limit the scope 
of their project, and the functionality which 
is available to their customers, this is entirely 
their prerogative. If a vendor decides to reduce 
the scope of the project, we will still commit to 
delivering the project. 
It should be noted that commitment to a 
single project by a vendor does not preclude 
for phasing some of the deliverables. The 
objective is simply to maximise the efficiency 
through which full functionality capability can be 
delivered. 
All of the data items required for reference 
pricing were clearly flagged in the stakeholder 
meetings held in November 2012 by the 
Department of Health. However, I will update the 
Department of Health of your position in relation 
to this issue.
Pradaxa Reimbursement Decisions
The HSE faced a huge challenge when the 
extended indication for the treatment of SPAF 
was approved by the EMA. The estimated budget 
impact for Schemes was very significant. The 
HSE sought guidance from the Department of 
Health in July 2012 and corresponded with all 
stakeholders including Hospital Physicians in 
relation to an individualised approval mechanism 
on the 25 July 2012. Such arrangements are 
a recognised rate limiting mechanism in other 
jurisdictions and the HSE is satisfied that the 
individualised mechanism served this purpose. 
You have referred to the Pharmacy Contract. 
As you are aware, Clause 9(1) of the Terms and 
Conditions of Agreement to the Community 
Pharmacy Contractor Agreement provides for a 
review of the medicine therapy of the individual 
for whom the prescription is issued. It is further 
provided in sub-clause (4) that “[t]he review 
provided for in sub-clause (1) shall also include 
an examination of the rational and cost effective 
use of the medicine prescribed, including the 
choice of the medicine and the potential for 
wastage.” It remains the HSE’s view that the 
continued supply of Pradaxa 2x75mg against the 
backdrop of a reimbursable Pradaxa 150mg is 
neither rational nor cost effective.
I do not accept the point in your email 
communication that pharmacists were not 
aware of the fact that they would not have carte 
blanche regarding reimbursement for dispensing 
2x75mg Pradaxa. We were very clear to the IPU 
and to pharmacists, through the agreed reporting 
mechanism, i.e. their monthly printout, in 
relation to those claims that are not reimbursed. 
In addition, in order to be reimbursed it was 
and is a requirement that approval to dispense 
Pradaxa for particular indications would first be 
obtained from the HSE. We made this clear in 
our Circular 010 -12 in July 2012.
Furthermore, the implication that it is 
appropriate to displace the fundamentals of 
appropriate claiming practices whereby the 
most suitable formulation to satisfy the dosage 
requirement of the patient is supplied by the 
dispensing pharmacist is disconcerting. To even 
suggest that it would be appropriate to pay 
double the cost because either or both GP and 
Pharmacy Computers have not updated their 
medication histories is regrettable. Taxpayers 
would find it really difficult to understand that 
resources could be consumed in the manner 
suggested by the IPU, as the HSE continues its 
focus on sustaining essential services for the 
most vulnerable in our communities.  
Vaccination
As referred to in previous communications, 
the HSE is awaiting clarification from the 
Department of Health in relation to (i) 
Vaccination Grants and (ii) Treating patients from 
Northern Ireland.
In relation to claims submitted for 
reimbursement without the correct code, it is 
necessary for Pharmacies to resubmit claims for 
items for which they did not enter a pharmacy 
code prior to submission, in line with the 
established and agreed process.
As you know we have put in place a specific 
Customer Service function to maintain and 
develop communications between pharmacists 
and the HSE. I believe that the IPU and the 
HSE should work this process to ensure that 
the issues discussed above can be managed 
appropriately.
I believe that we should also hold a Joint 
Consultative Group (JCG) meeting as you and I 
discussed recently and we should agree how we 
can further work in improving communication 
streams to the benefit of all. I will ask my office 
to contact the IPU later today and arrange a 
meeting of the JCG in the coming weeks.
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EXTEMPORANEOUS 
PREPARATIONS
From Director of Pharmacy Services to 
Chief Pharmacist, DoH 
[11 July 2012]
Re: Regulations regarding Extemporaneous 
Preparations in Pharmacies
I am writing to you on behalf of the Irish 
Pharmacy Union (IPU) in relation to regulations 
regarding extemporaneous preparations of 
medicinal products in community pharmacies. 
The Medicinal Products (Control of 
Manufacture) Regulations 2007 (S.I. No. 539 
of 2007), Paragraph 5, allows for an exemption 
to the requirement of a manufacturer’s 
authorisation for 
“the extemporaneous manufacture of a 
medicinal product in response to a bona 
fide unsolicited order to fulfil a special need 
and which is carried out – in a dispensing 
pharmacy by or under the personal 
supervision of a pharmacist
n in accordance with the specifications 
of a registered medical practitioner or 
registered dentist for use by his or her 
individual patients on his or her direct 
personal responsibility, or
n for the purpose of maintaining a stock 
of medicinal product for dispensing 
exclusively in such pharmacy to meet the 
orders of the aforementioned registered 
medical practitioner or registered dentist, 
or
n in accordance with the prescriptions of 
a pharmacopoeia for supply to patients 
attending that pharmacy 
…….and, provided in each case that 
the medicinal product concerned is 
not the subject of any advertisement 
or representation and that no other 
medicinal product of appropriate 
composition, that is the subject of a 
marketing authorisation, is available for 
use in the circumstances”.   
Schedule 1 of the Medicinal Products (Control 
of Placing on the Market) Regulations 2007 (S.I. 
No. 540 of 2007) also allows for exemptions 
from the authorisation requirements. Paragraph 
2 specifies that the regulations: “shall not apply 
to the sale or supply of a medicinal product 
in response to a bona fide unsolicited order, 
formulated in accordance with the specifications 
of a practitioner for use by his individual patients 
on his direct responsibility, in order to fulfil the 
special needs of those patients….”.
In recent weeks, the IMB has contended that 
their interpretation of these regulations is that 
pharmacists can only supply an extemporaneous 
medicinal product if it is on foot of a prescription. 
The IPU would contend that this was not the 
intention of the regulations when they were 
drafted. Pharmacists are taught how to prepare 
a range of extemporaneous medicinal products 
while at university. Generations of pharmacists 
have produced pharmacy-specific formulations 
designed to meet the “special needs of their 
patients”. It would be a sad, sad day for the 
practice of pharmacy if pharmacists were now 
prohibited from utilising their professional skills 
to respond to the individual needs of their 
patients. The IPU would ask the Department for 
urgent clarification on this issue.   
We raised this issue in our recent submission 
to the Department on the Transposition 
of Directive 2010/84/EU and Regulation 
1235/2010/EU on Pharmacovigilance but felt 
that the issue was so important as to warrant a 
separate letter. 
Please do not hesitate to contact me if you 
would like any further information or clarification 
on the points raised in this letter.
PRADAXA
From Director of Pharmacy Services to Mr 
P Burke, PCRS 
[15 February 2013]
Re: Pradaxa Dispensing
I wish to highlight some serious concerns about 
the manner in which the HSE is dealing with the 
matter of Pradaxa. 
Since November 2011, communications from 
the HSE regarding Pradaxa and Xarelto have 
been chaotic, complicated and confusing. Time 
after time, the HSE has made decisions on 
issues of supply without communicating them 
to the relevant stakeholders, i.e. prescribers, 
pharmacists and patients. By doing this, the HSE 
continues to place pharmacists in a situation 
whereby they are being asked to dispense 
medicines with the vague hope of being paid at 
some unknown date in the future and patients 
unsure of whether they will get the medicines 
that have been prescribed for them.
Having regard to patient care needs, 
pharmacists have, up to this point, tolerated the 
inefficient work methods of the HSE. However, 
the most recent communications from the HSE 
on these medicines has pushed pharmacists’ 
patience to breaking point.
Following queries on the matter, the HSE 
issued the following advice to the IPU:
n Supply of 2 x 75 mg Pradaxa 
The IPU accepts that the HSE wishes 
to restrict dispensing to the most cost 
effective formulation for Pradaxa. 
However, pharmacists received no 
notification that from October 2012 their 
claims for 2 x 75mg would be rejected. 
The PCRS has also confirmed that where 
the GP prescribes Pradaxa 2 x 75 mg 
due to patient care issues (i.e. difficulty 
in swallowing) these claims will also be 
rejected. The HSE has stated that no 
matter what formulation is prescribed,  
no claims for Pradaxa 2 x 75mg will  
be reimbursed.
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This is a worrying development for 
pharmacists and patients as the HSE is 
now advising a pharmacist that despite 
what is written on the prescription they 
are to be guided, not by their professional 
duty, but by cost effectiveness. This 
breaches the pharmacy contract and may 
adversely affect patient care.
• Supply of 30 Days of Pradaxa for VTE 
The IPU has raised the matter of the 
30 day supply of Pradaxa for Venous 
Thromboembolism (VTE). Again the 
advice from the HSE is that even though 
the prescription may be for a 35 day 
supply, they will only reimburse 30 days.
This raises professional, contractual 
and liability concerns for pharmacists. 
It is also pushing pharmacists into a 
situation whereby they are policing 
prescribing habits of GPs and Hospital 
Consultants. This is completely 
unacceptable.  
• Waiting time for letter of approval  
for Pradaxa 
Pharmacists are receiving a number of 
complaints from patients who are present 
at the pharmacy with prescriptions but 
no approval letter. Can you please ensure 
that all prescribers are aware of their 
obligations to ensure that patients have 
an adequate supply of medicines when 
they are discharged from hospital? 
While the IPU understands the tough 
economic situation that we all find ourselves in, 
it is completely unacceptable for the PCRS to 
advise pharmacists to breach their contract and 
professional obligations.
ICCPE / PHARMACY TRAINING 
GRANT / CONTINUING 
EDUCATION
Letter 1
From Secretary General to Assistant 
Secretary General, DoH 
[12 November 2012]
Re: ICCPE Funding
We have written to you on a number of 
occasions over the past year or two, expressing 
concern about the future of the Irish Centre for 
Continuing Pharmaceutical Education (ICCPE) 
and its funding in the context of establishing the 
Irish Institute of Pharmacy.
In the last few weeks, a HSE official has 
informed the Management Committee of ICCPE 
that it must wind up its affairs by the end of 
the year and that all future ICCPE funding will 
transfer to the Institute.  
Funding for the ICCPE was agreed between 
the Irish Pharmacy Union (IPU) and the 
Department of Health as part of the 1996 
Community Pharmacy Contractor Agreement. 
The purpose of this funding was to enable 
community pharmacists to continually update 
their professional skills by attending approved 
continuing education courses in the practice of 
pharmacy. ICCPE has delivered admirably on 
this remit since its inception, despite ongoing 
staffing issues as a consequence of the HSE 
recruitment embargo.
The Pharmaceutical Society of Ireland (PSI) 
has previously confirmed that the new Institute 
will not deliver continuing education; rather it will 
accredit and commission providers of continuing 
education. 
The IPU feels it is imperative that no decision 
should be made about the future of the ICCPE or 
its funding without first having discussions and 
agreement with the IPU on the matter.
We would welcome a meeting with you, as a 
matter of urgency, to discuss this matter.
Letter 2
From Secretary General to Assistant 
Secretary, DoH
[19 December 2012]
Re: Pharmacy Training Grant
In September 2011, the Department of Health 
confirmed that the IPU/Hibernian Healthcare 
Vaccination Training Course, which was 
accredited by Trinity College Dublin (TCD) 
and approved by the Pharmaceutical Society 
of Ireland (PSI), would be added to the List 
of Approved Courses for the training grant 
arrangements. It was subsequently given the 
code IPU08. We offered this ab initio course 
again this year to pharmacists who did not 
complete vaccination training last year. 
In August 2012, the PSI informed us that 
all pharmacists who completed vaccination 
training last year needed to undergo refresher 
vaccination training this year, including a face-to-
face element. The IPU and Hibernian Healthcare 
consequently developed a Refresher Vaccination 
Training Course which was also accredited by 
TCD and approved by the PSI. 
The cost of this half-day course, including an 
element of e-learning in advance of the face-to-
face element, was €170. I would now ask that 
this Refresher Vaccination Training Course be 
added to the List of Approved Courses for the 
training grant arrangements and that a code be 
allocated.
In addition, the IPU and the Irish Heart 
Foundation joined forces earlier this year to 
produce Cardiovascular Risk Assessment 
Training for Pharmacists. The one-day course 
was designed to give participants:
n Individual practical experience of 
assessing cardiovascular risk including 
blood pressure, cholesterol, glucose, 
body mass index and waist circumference 
measurements;
n An understanding and knowledge of 
appropriate GP referral guidelines;
n An understanding and knowledge of 
advice to patients of appropriate  
lifestyle behaviours;
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n Information on standards and quality 
assurance when conducting the risk 
assessments; and 
n An overview of cardiovascular disease, 
risk factors and the range of interventions 
available to those at risk.
I’m sure you will agree that this course 
will prepare pharmacists to participate in the 
forthcoming HSE Clinical Care Programmes. The 
course was devised using the PSI Generic Interim 
Accreditation Standards for Formal Programmes 
of Learning for Pharmacy in Ireland. The 
training day was led by Dr Angie Brown, Medical 
Director of the Irish Heart Foundation and 
Consultant Cardiologist, supported by Irish Heart 
Foundation nurses and dieticians. A community 
pharmacist led a session on how to incorporate 
health checks into pharmacy practice. 
The course cost €250 per pharmacist and 
the IPU would like you to include this training 
course on the list of courses eligible for the 
Pharmacy Training Grant.
Letter 3
From Secretary General to  
Assistant Secretary, DoH
[1 February 2013]
Re: Continuing Education Funding/ 
Pharmacy Training Grant
I am writing to you to get some resolution on 
two issues that the Irish Pharmacy Union (IPU) 
has concerns about: funding for continuing 
education for community pharmacists; and the 
pharmacy training grant.
Funding for Continuing Education for 
Community Pharmacists
We have written to you on a number of 
occasions over the past three years, expressing 
concern about the future of the Irish Centre for 
Continuing Pharmaceutical Education (ICCPE) 
and its funding in the context of establishing the 
Irish Institute of Pharmacy.
In October last, the HSE ordered the 
Management Committee of ICCPE to wind 
up its affairs by the end of the year. The HSE 
confirmed at that time that all future ICCPE 
funding would transfer to the Irish Institute 
of Pharmacy which will implement a new 
Continuing Professional Development (CPD) 
system for pharmacists.  
Funding for ICCPE was agreed between the 
IPU and the Department of Health as part of 
the 1996 Community Pharmacy Contractor 
Agreement. The purpose of this funding 
was to enable community pharmacists to 
continually update their professional skills 
by attending approved continuing education 
courses in the practice of pharmacy. ICCPE 
has delivered admirably on this remit since its 
inception, despite ongoing staffing issues as a 
consequence of the HSE recruitment embargo.
The Pharmaceutical Society of Ireland (PSI) 
has confirmed that the new Institute will not 
deliver continuing education; rather it will 
accredit and commission providers of continuing 
education. The IPU therefore feels that it is 
necessary for us to have a discussion to ensure 
that the funding agreed on in 1996 is ring-fenced 
to fund continuing education for community 
pharmacists into the future. This is especially 
important now more than ever, given that the 
Minister for Health has made it clear that 95% 
of healthcare should be delivered in the primary 
care sector and community pharmacists are 
willing to make a significant contribution to this 
care in the community.
Given the sudden closure of the ICCPE and to 
prevent a vacuum in Continuing Education (CE) 
developing, the IPU is developing and will deliver 
an inaugural IPU Academy Spring Programme. 
This CE programme is modelled on similar 
lines to the live learning programmes previously 
offered by the ICCPE. 
Not surprisingly, the IPU will incur significant 
costs in the roll out of this Spring Programme 
and any subsequent programmes. Given that the 
funding for ICCPE was a contractual obligation, 
the IPU is of the view that the money previously 
allocated to ICCPE should not be directed to the 
Institute until the IPU and the Department have 
an agreement on how that money will be utilised 
for pharmacist education and training. 
Pharmacy Training Grant
In July 2001, agreement was reached between 
the IPU and the Department of Health on 
a remuneration package for all pharmacist 
contractors, arising from the granting of 
automatic medical card eligibility for citizens 
over 70. As part of the agreement, it was also 
agreed that the Department would introduce 
Training and Education grants for pharmacists 
and their staff. Since then, pharmacists have 
been able to claim up to €1,270 per year as a 
contribution towards training themselves and 
their pharmacy staff. It is important to note that 
this is a contribution; many pharmacists spend 
much more than this on training. 
In September 2011, the Department of 
Health confirmed that the IPU/Hibernian 
Healthcare Vaccination Training Course, which 
was accredited by Trinity College Dublin (TCD) 
and approved by the PSI, would be added to 
the List of Approved Courses for the training 
grant arrangements. It was subsequently given 
the code IPU08. We offered this ab initio course 
again this year to pharmacists who did not 
complete vaccination training last year. 
In August 2012, the PSI informed us that all 
pharmacists who completed vaccination training 
in 2011 needed to undergo refresher vaccination 
training, including a face-to-face element. The 
IPU and Hibernian Healthcare consequently 
developed a Refresher Vaccination Training 
Course which was also accredited by TCD and 
approved by the PSI. 
The cost of this half-day course, including an 
element of e-learning in advance of the face-to-
face element, was €170. I would now ask that 
this Refresher Vaccination Training Course be 
added to the List of Approved Courses for the 
training grant arrangements and that a code 
be allocated. We have taken this issue up with 
the HSE but we understand that the matter has 
been referred to your Department for approval.
In addition, the IPU and the Irish Heart 
Foundation joined forces in 2012 to produce 
Cardiovascular Risk Assessment Training for 
Pharmacists. The one-day course was designed 
to give participants:
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n Individual practical experience of 
assessing cardiovascular risk including 
blood pressure, cholesterol, glucose, 
body mass index and waist circumference 
measurements;
n An understanding and knowledge of 
appropriate GP referral guidelines;
n An understanding and knowledge of 
advice to patients of appropriate lifestyle 
behaviours;
n Information on standards and quality 
assurance when conducting the risk 
assessments; and 
n An overview of cardiovascular disease, 
risk factors and the range of interventions 
available to those at risk.
I’m sure you will agree that this course 
will prepare pharmacists to participate in the 
forthcoming HSE Clinical Care Programmes. The 
course was devised using the PSI Generic Interim 
Accreditation Standards for Formal Programmes 
of Learning for Pharmacy in Ireland. The 
training day was led by Dr Angie Brown, Medical 
Director of the Irish Heart Foundation and 
Consultant Cardiologist, supported by Irish Heart 
Foundation nurses and dieticians. A community 
pharmacist led a session on how to incorporate 
health checks into pharmacy practice. 
The course cost €250 per pharmacist and 
the IPU would like you to include this training 
course on the list of courses eligible for the 
Pharmacy Training Grant.
We would welcome a meeting with you to 
discuss both of these issues.
Letter 4
From Director of Pharmacy Services to 
Head of Professional Development & 
Learning, PSI
[8 March 2013]
Re: Eligibility of Training Establishments
I wish to refer to the eligibility criteria for 
recognition of a training establishment as 
determined by the PSI. I note the following 
criteria from your website:
1. Convictions under medicines legislation 
(that includes human and veterinary 
medicines) and/or pharmacy legislation 
prior to application for recognition will lead to 
automatic ineligibility. If a conviction is being 
appealed through the Courts, the training 
establishment will be considered ineligible 
in the interim. The matter can be addressed 
again at the point of the appeal outcome.
2. Convictions under medicines legislation (that 
includes human and veterinary medicines) 
and/or pharmacy legislation during the 
period approved will lead to the automatic 
rescinding of the approved status. The 
automatic rescission will commence at the 
date of the conviction. In order to protect the 
tutee, the PD&L Committee will be entitled to 
recognise the duration of supervised training 
completed by the tutee at that training 
establishment. This will be carried out on a 
case by case basis by the PD&L Committee.
3. Furthermore, the pharmacy owner, or the 
nominated representative, will be required 
to inform the PSI and the tutee (pharmacy 
intern or TCQR applicant) with regard to all 
impending prosecutions once the relevant 
summons has been served, irrespective of 
the prosecuting agency.
4. Any sanction arising from proven complaints 
under Part 6 of the Pharmacy Act 2007 prior 
to application for recognition will lead to 
automatic ineligibility.
5. Any sanction arising from proven complaints 
under Part 6 of the Pharmacy Act 2007 
during the period approved will immediately 
lead to the automatic rescission of the 
approved status. The automatic rescission 
will commence at the date the sanction is 
imposed by Council. In order to protect the 
tutee, the PD&L Committee will be entitled to 
recognise the duration of supervised training 
completed by the tutee at that training 
establishment. This will be carried out on a 
case by case basis by the PD&L Committee.
6. In the event that a pharmacy owner and/
or superintendent pharmacist and/
or supervising pharmacist for a training 
establishment has been convicted under 
medicines and/or pharmacy legislation 
or subject to any sanction by Council, 
and where the pharmacy owner and/
or superintendent pharmacist and/or 
supervising pharmacist is neither the tutor 
pharmacist nor the pharmacy owner, this 
could have the effect of rendering the training 
establishment ineligible for recognition. The 
circumstances of each such matter would 
be required to be considered by the PD&L 
Committee on a case-by-case basis.
7. In the event of convictions other than those 
under medicines or pharmacy legislation, the 
tutor pharmacist/pharmacy owner will be 
required to inform the PSI as and when these 
occur. In such cases, the PD&L Committee 
may be required to determine if recognition of 
the tutor pharmacist/training establishment 
may be given or continued.
8. The decision of the PD&L Committee in 
such instances may be subject to an appeal 
to Council of the PSI by the registered 
pharmacist/retail pharmacy business.
I have a few questions about these criteria which 
I hope you will clarify.
1. In No. 1, it is unclear how long the automatic 
ineligibility will apply. Is this for life or for 
a period of time? Who decides this? It is 
unclear who the conviction applies to? If, 
for example, it was a conviction against 
the supervising pharmacist or an employee 
pharmacist and they moved on, would that 
training establishment then be considered 
eligible?  
2. Again in No. 2, it is unclear as to who 
the conviction applies to. If an employee 
pharmacist was convicted and their 
employment subsequently terminated, 
would the training establishment then be 
considered eligible?
3. In No. 3, once the pharmacy owner has 
informed the PSI of the pending prosecution, 
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is the intern allowed to remain in situ pending 
the outcome of the case?
4. Similar questions arise in relation to No. 
4. Does this cover sanctions against the 
pharmacy, pharmacy owner, superintendent 
pharmacist, supervising pharmacist, other 
employee pharmacists? Do sanctions 
against any one of them lead to automatic 
ineligibility? How long will this last? What 
if the employee pharmacist moves on? Is 
eligibility restored?
5. In criteria No. 5, the questions outlined in 
No. 1, 2 and 4 apply. In addition, perhaps 
you could clarify which particular sanctions 
result in the establishment becoming 
ineligible? Admonishment? Censure?
6. No. 6 seems to imply that if a pharmacy 
owner or superintendent pharmacist of 
a chain were convicted or sanctioned, 
all pharmacies in that chain would be 
considered ineligible. Is this really the case?
7. No. 7 requires the tutor pharmacist/
pharmacy owner to inform the PSI of all 
convictions other than those under medicines 
or pharmacy legislation. The PSI’s continued 
registration process for pharmacists requires 
only notification of offences which would 
appear to have a bearing on a pharmacist’s 
fitness to practise. Why is there a discrepancy 
between the two? Will a pharmacy be 
considered ineligible if the pharmacy owner 
was convicted of speeding, for example?     
I would appreciate clarification on the issues 
outlined above. 
I also find it extraordinary that pharmacists 
are being advised, when seeking clarification 
on any issue from the PSI, that “it is PSI policy 
that all queries should be put in writing in order 
to ensure that the correct information can be 
provided”. Pharmacists are under considerable 
pressure, financial and otherwise, as it is without 
having to take time out to put queries to the PSI 
in writing. I would ask that you review this policy.  
DRIVING LICENCE 
PHOTOGRAPHS
Driving Licence Photographs – Letter 1
From Secretary General to CEO,  
Road Safety Authority for Health 
[29 November 2012]
Re: Photographs for Proposed New  
Driving License
I am writing to outline the concerns of the Irish 
Pharmacy Union (IPU) to the proposed capture 
of photographs for the new credit card style 
driving license being introduced in January 2013. 
It is our understanding that SGS has been 
awarded the tender to administer the new 
driving license and it is the intention that, from 
September 2013, photographs for licenses will 
have to be directly captured in their premises 
on their machines. There will, apparently, be 
no option for individuals applying or renewing 
a license to post in a photograph or have their 
photograph scanned.
While the IPU is not against the introduction 
of credit card driving licenses, we would have 
serious concerns about the impact of this new 
policy not only on members, the vast majority 
of who supply photographic services, but also 
the serious inconvenience to the general public, 
who will no longer have the option of getting their 
photographs locally.
Many pharmacists have invested considerable 
sums on photographic equipment, which will 
become obsolete when the new initiative is 
introduced. The loss of income could potentially 
have an impact on jobs.
The IPU cannot see any justifiable reason why 
SGS cannot accept a scanned photograph or 
accept postal photographs as has been the case 
to date.
We would urgently request that you reconsider 
your stance on this issue and allow individuals 
the right to capture their own photo, in their local 
pharmacy, if they so wish.
The IPU would welcome the opportunity to 
discuss this issue in greater detail.
Driving Licence Photographs – Letter 2
From Secretary General to Minister for 
Transport, Tourism & Sport 
[6 December 2012]
Re: Photographs for Proposed New  
Driving Licence
I am writing to outline the concerns of the Irish 
Pharmacy Union (IPU) to the proposed capture 
of photographs for the new credit card style 
driving licence being introduced in January 
2013. 
It is our understanding that the Road Safety 
Authority (RSA) has awarded a tender to a 
company called SGS to administer the new 
driving licence. The intention, as confirmed 
by the RSA, is that from September 2013 
photographs for licences will have to be directly 
captured on machines in premises to be set 
up by SGS nationwide. This will ensure that 
members of the public applying or renewing a 
licence from September 2013 will not be allowed 
to post in a photograph or have their photograph 
scanned.
While the IPU is not against the introduction 
of credit card driving licences we would have 
serious concerns about the impact of this new 
policy not only on members, the vast majority 
of who supply photographic services, but also 
the serious inconvenience to the general public, 
who will no longer have the option of getting their 
photographs locally.
Many pharmacists have invested considerable 
sums on photographic equipment, which will 
become obsolete when the new initiative is 
introduced. The loss of income could potentially 
have an impact on jobs.
Furthermore, the IPU does not accept that the 
RSA issues a tender that allows the successful 
recipient of that tender to exclude the services of 
a significant proportion of participants currently 
operating in the market, including pharmacists. 
This consequently raises competition issues, 
which we will be pursuing further.
The IPU would welcome the opportunity to 
discuss this issue in greater detail with you and 
your officials 
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Driving Licence Photographs – Letter 3
From Secretary General to Chairperson, 
The Competition Authority
[10 December 2012]
Re: Proposed New Driving Licence
I am writing on behalf of the Irish Pharmacy 
Union (IPU) to put forward the concerns of 
our members, with regard to the introduction 
of a new driving licence in January 2013 
and in particular the impact on members 
providing photographic services, when a single 
party begins administering the scheme from 
September 2013.
The Road Safety Authority (RSA) as the 
centralised licensing authority sought a service 
provider through an EU Tender process to 
administer the scheme on their behalf.  The 
tender specified two potential options for 
bidders that would deliver either paper or digital 
photographs.  A company, SGS, successfully 
applied for the tender. As part of its successful 
bid SGS will only accept photographs captured 
on their premises by their machines. This is 
despite the fact that they had the option to scan 
photographs brought in by applicants, which is 
the current situation.  SGS did not present this 
as an option in their tender, which was accepted 
by the RSA.
The result of this exclusive contract will mean 
that members of the public applying or renewing 
a licence from September 2013 will be prevented 
from obtaining a photograph from a supplier of 
choice and having their photograph scanned. It 
will also have a devastating and unfair impact 
on the hundreds of companies, including 
community pharmacists, who have invested 
considerable sums on photographic equipment, 
which will become obsolete when the new 
scheme is introduced.
The awarding of this tender opens up serious 
competition issues, allowing only one provider of 
photographic services for driving licences, where 
previously there were a significant number of 
players. The awarding of the tender specifically 
excludes the vast majority of service providers 
to the benefit of one company, who will operate 
as a monopoly in the supply of photographs for 
driver licences. The RSA should have insisted 
that any successful tenderer should be able to 
accept photographs in a number of different 
formats.
I would like to get your opinion on this matter 
and on any action the Competition Authority can 
take to ensure that consumer choice and a level 
playing field prevails in this market.
The IPU would also be happy to meet with you 
to discuss the issue in greater detail.
Driving Licence Photographs – Letter 4
From Director of Communications & 
Strategy to CEO, Road Safety Authority  
for Health 
[8 January 2013]
Further to your correspondence of 8 January 
concerning an interview aired on the ‘The Right 
Hook’ Radio programme on Newstalk, Monday 
7 January about the new plastic card driving 
licence, we would like to respond to a number of 
issues raised in your letter.
We do not agree with a number of the points 
raised in your letter. The main purpose of the 
interview was to highlight the legitimate concerns 
that the Irish Pharmacy Union (IPU) has with 
regard to the capture of the photographs and 
how this is going to be done from September 
2013.
Firstly, the IPU outlined that we welcomed the 
introduction of the new credit card-style licence.
In the process of the interview, while reference 
was made to one tender, this was relayed 
incorrectly; the intention was to outline the 
‘accepted tender’ as opposed to ‘received one 
tender’. We are happy to clarify this point to you.
Secondly, it is our understanding, as 
confirmed by the RSA, that there were two 
options provided in the original tender. While they 
may have been assigned ‘equal weighting’ the 
point made is that the RSA should have insisted 
on both options being used by the successful 
bidder and not just accept the option that was 
provided by the bidding companies. This was not 
to question the RSA’s procurement procedures 
but simply to question why both options were 
not insisted upon, considering that the option 
of posted or scanned photographs is acceptable 
on the new credit card-style licence from 19 
January.
Thirdly, I am confused at your reference that 
our spokesperson “claimed that the Gardaí 
verify photographs and identity of driving licence 
applicants”. The reference in the interview was to 
passports and the identity security as part of the 
process of getting a passport. As stated already, 
we are not against the introduction of the credit 
card-style of licence, but the passport is the 
template for identity standards and photographs 
from pharmacies are accepted as part of the 
entire process of getting a passport. This was the 
point that our spokesperson was making.
There seems to be an element of confusion 
with regard to the entire process and who is 
responsible for what. For example, we were 
informed that a company, SGS, was awarded 
the contract. It has now come to our attention, 
through the media, that Credit Card Systems 
Ltd Ireland has the contract. We have been 
attempting, without success, to communicate 
with these companies to establish information, 
including: 
n the type of photographic equipment that 
will be used when the new proposed 
system is up and running;
n the locations from which they will operate; 
and 
n who has ownership rights to the 
photographs?
It may be worthwhile for the RSA to clarify 
these points and make the public aware of the 
actual process.
I trust this addresses your issues of concern 
and our delegation looks forward to meeting with 
you on 21 January.
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Driving Licence Photographs – Letter 5
From Director of Communications & 
Strategy to CEO, Road Safety Authority  
for Health 
[9 January 2013]
I am responding with regard to your letter dated 
9 January 2013. 
While the IPU acknowledges the concerns of 
the RSA, we have confirmed that an incorrect 
reference was relayed, inadvertently, with 
reference made to one tender. However, we 
find it difficult to accept that the content of the 
interview could be construed as questioning the 
integrity of the public procurement process. 
The reference to the Passport Office was 
in direct response to your allegation that our 
spokesperson claimed that the “Gardaí verify 
photographs and identity of driving licence 
applicants”, which was not the case.
I also note that a number of points that you 
have concerns with were clarified on the “Right 
Hook” show yesterday evening.  If you still 
wish to pursue this issue with the “Right Hook” 
show we would suggest that we forward the 
correspondence from both our Organisations 
clarifying each side’s position.
Driving Licence Photographs – Letter 6
From Secretary General to Chairperson, 
The Competition Authority
[11 January 2013]
Re: Proposed New Credit Card-Style  
Driving Licence
I am writing with reference to my letter of 
December 10 2012 (copy attached), where 
concerns were raised with regard to the 
introduction of a new credit card-style driving 
licence and its impact on our members who 
provide photographic services. 
I wish to enquire whether the Competition 
Authority has formed an opinion on this matter 
and, if so, what action you propose to take.
The IPU would be happy to meet with you to 
discuss the issue in greater detail.
Driving Licence Photographs – Letter 7
From Director of Communications & 
Strategy to CEO, Road Safety Authority  
for Health 
[23 January 2013]
Re: Driving Licence Changes
Many thanks for meeting with me on 21 January 
to discuss the concerns of the IPU with regard 
to the introduction of the new credit-card style 
driving licence. I would just like to clarify a few 
points from the meeting.
As I outlined, the IPU is concerned at both 
the inconvenience to consumers and the loss 
of business to members from September when 
photographs are due to be captured on-site. We 
are particularly concerned that this business is 
essentially being lost to a single company that 
will administer the process on behalf of the 
State. This loss of business and the knock-
on impact on footfall will have an immediate 
effect on the 93% of pharmacies that provide 
photographic services. 
It is the IPU’s preference that applications 
could be received after September by post, 
with the option to have photos scanned at the 
location points. While you have dismissed the 
postal option, you did outline that you will revert 
to SGS to establish if a scanning option is viable. 
While it would be preferable from the IPU’s 
viewpoint that digital capture was not an option, 
I would appreciate it if you can confirm when 
you would be able to revert with regard to the 
scanning option.
You outlined in the course of the meeting 
that the validation process is a one-off and 
that renewed driving licences can use photo 
ID’s, including those from pharmacies. Does 
this apply to lost and/or stolen driving licences 
of individuals that have been validated after 
September? 
I look forward to hearing from you.
Driving Licence Photographs – Letter 8
From Director of Communications & 
Strategy to CEO, Road Safety Authority  
for Health 
[20 March 2013]
Re: Plastic Card Licence
Many thanks for your recent letter regarding the 
implementation of the new Plastic Card Driving 
Licence in Ireland.
From the outset I would like to outline that the 
IPU is extremely disappointed that paper capture 
of photos will not be included as part of the 
process for new licences and licence renewals 
when the changes to the Driving Licence 
application takes place from September.
As outlined previously, the IPU is extremely 
concerned that a significant portion of business 
to members is essentially being lost to a service 
provider appointed by the State. This will have 
an impact on members currently providing photo 
services, particularly for those pharmacists that 
have invested considerable sums in equipment 
that will no longer generate the same level of 
business. Consequently, there is the real concern 
that jobs may be impacted.
We would appreciate it if this policy could be 
reviewed and that the paper capture of photos 
will be included as part of the application for a 
new or renewed driving licence and accepted as 
such by the service provider.
I look forward to receiving your response.
Appendix II
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OTHER MATTERS
Bankruptcy – Letter 1
From Secretary General to  
Minister for Health 
[21 September 2012]
Re: Section 14 (1) of the Pharmacy Act 2007.
I am writing to you on behalf of the Irish 
Pharmacy Union (IPU) with regard to a serious 
issue impacting on pharmacists, which is not 
addressed in the Personal Insolvency Bill 2012.
Section 14(1)(f) of the Pharmacy Act 2007 
provides that ‘the Council shall register a person 
in the pharmacists’ register if the person – is 
not an undischarged bankrupt.’ This provision 
effectively removes the right of a person, 
otherwise capable of registering as a pharmacist, 
to earn a livelihood if they are an undischarged 
bankrupt. This restriction is not imposed on other 
healthcare professionals and is not referenced 
in any existing bankruptcy legislation. It is 
unclear why pharmacists should be subject to 
this restriction, particularly as it relates to their 
financial situation and not their professional 
competence.  
The IPU would appreciate if you would 
consider engaging with the Department of 
Justice with a view to using the Personal 
Insolvency Bill to introduce a provision to delete 
Section 14(1)(f) of the Pharmacy Act 2007. 
If this section was deleted, it would enable 
a pharmacist to continue to practice their 
profession in the event that they are declared 
bankrupt, provided of course that they comply 
with all other ethical, legal and professional 
requirements.
Should you or your officials require any further 
information or clarification on this matter, please 
do not hesitate to get in touch with me. 
Bankruptcy – Letter 2
From Director of Communications & 
Strategy to Acting Registrar, PSI
[12 April 2013]
Re:  Section 14(1)(f) of the Pharmacy Act 
2007
As you are aware, Section 14(1)(f) of the 
Pharmacy Act 2007 provides that ‘the Council 
shall register a person in the pharmacists’ 
register if the person – is not an undischarged 
bankrupt.’ This provision effectively removes 
the right of a person, otherwise capable of 
registering as a pharmacist, to earn a livelihood 
if they are an undischarged bankrupt. 
The IPU has raised this issue on a number 
of occasions with the PSI and, recently, at a 
meeting with Minister Alex White T.D.
As discussed at a recent meeting between 
the IPU and PSI, there is now an opportunity 
to highlight this issue and to seek to have an 
amendment introduced in The Health (Pricing 
and Supply of Medical Goods) Bill 2012, to 
address this issue. This Bill is about to go to 
Report stage.
Due to the crucial importance of this issue to 
the profession we are seeking the assistance of 
the PSI in seeking an amendment to the Bill to 
have Section 14(1)(f) of the Pharmacy Act 2007 
deleted. There appears to be broad political 
support for such an amendment.
We have proposed therefore that an 
amendment under Section 32 of the Bill be 
made for the “Deletion of Section 14(1)(f) of 
the Pharmacy Act 2007”. If accepted, this 
amendment would form a new subsection (e) on 
page 35.
Section 32 subsection (e) would therefore 
read “Deletion of Section 14(1)(f) of the 
Pharmacy Act 2007”.
The implementation of this amendment would 
enable a pharmacist to continue to practice their 
profession in the event that they are declared 
bankrupt, provided they comply with all other 
ethical, legal and professional requirements.
Please do not hesitate to contact me if you 
would like any further information or clarification 
on the issues raised in this letter.
Switching
From Secretary General to  
Deputies Kelleher and Ó Caoláin
[3 October 2012]
Thank you for taking the time to meet with 
Pamela and I yesterday to discuss the detail of 
and possible amendments to the Health (Pricing 
and Supply of Medical Goods) Bill 2012. I hope 
you found the meeting constructive.
You mentioned the attendance of the IMB 
at the Joint Oireachtas Committee on Health 
last Thursday. I thought the enclosed Self-
Care Framework, which we launched on 20 
September 2012, in conjunction with the Irish 
Pharmaceutical Healthcare Association (IPHA) 
may be of interest to you. The Framework 
advocates that the range of medicines made 
available to patients be expanded through 
switching. Recommendations of the types of 
medicines to be switched are in Annex 2.  
Please feel free to contact me should require 
more information on these issues or indeed any 
other issues.
Directive on Recognition of  
Professional Qualifications
From Director of Pharmacy Services to 
Chief Pharmacist, DoH
[29 May 2012]
Re: IPU proposed modifications to the 
proposed Directive on Recognition of 
Professional Qualifications
I am writing to you on behalf of the Irish 
Pharmacy Union (IPU) in relation to the Directive 
on the Recognition of Professional Qualifications 
(RPQ).
The IPU is a member of the Pharmaceutical 
Group of the European Union (PGEU), the 
association representing more than 400,000 
community pharmacists in 31 European 
countries. Within PGEU, we have considered 
the RPQ proposal and put together a series of 
suggestions that we believe are crucial to reflect 
the pharmacy practice and to allow the smooth 
recognition of pharmacy titles. 
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We would like you to consider 17 
amendments: 10 amendments to the 
provisions relating specifically to pharmacists 
and seven amendments to the provisions of 
general application. I encourage you to pay 
special attention to the pharmacist’s specific 
amendments and in particular to our suggestion 
on pharmacy activities. 
Please find attached for your convenience 
the complete set of amendments in a separate 
annex to this letter.
Amendments to provisions specifically 
relating to pharmacists 
Pharmacy Activities  
(suggested amendments 1, 2, 3, 4 and 5)
The activities listed for pharmacies in the 
Directive are clearly out of date; the current 
wording dates back to 1985. The list needs  
to be further extended to properly reflect 
pharmacy practice. 
The IPU would like to add: 
n	 Sourcing and dispensing of safe and 
secure medicinal products: Source: 
pharmacists ensure that patients 
receive the prescribed medicine. If the 
medicine is not available in their stock, 
pharmacists will obtain that medicine with 
the minimum delay. Safe and secure: 
pharmacists need to undertake the 
necessary steps to ensure that dispensed 
medicines are authentic and of high 
quality.
n	 Medicines management and provision 
of information on health related issues:  
Medicines management: pharmacists 
are experts on medicines and they 
must be able to help patients to achieve 
the best outcome of their prescribed 
treatment and at the same time minimise 
risks linked to side effects and potential 
interactions. In addition to information on 
medicines, they provide information on 
other issues such as medical devices and 
healthy lifestyles.
n	 Support individual patients on non-
prescription medicines and self-care:  
In all EU Member States, pharmacists 
help patients with minor ailments such 
as coughs or headaches and when 
appropriate advise on the non-prescription 
medication that needs to be taken to cure 
or relieve symptoms. Pharmacists support 
individuals in self-care (healthy lifestyle, 
independent management of one’s 
condition) and when necessary refer the 
patient to other healthcare services or 
health providers.
n	 Contribute to public health campaigns: 
Community pharmacists need to 
participate and contribute to public 
health campaigns organised to tackle 
specific problems, such as antimicrobial 
resistance, healthy lifestyles, cancer 
screening etc. The high accessibility of the 
community pharmacy networks facilitates 
the contact with citizens and therefore 
contributes to the effectiveness and 
outreach of those campaigns.
It is important to note that in our view, this 
expansion of the list of pharmacy activities is 
modest in scope, reflects current pharmacy 
practice in the vast majority of Member States 
and does not represent therefore an expansion of 
pharmacy services into areas reserved for other 
health professionals. This change will show the 
evolution of the pharmacist’s profession and the 
commitment of our profession to face further 
challenges and roles decided by Member States 
within the context of their public health policies.
Delegated Acts by the Commission  
on pharmacists training  
(suggested amendment 6, 7 and 8)
We have some concerns regarding the 
Commission proposal to decide, by delegated 
acts, some aspects of pharmacy training. 
The Commission proposes to decide on the 
adequate knowledge of pharmacists and on 
pharmacist competences through delegated 
acts. Decisions on this matter should be taken 
following extensive discussions with Member 
States. Therefore we propose the use of the 
examination procedure for the adoption of 
such a decision. Pharmacists accept the use of 
delegated acts to amend the course of training 
for pharmacists (suggested amendment 5) 
but we would welcome in the provision a clear 
mandate to consult with the relevant parties 
before the adoption of the delegated acts.
The IPU would like to: 
n	 Use the examination procedure to 
decide on the adequate knowledge of 
pharmacists
n	 Before deciding on the course of training 
for pharmacists, the Commission must 
consult with the relevant parties
Pharmacist traineeship  
(suggested amendment 9)
The Commission proposes to complete the six 
month traineeship in a block at the end of the 
course of training. The new provision could be 
problematic for some countries that split the 
traineeship during the course of studies. Our 
amendment would maintain national flexibility in 
this respect.
The IPU would like to:
n	 Provide Member States with the flexibility 
to decide on the structure of the 
pharmacy course.
The IPU does not support PGEU’s proposed 
amendment 10. 
Amendments to provisions of  
general application
Partial Access (Suggested amendment 11)
We have strong concerns regarding the 
application of partial access to professions 
providing public health services. This proposal 
has the potential to create significant disruption, 
and possibly undermine the level of competences 
and quality of health care provision. 
Appendix II
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The IPU would like to:
n	 Introduce a general derogation of partial 
access for professions involved in public 
health services.
Language Knowledge  
(Suggested amendment 12) 
It is important to ensure the adequate language 
knowledge of health professionals dealing 
with patients. The Commission seems to 
be supportive of the idea of amending the 
Directive in this regard. However, the proposal 
of the Commission lacks clarity and needs 
to be improved. In addition, limiting the 
language control to one language chosen by 
the applicant could be very problematic in 
Member States with several official languages 
and where not all official languages are 
understood by patients. 
The IPU would like to:
n	 Introduce some clarification regarding the 
language knowledge control.
European Professional Card (EPC)  
(Suggested amendment 13, 14, 15 and 16)
I would also like to use this opportunity to 
mention some concerns and changes regarding 
the European Professional Card.  
The IPU would like to:
n	 Extend the deadlines proposed to 
complete the procedure of recognition by 
competent authorities.
n	 Delete de facto validation (in cases 
where the competent authority is not able 
to solve the recognition within the relevant 
time periods).
n	 Request that the original 
documentation must be controlled at 
some point by the home Member State 
before entering the IMI System.
Alert Mechanism  
(Suggested amendment 17)
We have a final point on the alert mechanism. 
In some Member States competent authorities 
are only able to exchange information on 
professionals when the decision adopted is 
definitive (not subjected to appeals). 
The IPU would like to:
n	 Ensure that information on health 
professionals is exchanged when this is 
possible according to national legislation.
Thank you in advance for taking into 
consideration these suggestions. Please do not 
hesitate to contact me if you would like any 
further information or clarification on the points 
raised in this letter.
High Tech Medicines
From Secretary General to PCRS
[14 February 2013]
Re: High Tech Medicines
I wish to refer to your letter dated 8 February 
2013. 
I would like to draw your attention to the Criteria 
for High Tech Medicinal Products Annex B in 
the Agreement on the Future Provision and 
Improvement of Community Pharmacy Services 
under the Health Act, 1970.
‘Any medicines to be included or deleted 
from this Scheme will be the subject 
of agreement between the Department 
of Health, the Irish Pharmaceutical 
Healthcare Association and the Irish 
Pharmaceutical Union. The list of medicines 
will be reviewed on a regular basis by the 
above parties. This scheme will only consider 
medicinal products in respect of which their 
principal use is for the treatment of the 
primary medical condition for which they are 
authorised.’ [emphasis added]
If the PCRS wish to discuss changes to this 
arrangement or any other agreement, the matter 
should be raised and agreed by both parties 
through the IPU/ HSE Joint Consultative Group. 
In the meantime, existing arrangements should 
continue.
National Consumer Agency (NCA) Survey
From Director of Communications & 
Strategy to CEO, NCA 
[2 April 2013]
Re: Prescription Medicines Price Study
I am writing on behalf of the Irish Pharmacy 
Union (IPU) to outline our concerns at 
revelations in the Irish Times (Saturday 30 
March) that a survey of medicine prices 
charged by pharmacies to private patients, for 
product and service, published by the National 
Consumer Agency (NCA) is flawed and contained 
inaccurate and misleading information.
The IPU is disappointed that the NCA, 
in attempting to justify the inaccuracies, 
has apportioned blame to the responding 
pharmacists. As a State agency with 
considerable resources it is your responsibility 
to ensure that the information published and 
reported is both accurate and fair. 
It is regrettable that you did not share the 
outcome of the survey with the IPU in advance 
of publication, which would have helped to 
identify the errors contained in the report and 
accompanying press release. 
I would respectfully suggest that it is important 
that you contact us in advance of conducting 
and publishing results of any future surveys 
being undertaken by the NCA that impact on the 
pharmacy sector.
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2012
28 April  Patient Safety Threatened by Shortage of Vital Medicines 
26 April  Public want greater role for pharmacists – new survey 
28 April  Pharmacists raise concerns about over-use of Antibiotics 
28 April Pharmacists warn of rise in heart disease – now responsible for 36% of all deaths in Ireland 
29 April Irish Pharmacy Union elects Donegal man as new President 
29 April  Pharmacists Demand Right to Dispense Generic Medicines 
29 April  Pharmacists hear that up to 1-in-3 adults may be suffering from Chronic Pain 
14 May  Four-in-10 People Would Not Want to Know if a Loved One was Suffering from Depression 
23 May  Students Warned to Protect Against Stress as Exam Time Begins 
30 May  Pharmacists issue advice to help people stop smoking 
08 June  Pharmacists Call for a cut in Commercial Rates 
11 June  Look Out for New Emergency Contraception Logo in Pharmacies 
27 June  Pharmacists Issue Safe Guide for Sun Holidays 
09 July  Statement by the Irish Pharmacy Union 
22 July  Business Trends Survey reveals challenges facing pharmacists  
27 July Pharmacists Concerned at Dropping Sales 
02 August  Recession Increases Reliance on Community Pharmacists 
17 August  IPU warns about Dos and Don’ts of giving medicines to young children 
24 August  Getting Ahead of Head Lice 
30 August  Pharmacists Warn Electric Picnic Revellers to Look after their Health this Weekend 
03 September HSE confirms withdrawal of Gluten-Free products from State Schemes 
10 September Limerick Pharmacists Urge Public to Take Part in Think Ahead Initiative 
20 September Expert Healthcare Group Proposes a Framework for Self-Care in Ireland 
28 September Pharmacists to Deliver Flu Vaccination to Patients from Next Week 
15 October  Pharmacists Welcome Deal to Lower Medicine Prices 
23 October  Pharmacists warn of dangers of using internet for buying medicines 
01 November IPU Pre-Budget Submission 2013 
06 November Pharmacies increasingly pessimistic about business prospects – IPU survey reveals 
21 November Pharmacists lead the way in the fight against antibiotic resistance 
05 December Pharmacists respond to harsh measures announced in Budget 2013 
14 December  Pharmacists Give Tips for Fighting Colds and Flu 
18 December Pharmacists warn of the dangers of mixing alcohol with medicines over the festive season
28 December Three-quarters of pharmacists victims of crime this year – Irish Pharmacy Union
2013
04 January Pharmacists Concerned at Decision to Centralise Photos for Driving Licences
27 January Majority of Irish Pharmacies Gloomy about Business Prospects – IPU Survey
11 February Pharmacists promote the benefits of Giving up Smoking
04 March Irish Pharmacy Union Graduation Day
15 March Headache Awareness Week (16-23 March)
09 April Pharmacists warn parents of health risks when giving medicines to children
Appendix III
A List of Press Releases Issued to the National 
Media during the Year on Various Matters
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Appendix IV
Letters Published in Newspapers
Irish Times, 1 June 2012
Sir, - When Mary Rose Burke “told” The Irish 
Times (Front page, May 29th) that Boots 
chain had been through “two world wars and 
depressions”, she conveniently overlooked the 
causative history for these events, in place of 
being sensational.
History has shown that without greed, 
colonialism and expansionism these events 
would not have happened to the devastating 
extent that occurred.
History also shows that Britain and Germany 
were most culpable in sharing the blame for the 
grievances created that ultimately ended in two 
world wars. Ireland was faultless.
Worryingly, Irish Pharmacy is becoming 
the latest theatre of war between Britain and 
Germany (Boots versus Doc Morris/Unicare). 
Under a false guise of patient price benefit/
value they are attempting to conquer the Irish 
Pharmacy market in the commercially viable 
areas while ignoring the national requirement for 
Pharmacy services.
The Irish public and particularly the Irish 
health administrators should not stand idly by. 
Currently we are in a phoney war; soon it will be 
all-out conflict.
Irish Pharmacy is not a toy for the playful 
amusement of our German and British friends. 
Both are welcome to compete in our market, 
fairly and honestly and present information and 
prices in a truthful sustainable manner. Ireland is 
more than cities and large shopping centres.
In attempting to divide the spoils of war 
between them the Irish public should be informed 
of the long-term danger of damaging the already 
wounded independent pharmacist, who, by the 
way, has also survived two world wars etc.
These two really are not any cheaper than the 
independent Irish-owned and staffed pharmacy. 
I know that because I am one. Proud Irish and 
happy to be both. They should play fair or go 
home. Ministers should represent the nation, not 
foreign greed. 
Yours, etc,
JP Magner,  
Howth Road, Killester, Dublin 3. 
Irish Examiner, 5 November 2012
Potential Health Issues with E-Cigarettes
Your article (Nov 1) refers to e-cigarettes as 
“harmless”.
According to the Pharmaceutical Society of 
Ireland’s guidance these should not be supplied 
through retail pharmacy businesses in Ireland 
because their quality, safety and efficacy have 
not been appropriately established.
The FDA in the USA has also warned 
consumers about the potential health risks 
associated with electronic cigarettes.
A study in the University of Athens found they 
caused “significant airways resistance”.
The cartridges contain chemicals filled with 
nicotine, flavour and other chemicals that are 
vaporised and inhaled by the user and have 
been found to contain carcinogens, including 
nitrosamines.
Industry sources say the products have 
improved since then, but because they are 
unregulated we cannot be sure.
I would suggest that while these products 
may have potential as a smoking cessation 
method in the future smokers and are probably 
less harmful than smoking, smokers should 
instead consider those products that have been 
approved for this purpose. 
Conor Phelan,  
Phelans Pharmacy,  
Carrigaline, Co Cork 
Irish Times, 20 April 2013
Sir, - The HSE, while teetering on the edge, 
has issued one more missive that should truly 
indicate dysfunction.
In its enthusiasm to cut costs it has issued 
a missive to all prescribers, signed by the DG 
designate, asking them to use “preferred drugs” 
from particular classes of medicines. In both 
cases it uses the two man proprietary names.
This is despite the stated objective of 
the Government and the HSE, that doctors 
would prescribe using generic names. Truly 
an organisation that needs some internal 
communication lessons.
 
Jack Shanahan,  
Church Street,  
Castleisland, Co Kerry.
59
AnnuAl RepoRt 2013
Notes
60
AnnuAl RepoRt 2013

IRISH PHARMACY UNION
Butterfield House  
Butterfield Avenue  
Rathfarnham  
Dublin 14
T 01 4936401  
F 01 4936407 
E info@ipu.ie 
www.ipu.ie
